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Summary 
Despite being closely related viruses with similar replication cycles, HIV-2 
replicates more slowly than HIV-1 and produces fewer particles, resulting in a 
lower plasma viral load. Expression of the major structural gene, gag, from 
HIV-1 and HIV-2 proviruses was compared to investigate whether this could 
play a role in the difference in particle production observed between HIV-1 
and HIV-2 infection. 
Using quantitative RT-PCR, significantly less full-length HIV-2 gag mRNA 
was found to be transcribed from its provirus than for HIV-1. Sub-cellular 
fractionation allowed us to determine HIV-1/2 gag mRNA levels in the 
nucleus and cytoplasm throughout a time course. RNA export of HIV-2 gag 
mRNA was shown to be slower than for HIV-1 gag mRNA.  
HIV-2 full-length gag RNA was shown to be translated much less efficiently 
than HIV-1 in a range of cell lines. Both HIV-1 and HIV-2 Gag have been 
proposed to be translated by internal ribosome entry. Shutting down cap-
dependent translation (by poliovirus-mediated eIF4G cleavage) significantly 
reduced translation from both HIV-1/2 gag RNAs, with no evidence of 
compensatory IRES activity. This suggests that cap-dependent translation is 
the predominant mechanism for translation of both HIV-1 and HIV-2 RNA. 
Additional work explored HIV RNA-protein interactions by UV cross-linking 
experiments using cellular proteins. Several proteins differentially binding to 
HIV-1/2 5’ UTR RNAs were identified and, in particular, a 45 kDa protein 
binding only to the HIV-1 5’ UTR. Attempts were made to characterise the 
proteins binding with different affinities to HIV-1 and HIV-2 RNAs. 
Confocal microscopy was used to visualise HIV-1/2 Gag expression within 
the cell. Both HIV-1 and HIV-2 Gag expression was shown to be reduced 
when siRNA was used to inhibit the cellular clathrin adaptor protein AP-1. 
In conclusion, HIV-2 Gag gene expression was found to be less efficient than 
HIV-1 at the level of transcription, RNA export and translation. Future work 
will continue to investigate the mechanisms behind these differences.  
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1. CHAPTER 1: INTRODUCTION 
1.1 The origin of HIV 
Human immunodeficiency virus (HIV) is a lentivirus of the family Retroviridae 
and subfamily Orthoretrovirinae. HIV is the causative agent of acquired 
immune deficiency syndrome (AIDS). Lentiviruses are characteristically 
responsible for long-term illnesses: commencing with subclinical infection 
and a prolonged incubation period, and progressing insidiously to 
degenerative disease syndromes (Narayan and Clements, 1989). Other 
lentiviruses include bovine (BIV), feline (FIV), and simian (SIV) 
immunodeficiency viruses, caprine arthritis encephalitis virus (CAEV), equine 
infectious anemia virus (EIAV), puma lentivirus (PLV) and visna-maedi virus 
(VMV) [figure 1]. Lentiviruses are distinguished from other retroviruses by 
their morphologically distinct, cone-shaped nucleoid in mature virus particles 
and the presence of regulatory elements rev and tat. Infection with 
lentiviruses is also species-specific (Coffin, J.M. et al., 1997).  
There are two types of HIV: HIV-1 and HIV-2. HIV-1 is the predominant 
subtype and is found globally, whereas HIV-2 is largely confined to West 
African countries such as Senegal and Ivory Coast (Coffin, J.M. et al., 1997). 
Until recently, three major groups of HIV-1 had been identified; group M 
(Main) which is responsible for the majority of global infections, group O 
(Outlier group) mainly responsible for infections in Cameroon, France and 
Gabon and the rarer group N (non M or O) discovered in Cameroon (Levy, J., 
2007; Sleasman and Goodenow, 2003). Additionally, group M has 9 distinct 
subtypes known as ‘clades’: A, B, C, D, F, G, H, J and K [figure 2]. Genetic 
recombination between different HIV-1 subtypes has also resulted in many 
HIV-1 variants known as circulating recombinant forms (CRFs) (Coffin, J.M. 
et al., 1997; Sharp et al., 2001). Recently, transmission of a gorilla retrovirus 
(SIVgor) into humans has been reported and will potentially form a new, fourth 
HIV-1 group classified as Group P (Broder, 2010). The HIV-2 virus is divided 
into 8 groups: A-H, of which groups A and B are the most prevalent whereas 
groups C-H have only been isolated from one person (Santiago et al., 2005). 
  
  
 
Figure 1: Taxonomy of HIV highlighted in blue: the HIV species is classified as part of the Retroviridae family, Orthoretrovirinae subfamily, and 
lentivirus genus [International Committee on the Taxonomy of Viruses (ICTV): http://www.ictvonline.org/virusTaxonomy.asp?version=2009]. 
Chapter 1           Introduction 
 
3 
 
 
 
Figure 2: Phylogenetic tree of primate lentiviruses based on the similarities within the 
HIV pol gene region. The relationship of HIV-1 (groups M, N and O) to SIVcpz and HIV-2 
to SIVsmm are shown [Image: http://svr225.stepx.com:3388/hiv and description from 
(Reeves and Doms, 2002)]. 
It is thought that cross-species transmission events are responsible for the 
presence of HIV in humans. Viruses related to HIV-1 have been identified in 
chimpanzees (Pan troglodytes) (Sharp et al., 2001). In particular, 
phylogenetic analysis has shown that another lentivirus - chimpanzee simian 
immunodeficiency virus (SIVcpz) - is closely related to, and therefore believed 
to be the origin of, HIV-1 groups M, N and O (Chen, Z. et al., 1997). SIVcpz 
infection is non-pathogenic in chimpanzees and is not accompanied by the 
vast destruction of immune tissue seen in HIV-1 infection of humans 
(Forsman and Weiss, 2008). Sooty mangabey simian immunodeficiency virus 
(SIVsmm) which infects sooty mangabeys (Cercocebus atys) closely 
resembles HIV-2 and sooty mangabeys are native to western Africa; 
coincident with endemic HIV-2 (de Silva et al., 2008). It is believed that 
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SIVsmm crossover into the human population may have occurred on at least 8 
occasions resulting in the HIV-2 subgroups A-H (Broder, 2010; de Silva et al., 
2008). Independent transmission events from primates infected with 
genetically distant lentiviruses are therefore thought to account for the 
emergence of both HIV-1 and HIV-2.  
In terms of timing, HIV-1 M group isolates have been detected in samples 
from as far back as 1931, yet the HIV virus was not detected until 
considerably later during the 20th century (Chen, Z. et al., 1997). However, 
symptoms of HIV infection are diverse, not easily recognisable and manifest 
in a way that makes HIV infection difficult to distinguish from other 
autoimmune diseases. Coupled with a latency period of around ten years 
between HIV infection and AIDS, HIV may thus have gone undetected 
(Chevret et al., 1992). This may account for the extended period between the 
first, dormant cases of HIV within the human population and its actual 
detection and recognition as part of the AIDS epidemic in the 1980s (Yusim 
et al., 2001). 
Although unreported incidents of the disease may have existed earlier, the 
first identified cases of AIDS occurred in June 1981. Immune deficiency was 
identified following an unusually high incidence of rare, opportunistic 
infections: Pneumocystis carinii pneumonia and Kaposi’s sarcoma, amongst 
previously healthy, homosexual men living in Los Angeles (Gottlieb et al., 
1981). The disease was therefore, initially, termed gay-related immune 
deficiency syndrome (GRID). However, after subsequent detection of disease 
in patients outside of the gay community, the disease was given the name 
AIDS (acquired immunodeficiency syndrome) by the Center for Disease 
Control and Prevention (CDC). 
In 1983 Luc Montagnier isolated a new virus from the swollen lymph nodes of 
AIDS patients, which resembled another retrovirus: equine infectious anemia 
virus (EIAV). Initially called lymphadenopathy-associated virus (LAV), 
Montagnier subsequently relabelled the virus immune-deficiency-associated 
virus (IDAV) due to its isolation from AIDS patients, and confirmed an 
association with AIDS pathogenesis (Barre-Sinoussi et al., 1983; Montagnier 
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et al., 1984). Around a similar time, in 1984, Robert Gallo identified a new 
retrovirus which was isolated from AIDS patients and shared several features 
of previously identified human T-lymphotrophic viruses (HTLV). Named 
HTLV-III, this new retrovirus was distinguishable from HTLV-I/II due to its 
morphological, biological and antigenic differences. Gallo suggested that 
HTLV-III was the causative agent of AIDS (Gallo et al., 1984). In 1985 Jay 
Levy isolated AIDS-associated retrovirus (ARV) from homosexual men and 
showed this to be the cause of neurological syndromes presented in AIDS 
patients (Levy, J.A. et al., 1985). In the same year, HTLV-III, LAV and ARV 
were shown to be genetic variants of the same virus (Ratner et al., 1985). 
Consequently, these viruses were grouped and collectively coined HIV in 
1986 (Coffin, J. et al., 1986). 
In 1985, a new retrovirus was isolated from AIDS patients in West Africa 
(Clavel et al., 1986). Although related to HIV, this new virus was distinct and 
its envelope glycoproteins more closely resembled those of simian 
retroviruses. However, in 1987 it was shown that this new retrovirus also 
caused AIDS. The virus was, therefore, named HIV-2 and its predecessor 
became known as HIV-1 (Le Guenno et al., 1987). 
1.2 HIV pathology 
1.2.1 The global disease burden of HIV 
Currently, 33.3 million people are infected with HIV, with 2.6 million new 
infections, and 1.8 million deaths from AIDS occurring during 2009 [figure 3]. 
The highest prevalence of HIV is in Sub-Saharan Africa with 22.4 million 
people living with HIV (UNAIDS, 2010). 
Subtypes A, B and C (group M) are the most prevalent amongst HIV-1 
patients with subtype C responsible for nearly 50% of infections. 
Geographically, subtype A is found in Central/East Africa and East Europe, 
subtype B is primarily located in Central/West Europe, Australia, the 
Americas, North Africa, Southeast Asia and the Middle East, whilst subtype C 
is predominant in Africa and India. The burden of infection is not evenly 
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distributed as around 80% of all global infections are found in Africa and 
India, coincident with the dominance of subtype C (Buonaguro et al., 2007). 
Figure 3: The number of adults 
and children living with HIV and 
the distribution of adult and child 
deaths due to AIDS in 2009 
(UNAIDS, 2010). 
The range of HIV-2 infection is more limited, occurring principally in West 
Africa and Europe. The majority of HIV-2 infections in Guinea-Bissau and 
Europe, are due to subtype A, whereas HIV-2 subtype B infections are found 
more commonly in Ghana and the Ivory Coast. The highest diversity of HIV-2 
is found in Sierra Leone, with identifed subtypes A, B, E and F causing 
infection (Reeves and Doms, 2002). Dual infection (with HIV-1 and HIV-2) 
has also been identified in areas with increasing HIV-1 prevalence and 
endemic HIV-2 (Reeves and Doms, 2002). This introduces the possibility of 
recombination between the two types of HIV, although this has not yet been 
detected. Interestingly, whilst the prevalence of HIV-1 continues to increase, 
the prevalence of HIV-2 is declining. A simple explanation is the low viral 
load, and thus inefficient transmission efficiency, of the HIV-2 virus (de Silva 
et al., 2008). 
1.2.2 HIV transmission 
Transmission of HIV occurs via direct sexual contact, through blood, by 
perinatal transmission from mother to child (MTC) or through breast milk 
(Coffin, J.M. et al., 1997). 85% of HIV-1 infections are transmitted 
heterosexually (Forsman and Weiss, 2008). Although MTC transmission of 
HIV can occur, due to the limited lifespan of infants born with HIV, the virus is 
Area 
Estimated adult 
and child deaths 
due to AIDS 
Sub-Saharan Africa 1300000 
South & South-East Asia 260000 
Eastern Europe & Central 
Asia 
76000 
Central & South America 58000 
East Asia 36000 
North America 26000 
Middle East & North Africa 24000 
Caribbean 12000 
Western & Central Europe 8500 
Oceania 1400 
TOTAL 1801900 
Total: 33.3 million (31.4 million -
35.3 million) 
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rarely transmitted further (Forsman and Weiss, 2008). The rate of MTC 
transmission varies according to different regions. In Europe, HIV-1 MTC 
transmission occurs for 15-20% of AIDS patients, whereas the rate is much 
higher in Africa at 25-35%. Breast feeding contributes to MTC transmission 
statistics. Notably, HIV-2 MTC transmission rates, at 0-1.2%, are much lower 
than for HIV-1 (O’Donovan et al., 2000). Risk factors for MTC transmission 
include obstetric issues, nutritional deficiency, advanced disease status and 
a low CD4 cell count (O’Donovan et al., 2000). HIV transmission is also 26-
fold more likely during stages of primary infection than during stages of 
asymptomatic, chronic infection. It has thus been estimated that 23% of 
transmission events occur whilst HIV positive individuals are experiencing 
primary infection (Forsman and Weiss, 2008). 
Genetic factors can also influence HIV transmission: some individuals show a 
genetic predisposition to be more resistant to HIV infection. For example, a 
homozygous CCR5∆32 deletion prevents HIV infection via the chemokine 
receptor CCR5, resulting in resistance to strains dependent on this co-
receptor. Additionally, variations in host restriction factors, such as 
APOBEC3G and Trim5α, have also been shown to confer resistance to HIV 
infection (Forsman and Weiss, 2008). 
Although equivalent routes of transmission are used by HIV-1 and HIV-2, 
transmission of HIV-2 is much less efficient (Reeves and Doms, 2002). 
Overall, it has been estimated that HIV-1 has a transmission rate of 24.4% 
compared to only 4.0% for HIV-2 (O’Donovan et al., 2000). 
1.2.3 HIV target cells 
Several tissues host HIV replication including the spleen, lymph nodes, 
lymph cells and macrophages (Wei et al., 1995). Initial infection may target 
mononuclear phagocytes which provide a means for early dissemination of 
the virus and are, therefore, important in establishing early infection and 
subsequent pathogenesis (Gartner et al., 1986). HIV is able to proliferate in 
CD4+ T-lymphocytes (T-cells), macrophages and both plasmacytoid (pcDC) 
and myeloid (myDC) dendritic cells (Forsman and Weiss, 2008; Patterson et 
al., 2001). HIV tropism is governed by the presence of suitable cell surface 
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receptors which are required for virus attachment and entry (Forsman and 
Weiss, 2008). CD4 is the primary HIV receptor whilst accessory chemokine 
receptors CCR5 and CXCR4 are co-receptors (Patterson et al., 2001). CCR5 
is the receptor most commonly used by HIV variants, although during later 
stages of infection variants which use the CXCR4 receptor tend to emerge 
(Forsman and Weiss, 2008).  
Co-receptor usage largely determines virus tropism, although additional host 
factors can also affect virus dissemination. Cell tropism also varies between 
different HIV isolates. CD4+ T-cells remain the prominent target of all HIV 
viruses, although other cells provide targets for HIV infection based on 
receptor compatibility with the infecting strain (Reeves and Doms, 2002). HIV 
isolates have, thus, been divided into groups based on their cellular tropism. 
X4 tropic viruses use the CXCR4 co-receptor and have a characteristically 
rapid replication rate leading to high virus titres in CD4+ T-cells. Additionally, 
X4 tropics induce the formation of giant, multi-nucleated cells, or syncytia, in 
vitro and are therefore sometimes referred to as SI (syncytia-inducing) 
isolates (Reeves and Doms, 2002). Non-syncytia inducing (NSI) strains 
preferentially infect macrophages using the CCR5 co-receptor. These 
isolates are sometimes called R5 tropic strains and typically replicate more 
slowly and to a lower titre than X4 tropic strains (Reeves and Doms, 2002). 
An additional group of HIV variants has been identified with an ability to infect 
both CD4+ T-cells and macrophages. These strains use both the CXCR4 and 
CCR5 co-receptors and are therefore referred to as R5/X4 tropic strains. 
Individuals lacking the CCR5 co-receptor have proven more resistant to HIV 
infection (Reeves and Doms, 2002). 
1.2.4 HIV disease progression 
There are essentially four phases of HIV disease progression; primary 
infection, clinical latency, symptomatic disease and progression to AIDS.  
1.2.4.1 Primary infection 
Following exposure and infection with HIV, there is a period of incubation 
lasting between 2-6 weeks. This is followed by primary infection which is 
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marked by a 4-8 week period of acute disease (Forsman and Weiss, 2008) 
[figure 4].  
 
Figure 4: A time course of HIV infection showing primary infection, clinical latency, 
symptomatic disease and progression to AIDS resulting in death. The relationship 
between viral load (the number of copies of HIV RNA per ml of plasma) and the level 
of CD4
+
 T-lymphocytes (CD4 count in cells per μl) during an untreated HIV infection 
are indicated. Following primary infection, wide dissemination of the virus results in 
CD4
+
 T-cell destruction (blue). Virus load (red) peaks during primary infection and, 
after a period of clinical latency, increases with the onset of AIDS 
[http://svr225.stepx.com:3388/hiv].  
Swollen lymph nodes (lymphadenopathy), fever, muscle pain (myalgia), 
nausea, fatigue and a sore throat (pharyngitis) are common symptoms of 
acute infection (Rogowska-Szadkowska and Chlabicz, 2008). During primary 
infection, HIV-1 replicates rapidly within CD4+ T-cells in mucosal-associated 
lymphoid tissue (MALT). Mass destruction of CD4+ T-cells is associated with 
damage to the mucosal epithelium. Subsequently, commensal organisms 
gain entry to the MALT where the presence of bacterial lipopolysaccharides 
(LPS) triggers an inflammatory immune response (Forsman and Weiss, 
2008). In response to this, the peripheral viral load begins to increase. 
HIV infection causes CD4+ T-cell destruction both directly, from cellular virus 
infection, and via the adaptive immune response. Immune activation is also 
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elevated by bystander effects including activation and apoptosis of 
neighbouring, uninfected CD4+ T-cells, and translocation of microbial LPS 
across damaged mucosa. Consequently, dissemination of virus particles into 
the blood results in extensive, systemic viremia. The humoral immune 
response is activated in response to the copious number of infected CD4+ T-
cells circulating in the blood (Coffin, J.M., 1995). The immune system begins 
to clear the infection by producing HIV-specific, CD8+ cytotoxic T-cells which 
kill virus-infected cells via antibody cytotoxicity (Forsman and Weiss, 2008). 
Innate immunity also has a role in clearing viral infection through the 
complement system, which causes opsonisation and destruction of viral 
particles. Viral destruction of target cells may result in insufficient CD4+ T-cell 
levels for continued viral replication. Additionally, impairment of thymic 
function prevents T-cells from regenerating, preventing sustainance of T-cell 
reservoirs and replacement of destroyed CD4+ T-cells (Forsman and Weiss, 
2008). Thus, at this stage, further viral replication is hindered and viral load 
begins to decrease.  
1.2.4.2 Latency and asymptomatic infection 
The subsequent decline in the level of circulating virus marks the onset of 
asymptomatic infection, during which few or no apparent symptoms are 
observed, before the final stage of HIV infection emerges in the form of AIDS. 
During asymptomatic infection, although cellular and integrated proviral 
levels are similar for both HIV-1 and HIV-2, HIV-1 viral mRNA levels are 
higher and the HIV-1 plasma viral load is up to 30 times greater than HIV-2 
(de Silva et al., 2008). Despite the lack of outward symptoms, the period of 
clinical latency conceals a dynamic phase of virus replication. The average 
lifespan of a HIV infected cell is 2.2 days and plasma virions have a lifespan 
of 0.3 days. In vivo, the minimum HIV-1 life cycle lasts an average of 2.2 
days with a generation time (from the release of virus particles, subsequent 
infection of a new host cell and the release of further viral progeny from that 
cell) of 2.6 days. During a productive infection, individuals produce daily an 
average of 10.3 x 109 virions via continuing replication in CD4+ T-cells. 
(Perelson et al., 1996). Consequently, there is a high level of infected CD4+ 
T-cell turnover; low levels of virus are constantly produced by replication and 
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removed by the host immune response (Coffin, J.M., 1995). However, 
initially, the immune system is able to regenerate at a sufficient rate to 
maintain the level of CD4+ T-cells. 
It may take up to 10 years for progression to AIDS. Individuals failing to 
progress to AIDS within 15 years are called long term non-progressors 
(LTNPs) (Forsman and Weiss, 2008). With an incubation period spanning 
months or years, the mechanisms of HIV infection are therefore the antithesis 
of those used by viruses causing acute disease (Narayan and Clements, 
1989). This is reflected by recovery failure in HIV infected individuals. 
Individuals infected with HIV-2 often undergo a longer period of clinical 
latency and progress more slowly to AIDS. This is represented by a reduced 
viral load during asymptomatic stages of infection (Chen, Z. et al., 1997). 
Consequently, the rate of mortality for HIV-2 infected patients is only 1/3 of 
the rate for HIV-1 (Reeves and Doms, 2002). Additionally, not all HIV-2 
infections progress to AIDS (Poulsen et al., 1997). However, once the onset 
of AIDS occurs, viral load, disease progression and the outcome of HIV-1/2 
infection are comparable (Reeves and Doms, 2002). 
During a HIV infection around 109 CD4+ T-cells are destroyed and 
replenished daily. This puts a substantial strain on the host immune system 
to compensate for the huge CD4+ T-cell turnover. Following such a long 
period of intense cell turnover and replacement, the body’s ability to mount 
an immune response is strained and slowly eroded (Coffin, J.M., 1995). 
Eventually, persistent T-cell activation depletes the reserves of naïve and 
memory CD4+ T-cell pools such that the the number of CD4+ T-cells in the 
host steadily decline [blue line, figure 4] (Brenchley et al., 2006). The 
regenerative capacity of the host immune response cannot continue 
indefinitely and immune reserves can no longer compensate for the mass 
destruction of CD4+ T-cells (Ho et al., 1995). It is this slow, continual erosion, 
rather than a pinnacle event, which results in the inevitable collapse of the 
immune system. Failure to mount an appropriate immune response coincides 
with a peak in viremia [red line, figure 4]; opportunistic infections persist and 
an accumulation of infections and disease syndromes indicative of 
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immunodeficiency are recognisable. Thus the clinical features of AIDS 
commence.  
1.2.4.3 Symptomatic infection and AIDS  
Human immunodeficiency virus causes a chronic and progressive disease 
culminating in the onset of clinical AIDS, cachexia (wasting) and, ultimately, 
death (Narayan and Clements, 1989). The progression of an HIV infection is 
measured by monitoring both the patient’s viral load and CD4+ T-cell count. 
AIDS is defined as a CD4+ T-cell count of less than 200 cells/μl (Forsman 
and Weiss, 2008).  
Clinical features such as weight loss are the most overt sign of HIV infection. 
HIV infection of cells in the central nervous system may result in dementia, 
seen in some AIDS patients. HIV can infect microglial cells and infiltration of 
the brain can occur via infected macrophages (Forsman and Weiss, 2008). 
AIDS deaths usually result from opportunistic infection due to a compromised 
immune system. Both virus infection and treatment, particularly with 
immunosuppressive anti-viral drugs for transplant patients, weaken host 
immunity such that candida, CMV (cytomegalovirus), pneumocystis, and 
tuberculosis infection are common amongst AIDS sufferers (Forsman and 
Weiss, 2008). Abnormal cellular proliferation is often seen in AIDS patients 
and oncogenic diseases such as cervical carcinoma, Kaposi’s sarcoma and 
non-Hodgkin’s lymphoma can result from re-emerging infection caused by 
resident viruses which are no longer under the control of the host immune 
system (Forsman and Weiss, 2008). 
1.2.5 AIDS Therapy 
Resolving the HIV epidemic is hindered by the lack of an adequate vaccine 
or effective therapeutic interventions. However, reducing the risk of 
transmission can be achieved through measures such as screening blood 
donors, practising safe sex and testing for HIV. Infectious particles can be 
inactivated by detergents which disrupt the viral lipid envelope, preventing 
fusion with host cells (WHO, 2009). Therefore, simple precautions and 
education on transmission prevention may extend a long way towards 
reducing the global impact of HIV. 
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The use of highly active antiretroviral therapy (HAART) is effective at 
prolonging the longevity of HIV infected individuals although the effectiveness 
of this treatment is challenged by the development of resistance to antiviral 
drugs (Bousquet et al., 2008; Venkat et al., 2008). The best prospect for 
combating HIV, therefore, lies in research and education. Further 
understanding of the way in which HIV replicates will provide better 
information about how this virus functions, thus enhancing the prospect of 
producing a therapeutic remedy or vaccine to combat HIV. 
1.2.5.1 AIDS therapy: vaccination 
At present, there is no vaccine offering total protection against HIV infection. 
Likewise, knowledge of both host and viral factors conferring protection 
against HIV infection and disease is currently lacking. Infection with HIV-2 
does not confer protection from infection with HIV-1 (de Silva et al., 2008). 
HIV-2 infection cannot thus be viewed as a mechanism of protecting against 
infection with the more rapidly progressing HIV-1 virus. However, vaccines 
designed against the HIV-2 virus may provide a proof of concept for HIV-1 
vaccine development (de Silva et al., 2008). The provision of considerable 
resources and funding to develop either prophylactic or therapeutic vaccines 
demonstrates the magnitude of the global HIV burden and the importance of 
therapeutic developments to ease this burden.  
Primary strategies for combating the virus focus on preventing viral-mediated 
destruction of immune cells, rather than enhancing lymphocyte regeneration. 
However, visna-maedi, like HIV, is a lentivirus which causes chronic 
pulmonary disease (maedi) and brain disease (visna) in sheep. Infection 
progression with visna-maedi virus is similar to that observed during AIDS; 
most notably disease of the central nervous system and wasting syndromes. 
However, the visna-maedi virus only infects dendritic cells and macrophages. 
It is likely that CD4+ T-lymphocyte infection by HIV is an additional 
emergence through adaption to CD4 receptor usage. Therefore, it is 
unknown whether combating immunodeficiency caused by CD4+ T-cell 
depletion will prove sufficient to halt the progression of HIV infection to AIDS 
(Forsman and Weiss, 2008).  
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Irrespective of the prospects of curing AIDS, current progress in slowing the 
process which links HIV infection to AIDS has provided significant benefit to 
patients (Ho et al., 1995). Likewise, the related social and economic benefits 
of a prolonged life for HIV sufferers in countries where HIV is endemic are 
irrefutable.  
There are several routes for potential vaccine therapy. In an ideal situation, a 
HIV vaccine would induce sterilizing immunity, conferring complete protection 
against HIV infection and thus halting transmission. As an alternative, HIV 
vaccination could promote transient infection, whereby infection occurs but 
the host immune system, as a result of vaccination, is equipped to deal with 
the infection and remove it. Vaccination could, alternatively, permit control of 
long-term infection resulting in undetectable HIV levels, no harmful decline of 
CD4+ T-cells and a reduced transmission rate. Despite some failures, several 
vaccine candidates look promising. The GeoVax HIV-1 vaccine 
(http://www.geovax.com) targeting HIV-1 subtypes A, B and C (group M) has 
been shown to induce a strong cellular and humoral immune response in 
primates and is, therefore, currently undergoing stage II clinical trials to 
assess its suitability for use as a human vaccine. Additionally, the RV 144 
vaccine, developed by Sanofi Pasteur (http://www.sanofipasteur.com), has 
shown promising results in phase III clinical trials in Thailand, lowering the 
rate of HIV infection by 31.2% compared to a placebo control (Rerks-Ngarm 
et al., 2009). This priming ALVAC® HIV and boosting AIDSVAX® B/E 
combination vaccine provides the first evidence that a HIV vaccine is 
feasible. Further developmental work is ongoing before this product will be 
suitable for licensing and global use (Ledford, 2008).  
1.2.5.2 AIDS therapy: drug development 
Despite vaccine difficulties, the last 25 years have seen enormous progress 
in the treatment of HIV. Whereas HIV was once thought to be an essentially 
untreatable retroviral disease, it is now recognised that HIV is susceptible to 
several antiviral agents. HIV patients have witnessed a reduction in the death 
rate associated with infection and, additionally, both an enhanced quality and 
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length of life attributed to long-term management of the virus via antiretroviral 
therapy (Broder, 2010).  
25 therapeutic agents are now available for the treatment of HIV (de 
Béthune, 2010) [table 1]. These are predominantly orally administered. 
Currently, antiretroviral drugs mainly target enzymatic products of the HIV pol 
gene: RT (Reverse transcriptase), IN (Integrase) and PR (Protease) (Broder, 
2010).  
Drug class # 
Protease inhibitor [PI] 10 
Nucleoside (nucleotide) RT inhibitor [N(t)RTI] 8 
Non-nucleoside RT inhibitor [NNRTI] 4 
Integrase inhibitor 1 
Fusion inhibitor 1 
CCR5 inhibitor 1 
 
Table 1: The number of HIV drugs in each class approved for use by HIV patients. 
HAART therapy recommends combining several classes of drugs from the 25 
therapeutic agents currently available (de Béthune, 2010). 
Two main classes of HIV drug target the viral RT; nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTIs/N(t)RTIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) (Haubrich et al., 2008). The first HIV 
antiretroviral agent, Zidovudine (3-azido-2-3-dideoxythymidine, AZT), was a 
nucleoside reverse transcriptase inhibitor (NRTI) approved for use in 1987 
(de Béthune, 2010). NRTIs inhibit the reverse transcription step of HIV 
replication: copying viral single-stranded RNA (ssRNA) into double-stranded 
DNA (dsDNA) prior to integration. NRTIs are functional analogues of 
deoxynucleotides lacking a 3’ OH group. They competitively inhibit DNA 
synthesis by incorporating into the nascent DNA and, instead of extending 
the DNA chain by formation of a phosphodiester bond, inducing chain 
termination. Combination therapy still uses AZT and other NRTIs such as 
didanosine (Broder, 2010). Alternatively, NNRTIs directly block virally 
encoded RT by binding to an allosteric site on RT and disrupting catalytic 
activity (Haubrich et al., 2008). 
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It is recommended that HIV is treated with a combination of three 
antiretroviral drugs. This is called highly active antiretroviral therapy (HAART) 
(Daugas et al., 2005). Drug treatment regimes typically include treatment with 
two NRTIs and either a PI (Protease inhibitor) or an NNRTI [table 2] 
(Haubrich et al., 2008). 
Drug Target Brand Generic Names Manufacturer Date 
Nucleoside 
Reverse 
Transcriptase 
Inhibitors (NRTIs) 
Retrovir 
 
 
Epivir 
Epzicom 
Zidovudine, 
azidothymidine, AZT, 
ZDV 
Lamivudine, 3TC 
Abacavir, lamivudine 
GSK 
 
 
GSK 
GSK 
1987 
 
 
1995 
2004 
Non-Nucleoside 
Reverse 
Transcriptase 
Inhibitors 
(NNRTIs) 
Viramune 
 
Intelence 
Nevirapine, NVP 
 
Etravirine 
Boehringer 
Ingelheim 
Tibotec 
Therapeutics 
1996 
 
2008 
Protease Inhibitors 
(PIs) 
Invirase 
 
Crixivan 
Prezista 
Saquinavir mesylate, 
SQV 
Indinavir, IDV 
Darunavir 
Hoffman-La 
Roche 
Merck 
Tibotec, Inc. 
1995 
 
1996 
2006 
Fusion Inhibitors Fuzeon Enfuvirtide, T-20 Hoffman-La 
Roche & 
Trimeris 
2003 
Entry Inhibitors 
(CCR5 
antagonists) 
Selzentry Maraviroc Pfizer 2007 
HIV Integrase 
Strand Transfer 
Inhibitors 
Isentress Raltegravir Merck & Co. 2007 
Multi-class 
Combination 
Products 
Atripla Efavirenz, emtricitabine, 
tenofovir disoproxil 
fumarate 
Bristol-Myers 
Squibb & 
Gilead 
Sciences 
2006 
 
Table 2: Some of the HIV-1 antiretroviral products used in single or combination 
therapy (Broder, 2010). 
HAART results in a reduction in viral load. Secondary benefits of HAART 
include a reduction in HIV transmission associated with a lower viral load 
(Montaner et al., 2010). Therapy has been shown to have an astonishing 
effect on patients such as reversing neurological symptoms and brain 
abnormalities. Drastic improvements in patient focus, memory and 
coordination have also been observed (Broder, 2010). It is now projected 
that, with appropriate therapy, a person infected with HIV at the age of 20 
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may live to 60 years or more, unless they develop resistance to multiple 
drugs (The Antiretroviral Therapy Cohort Collaboration, 2008). 
1.2.5.3 AIDS therapy: drug resistance 
HIV demonstrates a spectacular capacity to adapt to antiretroviral therapy; 
wild-type HIV strains are rapidly replaced by drug-resistant strains within 14-
28 days (Wei et al., 1995). Treatment with antiretroviral drugs results in an 
increase in circulating CD4+ T-cells. However, a rising level of mutant 
genomes and a decline in drug susceptibility coincide with a decrease in 
CD4+ T-cells back to pre-therapy levels (Coffin, J.M., 1995). The number of 
replicative cycles occuring within an HIV infected individual is extraordinarily 
high and presents a unique feature of HIV infection (Coffin, J.M., 1995). 
Furthermore, the virus exhibits an unusually high rate of mutation. Each HIV 
nucleotide exhibits a mutation rate of between 10-4-10-5 per replication cycle. 
Subsequently, during infection, a single position within the HIV genome is 
subject to 104-105 point mutations per day (Coffin, J.M., 1995; Perelson et al., 
1996). Consequently, both of these features give rise to a large amount of 
genetic variation. Whilst most mutations may prove deleterious to the virus, 
or have little effect on inducing protection to antiviral therapy, only one 
escape mutant is necessary to promote resistant viral replication and thereby 
confer drug resistance (Coffin, J.M., 1995). HIV mutants existing in numerous 
combinations present a pre-existing barrier to antiviral therapy and it is likely 
that the presence of mutants in an HIV infected individual predate the 
introduction of antiretroviral drugs and emerge once treatment is initiated 
(Coffin, J.M., 1995).  
Early treatment to block viral replication is therefore important in order to 
avoid the establishment of a reservoir of HIV mutants with the capacity for 
drug resistance (Coffin, J.M., 1995). However, it is often difficult to intervene 
immediately after exposure to HIV as the generic nature or lack of early stage 
symptoms often prevents easy recognition of the virus. However, hope 
remains as HIV mutants, albeit resistant to therapeutic interventions, are 
likely to be more defective at replicating than wild type virus. Therefore any 
mutations upheld within the emerging virus population are likely to be 
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detrimental to its infective capacity. Subsequently, it may be that the most 
effective compounds to treat HIV are not those which directly target the wild 
type virus, but instead, those therapies which cause the only escape mutants 
emerging to be severely crippled in function (Coffin, J.M., 1995). In the case 
of the HIV virus, effective treatment cannot result from antiviral agents which 
are overcome by resistance resulting from a single point mutation. Rather, 
effective therapy must elude viral resistance by necessitating multiple, 
simultaneous viral mutations (Perelson et al., 1996). The concurrent use of 
numerous antiviral agents against multiple HIV targets thus presents the 
contemporary approach to regulating HIV infection.  
Currently, mutants showing resistance to all therapeutic compounds have 
been identified and are thus now deemed to be an inevitable artefact of 
antiretroviral therapy (Coffin, J.M., 1995). The wild type HIV-2 virus has 
demonstrated resistance to Selzentry: currently the only entry inhibitor 
available. However, HIV-2 still shows susceptibility to newly developed 
Integrase inhibitors (de Silva et al., 2008). Likewise, Etravirine (an NNRTI) is 
a promising drug candidate to control HIV infection as it presents a difficult 
genetic challenge for the development of virus resistance [figure 5] (Broder, 
2010). Trials are also currently underway to investigate whether drugs can be 
administered as a pre-exposure prophylaxis (PrEP) (Broder, 2010). 
    
The challenges remaining in combating HIV are numerous and varied. In the 
long term, eradicating HIV may prove difficult due to the presence of HIV 
reservoirs. These include; latently infected memory T-cells, where the virus 
remains inactive and non-productive; chronically producing cells, which have 
Figure 5: Etravirine: presenting a 
high genetic barrier for the 
emergence of resistant HIV strains 
[http://www.ask.com/wiki/Etravirine]. 
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an extended life-span and therefore release virus for long periods of time; 
and cells infected with defective provirus, which are not recognised by the 
immune system as they do not produce either active virus or viral 
components eliciting an immune response. HIV reservoirs not only facilitate 
evasion of the immune response, they also provide a source of former viral 
genotypes allowing infection to persevere in spite of antiviral interventions 
(Coffin, J.M., 1995). Integrated provirus may remain latent and re-emerge to 
cause infection when treatment is interrupted or discontinued. A better 
understanding of viral latency and the mechanisms by which it is established 
and maintained will be required before the lifelong treatment of HIV patients 
is no longer a necessity (Marcello, 2006).  
Administering effective therapy is also hindered in developing countries by 
obstacles such as high prevalence, lack of access to drugs, cost, 
sustainability and poor infrastructure (Broder, 2010). The need for life-long 
therapy, drug associated toxicity and the inadvertent side-effects of treatment 
also generate a complex situation for HIV sufferers. Additionally, factors such 
as; high viral genetic variation, the emergence of drug resistance and the 
potential for new cross-species events to facilitate the transmission of viruses 
from previously unrecognised retroviral reservoirs into humans, all pose a 
threat to the future control and containment of HIV. These challenges will all 
have to be addressed before the control and potential eradication of HIV are 
a possibility. 
1.3 The HIV life cycle 
1.3.1 The viral particle 
HIV particles are predominantly spherical in shape, with a distinctive cone-
shaped core [figure 6b]. Although the diameter of each virus particle can vary 
from 106-183 nm, the overall structures are analogous (Briggs et al., 2006). 
The particle core is comprised of 1000-1500 Capsid proteins assembled into 
a hexameric lattice (Chen, J. et al., 2008). It encloses two copies of the RNA 
viral genome bound to Nucleocapsid proteins in a ribonucleoprotein complex, 
and viral enzymes Reverse transcriptase and Integrase [figure 6a] (Lever, 
2005). Numerous cellular proteins such as APOBEC3G and Cyclophilin A are 
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also found within the viral core (Arhel, 2010). A lipid bilayer, underlined by a 
shell of Matrix proteins, surrounds the core and the viral Protease enzymes 
(Cannon et al., 1997). The lipid bilayer encompasses transmembrane 
envelope proteins which anchor the exterior surface envelope proteins 
(Kwong et al., 1998; Sleasman and Goodenow, 2003). The complete viral 
particle comprises 35% lipid, 65% protein and 1-2% RNA (Coffin, J.M. et al., 
1997). 
 
(A)      (B) 
Figure 6: Retrovirus particle showing assembled Gag proteins (Matrix, Capsid and 
Nucleocapsid), Pol enzymes (Reverse transcriptase, Integrase and Protease) and Env 
proteins (transmembrane and surface Envelope) (A) [adapted from (Freed, 2001)]. A 
transmission electron micrograph of HIV (B) [http://www.profimedia.si/picture/aids-
virus-tem/0041375286/]. 
1.3.2 The HIV genome and viral proteins 
The HIV positive-sense, ssRNA genome is roughly 9.3kb in length, has a 5’ 
cap and 3’ polyadenylation, and exists as a non-covalent dimer (Jacob and 
DeStefano, 2008). A total of 15 viral proteins are encoded by nine open 
reading frames within the virus genome (Briggs et al., 2006). There are three 
principal open reading frames; ‘gag’ encoding structural proteins Matrix (MA), 
Capsid (CA) and Nucleocapsid (NC) and smaller peptides: Sp1, Sp2, p6; 
‘env’ encoding Envelope proteins (TM and SU); and ‘pol’ encoding viral 
enzymes: Protease (PR), Integrase (IN) and Reverse transcriptase (RT) 
(Sleasman and Goodenow, 2003). Six smaller accessory genes; nef, vpu, 
vpr, vif, tat and rev (Lever, 2005) are also encoded by the HIV genome, 
which is flanked by long terminal repeats (LTRs) (Marcello et al., 2004). The 
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viral 5’ LTR contains an RNA packaging signal (ψ) and a trans-activation 
response (TAR) element (Lawrence et al., 2003; Ricci et al., 2008) [figure 7]. 
 
 
 
Figure 7: The HIV genome showing gag, pol and env open reading frames and smaller 
accessory genes; vif, vpr, vpu, tat, rev and nef. The structural proteins MA, CA and NC 
in addition to smaller peptides Sp1, Sp2 and p6 encoded by gag are also shown 
[adapted from (Freed, 2001)].  
The HIV genome exhibits a high level of RNA structure (discussed further in 
Chapter 4) which plays a role in several stages of the virus life cycle such as 
initiating reverse transcription, altering reading frame usage, modulating RNA 
export from the nucleus, dimerization of the genome and viral packaging. 
Protein activity is also modulated by the structure of HIV RNA. Protein 
junctions are encoded by regions of highly-structured RNA which cause the 
ribosome to slow or pause during elongation. This provides time for the 
nascent protein to fold as it is translated; thus the RNA structure also 
provides a means of managing protein expression. Additionally, there are a 
large number of interactions between the HIV genome and both host and 
viral proteins (discussed further in Chapter 5) which serve to regulate viral 
gene expression  (Watts et al., 2009). 
1.3.3 Binding/entry 
The start of the HIV life cycle is marked by binding of virus particles to target 
cells [figure 8].  
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Figure 8: The HIV replication cycle showing stages of the viral life cycle from binding, 
fusion, proviral integration, transcription, translation, assembly and budding through 
to maturation. 
Multiple viral and cellular protein interactions occur during the stages of 
binding and entry. Binding is initiated by the two Env glycoproteins: gp120 
(surface subunit, SU) and gp41 (transmembrane subunit, TM) which bind to 
each other non-covalently, and form a trimeric spike structure on the surface 
of virions (Chan and Kim, 1998). Gp120 binds to the primary HIV receptor 
CD4 (a co-receptor of MHC II) present on the surface of target cells such as 
T-cells or macrophages (Chan and Kim, 1998). The CD4 receptor consists of 
four immunoglobulin-like domains; HIV gp120 binds to the amino-terminal 
domain (Kwong et al., 1998). Enhanced binding is provided by viral co-
receptors: the chemokine receptors CXCR4 and CCR5 [figure 9] (Sleasman 
and Goodenow, 2003).  
Binding of the Env surface subunit induces a conformational change in the 
shape of gp120/gp41 revealing a highly conserved fusion peptide at the N-
terminus ectodomain of gp41. The fusion peptide adopts an extended 
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conformation and elicits fusion by inserting into the host cell lipid bilayer 
(Chan and Kim, 1998). Folding of the N-terminus ectodomain into a bundle of 
six helices brings the virus and host membranes into alignment (Freed, 
2001). Subsequent fusion occurs with the viral membrane merging with the 
target cell membrane. The contents of the viral particle are consequently 
exposed, resulting in the release of the viral core into the cell cytoplasm. 
  
Figure 9: Binding of HIV to host cells is mediated by the viral gp120 receptor 
interacting with CD4 on the surface of target cells. Viral co-receptors CCR5 and 
CXCR4 enhance virus binding. Fusion with the host cell is promoted by an extended 
conformation of the fusion peptide within the viral envelope. Following fusion, the 
viral core is released into the host cell cytoplasm [Image: 
https://dokuwiki.noctrl.edu/doku.php?id=bio:440:hiv_-_group_1#retrovirus_ 
replication]. 
1.3.4 Uncoating 
Following entry, the viral core is uncoated by disassembly of Capsid proteins. 
Little is known about the mechanism of uncoating, although there is evidence 
to suggest that this stage is cell-cycle dependent. In particular, cellular 
factors activated during the G0-G1 transition of the cell cycle have been 
shown to be specifically required for uncoating (Auewarakul et al., 2005). 
Likewise, the exact cellular location of uncoating remains contentious; it is 
believed that this event occurs post-entry to the cytoplasm but pre-nuclear 
import. Viral uncoating may be promoted by the change in environment 
experienced by viral cores released into the cell cytoplasm. Alternatively, the 
loss of high concentrations of loose Capsid proteins, which are present in the 
viral particle and contribute to core stability, may trigger uncoating. Timing is 
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an essential feature of viral uncoating; HIV particles which undergo 
premature core disassembly cannot undertake reverse transcription. 
Likewise virus particles containing Capsid mutants with enhanced or 
diminished stability show compromised infectivity. This indicates that both the 
stability of the HIV core and the timing of uncoating are important during the 
early stages of infection (Arhel, 2010). Uncoating of the viral core releases a 
reverse transcription complex (RTC) consisting of Nucleocapsid proteins, 
Integrase and Reverse transcriptase enzymes, and the accessory protein Vpr 
(Arhel, 2010; Freed, 2001).The nucleoprotein RTC promotes reverse 
transcription of the viral positive-sense ssRNA genome into dsDNA. 
1.3.5 Reverse transcription 
HIV genomic RNA is reverse transcribed into dsDNA; a defining 
characteristic of retroviral infection (Lever, 2005). Viral Reverse transcriptase 
is an RNA- and DNA-dependent polymerase which catalyses this process 
(Isel et al., 2010). HIV RT is a heterodimer composed of two similar subunits; 
p51 (51 kDa) and p66 (66 kDa). HIV Protease removes a 15 kDa (RNaseH) 
domain from p66 to produce p51 [figure 10]. Although the two RT subunits 
are similar in terms of protein content, the conformations they assume are 
very different (Freed, 2001). 
     
Retroviruses are unique in that the virus particles contain diploid genomes. 
This allows recombination events to feature as part of viral replication. During 
a process termed copy choice, the RT enzyme is able to switch between the 
Figure 10: Structure of the HIV Reverse 
transcriptase heterodimer showing 
subunits p51 and p66 (including RNaseH) 
(Cameron et al., 1997). 
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two HIV genomic RNA templates. Genetic recombination may thus result if 
the two genomic sequences are divergent (Ramirez et al., 2008). Moreover, 
the high error rate of HIV RT contributes to mutations which enhance the 
genetic variability of HIV virions (Mansky and Temin, 1995).  
The process of reverse transcription is a multi-step process including two 
strand transfer events and several stages of RNaseH digestion [figure 11]. 
 
Figure 11: Reverse transcription of HIV genomic ssRNA to produce dsDNA [Adapted 
from (Sarafianos et al., 2001)].  
Reverse transcription is initiated by priming of the 5’ end of the HIV RNA with 
cellular tRNALys, which is packaged into virions [figure 11A] (Isel et al., 2010). 
Initiation takes place at a location within the HIV 5’ UTR called the primer 
binding site (PBS). 5’ to 3’ DNA synthesis produces a hybrid of viral RNA and 
newly synthesised DNA. RNaseH digests most of the RNA component of the 
RNA-DNA hybrid [figure 11B]. A section of DNA, complementary to the viral 
genome, remains and is referred to as minus (-) strand strong stop DNA 
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(Freed, 2001). First strand transfer of (-) strand strong stop DNA from the 5’ 
R region to the 3’ R region of genomic RNA occurs [figure 11C]. This is 
permitted by template homology (Basu et al., 2008). Subsequent (-) strand 
DNA synthesis, primed by (-) strand strong stop DNA, occurs in a 3’-5’ 
direction along the RNA template [figure 11D]. Following (-) strand synthesis, 
RNaseH degrades the RNA template. A small section of 3’ RNA within the 
polypurine tract (PPT) is resistant to RNaseH digestion [figure 11E]. This 3’ 
PPT RNA segment is able to prime synthesis of a plus (+) DNA strand using 
the (-) DNA strand as a template (Ramirez et al., 2008; Suzuki and Craigie, 
2007). HIV-1 has another, centrally located PPT (cPPT) region which acts as 
an additional primer of (+) strand DNA (Basu et al., 2008). (+) strand 
synthesis from the 3’ PPT to the 5’ end of (-) strand DNA produces (+) strand 
strong stop DNA [figure 11F], which undergoes second strand transfer to the 
3’ end of (-) strand DNA using homologous PBS regions. During this process, 
further degradation by RNaseH removes tRNALys and PPT [figure 11G]. 
Second strand transfer of (+) strand strong stop DNA to the 3’ end of (-) 
strand DNA primes second strand synthesis of (+) strand DNA [figure 11H]. 
Due to the complementarity of the DNA ends, circularisation occurs and DNA 
synthesis extends the 3’ ends to produce dsDNA flanked by long terminal 
repeats (LTRs) (Basu et al., 2008). As the central DNA synthesis termination 
site (CTS) is positioned 100 nucleotides 3’ of the cPPT, an excess of (+) 
strand DNA is produced. This central section of DNA is important for 
transport of dsDNA to the nucleus (Freed, 2001). The reverse transcription of 
genomic ssRNA, and subsequent integration of viral dsDNA into the host cell 
chromosome, is a defining feature of retroviral replication. 
1.3.6 Nuclear targeting/integration 
Following synthesis of full-length dsDNA (now termed proviral DNA) a pre-
integration complex (PIC) is formed (Arhel, 2010). The PIC functions to target 
proviral DNA to the nucleus and facilitate its integration into the host cell 
genome. Both cellular and viral factors contribute to PIC formation (Miller et 
al., 1997; Popov et al., 1998). Specific sequences within the cPPT region of 
viral DNA are involved in nuclear import through binding to Integrase proteins 
within the PIC (Schröder et al., 2002). Viral proteins Vpr and MA contribute to 
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PIC formation whilst RT has also been shown to co-localize to the PIC [figure 
12] (Miller et al., 1997). The mechanism by which the PIC migrates to the 
nucleus remains unclear, although it has been shown that the Vpr protein 
contains a nuclear localisation signal (NLS) which may aid this transport 
(Fouchier et al., 1998). 
 
Figure 12: The HIV pre-integration complex (PIC), composed of Matrix (MA), Vpr, 
Integrase (IN) and the central polypurine tract (cPPT) region of viral DNA, assists 
transport of dsDNA through the nuclear pore complex (NPC). The importin pathway is 
implicated in transport of the PIC from the cytoplasm to the nucleus [Adapted from 
(Suzuki and Craigie, 2007)]. 
Once in the nucleus, proviral dsDNA is integrated into host DNA; viral 
Integrase plays a key role in this process. Two activities are catalysed by 
Integrase; the 3’ processing of viral DNA and DNA strand transfer 
(integration) (Savarino, 2007). During the first stage of integration, Integrase 
catalyses the removal of two nucleotides from the 3’ end of each provirus 
DNA strand (Craigie, 2001; Shun et al., 2007). Terminal nucleotide cleavage 
exposes 3’ hydroxyl groups at each end of the viral DNA (Miller et al., 1997). 
3’ processing of viral DNA can take place soon after reverse transcription and 
before nuclear entry, when Integrase binds to both ends of newly transcribed 
DNA as part of the PIC (Savarino, 2007; Shun et al., 2007). 
After nuclear entry, the second stage of integration, termed DNA strand 
transfer, involves insertion of the viral DNA strand into host DNA [figure 13] 
(Craigie, 2001). Integrase cuts the host cell genome producing staggered 
ends 5 base pairs apart on the target DNA (Craigie, 2001; Shun et al., 2007). 
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The 3’ OH provirus ends form phosphodiester bonds with the exposed 5’ 
phosphates of the cut host DNA (Shun et al., 2007). During a repair process, 
likely undertaken by cellular repair enzymes, the two unpaired nucleotides at 
each end of the proviral DNA are removed, the five nucleotide gap adjoining 
each proviral DNA/host DNA junction is filled and ligation of the provirus into 
the target DNA is achieved (Savarino, 2007). The nuclear protein 
LEDGF/p75 regulates the activity of viral Integrase by tethering it to 
chromatin and preventing its degradation. Reducing the Integrase binding 
capacity of LEDGF/p75 inhibits viral replication (Poeschla, 2008). 
 
Figure 13: HIV integration of dsDNA provirus (A). During the first stage of integration, 
3’ processing of viral DNA occurs via viral integrase (B). Strand transfer is catalysed 
by viral Integrase to integrate proviral DNA into the host chromosome (C). DNA repair 
is undertaken by cellular enzymes to remove unpaired nucleotides (D), fill in 
nucleotide gaps and complete ligation of provirus into the host genome (E). [Adapted 
from (Savarino, 2007)]. 
There is little specificity as to the site of provirus integration which can, 
essentially, occur at any location within the host chromosome. However, 
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evidence suggests that integration may be favoured at gene-rich areas within 
target DNA and, in particular, at the site of actively transcribing genes (Lever, 
2005; Mitchell et al., 2004; Schröder et al., 2002). Retroviral vectors capable 
of inserting genes directly into the host genome of target cells are potentially 
a powerful tool for therapeutic intervention. However, retroviral integrations 
near transcriptional start sites can disrupt or enhance the normal levels of 
cellular transcription. This may lead to oncogenesis and thus poses a barrier 
to the success of retroviral gene therapy (Ambrosi et al., 2008). 
1.3.7 Dormancy and reactivation 
The human genome contains evidence of ancient integration events and a 
substantial proportion of the human genome consists of endogenous 
retroviruses or retroviral elements. This characteristic of retroviruses 
contributes to the dormancy evidenced in HIV infected patients. Following 
integration of the HIV provirus, the virus may remain dormant within the cell 
until an activation event occurs.  
Latency can result from integration into quiescent or non-dividing cells where 
transcription factors, needed to promote viral transcription, are at a low level 
(Mok and Lever, 2007). Dormant HIV provirus provides a viral reservoir, 
protected from clearance by the host immune response and immune to the 
effects of antiretroviral therapy. Thus latency presents a significant obstacle 
in curing HIV patients as seemingly virus-free individuals may relapse years 
later when undetected, latent virus is reactivated. The mechanism of HIV 
dormancy remains unclear, although the local environment and the site of 
provirus integration may be contributing factors (Mok and Lever, 2007). 
Recruitment of cellular proteins HDAC-1 (histone deacetylase type 1), HP1 
(heterochromatin protein 1) and Suv39H1 (histone methyltransferase) to 
chromatin surrounding the HIV LTR can also promote latency (Blazkova et 
al., 2009). Alternatively, methylation of DNA at cytosine-phosphate-guanine 
(CpG) sites within the HIV LTR has been shown to suppress HIV 
transcription and regulate reactivation (Blazkova et al., 2009).  
Reactivation of integrated viral genes can occur spontaneously, or activation 
may be triggered by chemical or physical stimuli (Leib-Mösch et al., 1990). 
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Likewise, T-cell activation signals, cellular NFкB, proinflammatory cytokines 
and viral Tat can promote reactivation. The HIV-1 promoter within the LTR 
contains numerous binding sites for transcription factors such as NFкB. Thus 
a complex and diverse regulatory network may be involved in the activation 
of provirus transcription (Yang et al., 2009). Blocking NFкB induction can 
prevent reactivation and, furthermore, silence LTR-driven transcription of HIV 
provirus (Blazkova et al., 2009).  
During activation, Tat also functions in a positive feedback loop [figure 14] to 
drive provirus transcription and establish stable transcription of viral genes. 
Tat may therefore be an evolutionary development designed to enhance the 
virus’ ability to counteract gene silencing. Consequently, the timely alignment 
of several factors either promotes entry of the virus into latency or, 
alternatively, permits reactivation (Mok and Lever, 2007). 
 
 
Figure 14: The Tat feedback loop: transcribed mRNA encoding Tat is exported to the 
cytoplasm; translated Tat shuttles back to the nucleus where it enhances viral 
transcription (Karn, 1999). 
Irrespective of how latency is achieved and established, once integrated into 
the host genome the provirus is an established artefact of the host cell. In this 
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way, HIV hijacks the host cell and proviral genes utilise the same cellular 
transcription machinery as normal, cellular genes to produce viral mRNAs. 
1.3.8 HIV Gene expression 
1.3.8.1 HIV transcription 
Transcription of proviral DNA occurs alongside cellular genes and therefore 
RNA polymerase II and the same host transcriptional machinery are required 
(Sleasman and Goodenow, 2003). The HIV LTR directs the production of 
viral mRNA by enhancing and promoting transcription (Mok and Lever, 
2007). Alike to cellular mRNA, viral RNA is capped and polyadenylated 
(Watts et al., 2009). The metabolic environment within the cell is influential to 
the rate of transcription as this process is reliant on cellular transcription 
factors; NFкB, NFAT, Sp1 and AP-1, which bind to the HIV LTR and regulate 
the activity of the HIV promoter (Wu, Y. and Marsh, 2003). T-cell activity is 
also promoted by these factors therefore activation of infected T-cells 
corresponds with the promotion of HIV transcription. HIV is unusual in that 
transcription may occur from both integrated and non-integrated DNA (Wu, Y. 
and Marsh, 2003). 
Transcription of HIV RNA is inefficient in the absence of Tat. Tat is one of the 
earliest viral proteins to be expressed (see below) and localises to the 
nucleus to trans-activate viral transcription. 
Spliced HIV-1 env mRNA is translated to produce Tat (trans-activator of 
transcription): a small 86-102 AA RNA-binding protein (Ponti et al., 2008). Tat 
binds to the trans-activation response (TAR) element at the 5’ end of the viral 
RNA, and enhances the level of transcription and gene expression. Cells 
over-expressing TAR RNA are more resistant to HIV-1 replication through 
sequestering viral Tat (Svitkin, Y.V et al., 1994).  
Tat binds specifically to the U-rich bulge within TAR; mutations in this region 
abolish Tat-activated transcription (Braddock et al., 1993). Cellular proteins, 
such as Tat-associated kinase (TAK) also bind to the TAR stem-loop (Coffin, 
J.M. et al., 1997). TAK is composed of a kinase component called CDK9 and 
a cyclin component: CyclinT1 [figure 15]. Conformational changes within Tat, 
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induced by CyclinT1, stabilise and enhance Tat interactions with TAR. 
Mutations in the TAR apical loop inhibit Tat activity, even though this region 
is not involved in Tat binding. This suggests that binding of cellular co-
factors, such as TAK, is essential for Tat activity (Braddock et al., 1993). 
 
 
 
During transcription initiation, the CDK7 kinase of initiation factor TFIIH 
activates RNA polymerase II by phosphorylating its carboxyl terminus domain 
(CTD). Tat stimulates additional phosphorylation via TAK; the protein kinase 
(CDK9) component of TAK hyper-phosphorylates the RNA polymerase II 
CTD [figure 16]. This enhances the activity of RNA polymerase II and allows 
efficient read through of RNA structure. Consequently, the presence of Tat 
effects more frequent RNA polymerase II binding to the HIV promoter and 
increased processivity. This results in an increased rate of transcription 
initiation and more efficient elongation. Furthermore, in the presence of Tat, a 
greater proportion of initiation events result in the production of full-length 
RNA. If Tat is absent, RNA polymerase frequently dissociates from template 
RNA resulting in truncated transcripts. Thus Tat imparts a significant 
contribution to HIV transcription (Karn, 1999). 
Figure 15: Recognition of HIV 
TAR RNA by viral Tat and TAK 
(CyclinT1 and CDK9) [adapted 
from  (Karn, 1999)]. 
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Figure 16: Activation of RNA polymerase II by cellular co-factors and viral Tat. RNA 
polymerase II is recruited to the HIV LTR for transcription initiation (A). The TFIIH 
CDK7 kinase phosphorylates the CTD of RNA polymerase II, which clears the 
promoter region and commences transcription of TAR (B). Nascent RNA, 
corresponding to TAR, folds and binds to RNA polymerase II. Tat binds to TAR RNA 
and forms a complex with TAK (C). Activated TAK kinase hyperphosphorylates the 
RNA polymerase II CTD; TAR is displaced from RNA polymerase II and transcription 
continues (D) [adapted from (Karn, 1999)]. 
1.3.8.2 Splicing 
Both nascent transcribed host and viral mRNA associate with numerous 
proteins that carry out processes such as capping, polyadenylation, the 
removal of introns by splicing and transport of mature transcripts to the 
cytosol. Transcription and splicing occur simultaneously therefore the 
removal of introns also progresses in a 5’-3’ direction (Bohne et al., 2005). 
Although transcription of provirus DNA generates a single RNA, more than 
40 HIV transcripts can be produced through alternative splicing (Madsen and 
Stoltzfus, 2006; Watts et al., 2009). 
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Figure 17: The HIV genome (A) and alignment of mRNAs to show the locations of 
known splice sites (B). Proteins produced from different splicing patterns are grouped 
by mRNA class with obligatory sequences represented by dark boxes and sequences 
produced by alternative splice sites usage shown by light boxes (C).  Export of 4 kb 
and 9 kb mRNAs requires the viral Rev protein. The reading frame usage to produce 
differing mRNAs is also indicated (D)  (Dimmock et al., 2001; Kammler et al., 2006). 
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HIV RNA undergoes a complex pattern of splicing to produce both Env RNA, 
with removed Gag and Pol coding regions, as well as several smaller 
proteins important in coordinating viral replication. Full-length HIV RNA 
contains 4 5’ splice donors (SD) and 8 3’ splice acceptors (SA) which 
contribute to the intricate splicing of HIV transcripts (Kammler et al., 2006; 
Purcell and Martin, 1993). Additionally, HIV transcripts contain several 
features which alter splicing efficacy. Suboptimal splice sites, not easily 
recognised by cellular splicing machinery, result in inefficient splicing. 
Likewise exonic splicing enhancers and both exonic and intronic splicing 
silencers interact with cellular proteins to induce or inhibit splicing of adjacent 
splice sites. Inefficient splicing increases the number of HIV transcripts 
available for translation by differential processing of nascent mRNA (Madsen 
and Stoltzfus, 2006). HIV RNAs can be singly-spliced (producing mRNAs that 
encode Env, Vif, Vpr, and Vpu), multiply-spliced (encoding Tat, Rev, and Nef) 
or unspliced (encoding Gag and Gag-Pol) (Asai et al., 2003). 
1.3.8.3 Nuclear export 
During replication, the expression of early genes and late genes requires 
temporal regulation to ensure that the correct levels of each viral protein are 
expressed at the required time. The export of viral mRNAs from the nucleus 
governs their temporal expression. Completely spliced RNAs are exported 
using the cellular mRNA export pathway. However, singly-spliced and 
unspliced RNA are retained in the nucleus due to the presence of introns 
which restrict their export (Li et al., 2006). Splicing of pre-mRNA and nuclear 
export are coupled events; recruitment of nuclear export factors such as Aly 
to the mRNA-protein splicing complex targets spliced transcripts for export 
(Luo et al., 2001). Therefore, in the absence of extenuating factors, intron-
containing mRNA cannot exit the nucleus and therefore splicing is a pre-
requisite for nascent mRNA export.  
Three early, regulatory proteins; Nef, Rev and Tat, are encoded by fully-
spliced HIV transcripts. Tat functions as a trans-activator of transcription 
through interactions with the TAR region of the HIV 5’ UTR (see above). Nef 
(negative regulatory factor) indirectly enhances transcription by promoting 
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transcription factors such as NFкB, NFAT and AP-1 (Wu, Y. and Marsh, 
2003). The transition from expression of early genes to late genes is 
controlled by an 18 kDa viral protein Rev (regulator of expression of viral 
proteins) (Pollard and Malim, 1998). Rev significantly contributes to the 
success of the viral life cycle through its role in regulating the transport of 
unspliced and singly spliced mRNA from the nucleus to the cytoplasm 
(Peterlin and Trono, 2003).  
The levels of Rev determine which transcripts are expressed, and the Rev-
RRE interaction (see below) alleviates the necessity for multiple pools of 
RNA by allowing temporal regulation of splicing (Purcell and Martin, 1993). In 
the absence of nuclear Rev, fully-spliced mRNA is able to undergo export 
directly. This favours expression of early, multiply-spliced gene products 
which encode regulatory proteins. However, in the presence of Rev, the rate 
of RNA export of singly-spliced and unspliced mRNAs is accelerated such 
that there is a limited time for splicing. Consequently, singly-spliced or 
unspliced transcripts encoding structural proteins are exported (Wu, Y. and 
Marsh, 2003). The export of unspliced transcripts requires the Rev/RRE 
pathway. Rev binds to the Rev responsive element (RRE) which is a large 
RNA structure within the env coding region of incompletely spliced, intron-
containing mRNA (Dayton, 2004; Pollard and Malim, 1998). The Rev protein 
is composed of two domains; an amino-terminus arginine rich domain (ARD) 
and a carboxyl terminus leucine-rich region containing a nuclear export signal 
(NES). The Rev ARD functions as both a nuclear localization signal (NLS) 
and an RNA-binding domain (RBD). Both of the Rev domains are involved in 
Rev-mediated export of viral mRNA [figure 18] (Pollard and Malim, 1998). 
A nuclear protein, Ran, regulates transport between the nucleus and 
cytoplasm (Seewald et al., 2002). In the nucleus, Ran-GDP is converted to 
Ran-GTP by Ran-guanine exchange factor (Ran-GEF). CRM-1 (sometime 
called exportin 1 or XPO1) binds to both Ran-GTP and to Rev via its NES. 
This enables RRE-containing viral mRNA to be exported from the nucleus by 
the CRM-1 complex. The DDX3 helicase binds to CRM-1 and helps to 
mediate mRNA export by unwinding RNA secondary structure, making it 
easier for mRNA cargo to pass through nuclear pores. Once exported to the 
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cytoplasm, Ran-GTP is converted to Ran-GDP by Ran-GTPase-activating 
protein (Ran-GAP) causing the release of CRM-1, Rev and the mRNA cargo 
(Dayton, 2004). Following the successful export of viral mRNA, Rev is 
recycled back to the nucleus; the ARD of Rev binds to importin-β and both 
are translocated into the nucleus (Wu, Y. and Marsh, 2003).  
 
Figure 18: Rev/RRE mediated CRM-1 dependent transport of viral mRNA from the 
nucleus to the cytoplasm. Rev forms a complex with Ran-GTP-bound CRM-1 and viral 
mRNA through binding to the RRE. Following nuclear export of the CRM-1 complex, 
conversion of Ran-GTP to Ran-GDP in the cytoplasm causes the release of Rev and 
its viral mRNA cargo. Rev is recycled back to the nucleus through interactions with 
importin-β. 
In the nucleus, Ran-GTP interacts with importin-β resulting in the release of 
Rev which is then available to continue shuttling more viral mRNA to the 
cytoplasm (Pollard and Malim, 1998). Ran-GAP and Ran-GEF are 
asymmetrically distributed between the cytoplasm and nucleus therefore 
producing a constant Ran-GDP/Ran-GTP gradient. This permits ongoing 
CRM-1 recycling and Rev/RRE export to occur (Dayton, 2004). 
1.3.8.4 HIV translation: viral proteins 
Following export to the cytoplasm, viral mRNAs are translated by host cell 
ribosomes and associated translation factors to produce viral proteins. The 
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mechanism and regulation of HIV translation will be considered in greater 
detail in Chapter 4. Translation of viral mRNA produces all of the proteins 
necessary to produce new viral particles. 
HIV proteins: Gag and Gag-Pol 
Unspliced genomic RNA contains the gag open reading frame (ORF) [figure 
7] which is translated into a Gag precursor polyprotein (Pr55Gag for HIV-1 and 
Pr57Gag for HIV-2) [figure 19]. 
 
Figure 19: Model of the HIV-1 Gag polyprotein showing the N-terminus Matrix (MA), 
Capsid (CA) N-terminal and C-terminal domains (NTD/CTD) and C-terminus 
Nucleocapsid (NC) domain (Ganser-Pornillos et al., 2008).  
HIV-1 Gag is cleaved into mature, structural proteins by viral Protease during 
maturation. This produces several smaller proteins; p17 (Matrix, MA), p24 
(Capsid, CA), p7 (Nucleocapsid, NC), p6 and two spacer peptides (Sp1 and 
Sp2) (Ganser-Pornillos et al., 2008). 
      
Within viral particles undergoing maturation, the first cleavage event 
separates NC from CA downstream of a 14 amino acid peptide, Sp1. Next, 
CA is cleaved from MA at around the same time as p6 is cleaved from NC 
Figure 20: Processing 
intermediates and structural 
proteins produced from 
cleavage of the HIV-1 Gag 
precursor (p55) [adapted from 
(Clavel and Mammano, 2010)]. 
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downstream of a second linker peptide, Sp2. Finally both linker peptides are 
cleaved; Sp1 from CA and Sp2 from NC [figure 20] (Clavel and Mammano, 
2010). 
Alternatively, during translation a (-1) frameshift event can occur at the 
frameshifting signal within the gag ORF (Ganser-Pornillos et al., 2008). The 
frameshifting signal is a downstream, structural RNA element near the 3’ end 
of the Gag coding region [figure 21] (Dulude et al., 2008). Ribosome stalling 
is induced by the hairpin structure which presents a barrier to translational 
machinery. Pausing of the ribosome at a heptameric slippery sequence 
(UUUUUUA) subsequently promotes mRNA realignment such that the 
ribosome slips a nucleotide backwards towards the 5’ end of the mRNA and 
translation continues in a -1 frame (Dulude et al., 2008; Mazauric et al., 
2009). This results in the extension of the gag ORF by continued translation 
into the pol ORF generating a Gag-Pol fusion protein, Pr160 (Buck et al., 
2001).  
    
Programmed ribosomal frameshifting (PRF) occurs for around 5-10% of 
ribosomes and provides a method of controlling both the rate of translation 
and the ratio of viral proteins produced (Clavel and Mammano, 2010; 
Ganser-Pornillos et al., 2008). The level of programmed ribosomal 
frameshifting is considerably higher than the amount of frameshifting caused 
by ribosomal error due to the combined effect of the slippery sequence and 
RNA structural element (Gaudin et al., 2005). The Gag-Pol frameshift protein 
is cleaved to produce viral enzymes; PR, IN, and RT, in addition to Gag 
cleavage products (Lever, 2005). 
Figure 21: The HIV 
frameshifting signal consisting 
of a slippery sequence and 
stem-loop structure separated 
by a spacer region (Gaudin et 
al., 2005; Watts et al., 2009). 
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HIV proteins: Env 
The HIV env gene is expressed from genomic RNA which has undergone 
splicing to remove gag and pol coding regions (see figure 17) (Lever, 2005). 
Leaky scanning of ribosomes past the rev and vpu start codons is 
responsible for production of Env and Nef proteins (Buck et al., 2001). 
Translation of env to produce envelope proteins takes place on endoplasmic 
reticulum-bound ribosomes. The amino terminus of the translating 
polyprotein contains a hydrophobic signal peptide. Recognition by signal 
recognition particle (SRP) results in transport to the rough endoplasmic 
reticulum (RER) where the envelope protein is co-translationally translocated 
into the RER [figure 22].  
 
 
Figure 22: 160 kDa HIV Env proteins (gp160) are co-translationally transported to the 
rough endoplasmic reticulum (RER) where they undergo glycosylation and folding. 
Following transport to the Golgi, cleavage of gp160 by cellular proteases produces 
surface gp120 proteins which are non-covalently bound to transmembrane gp41 
proteins. Env proteins are subsequently transported to the plasma membrane and 
incorporated into new virus particles [Image adapted from 
http://legacy.lclark.edu/~Ebkbaxter/200lecture/lecture_images/4_16_env_maturation.jpg]. 
HIV-1 env encodes gp160; a 160 kDa precursor protein (140 kDa for HIV-2) 
which undergoes cleavage by cellular proteases to make surface (SU) gp120 
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and transmembrane (TM) gp41 glycoproteins (gp125 and gp36 for HIV-2) 
(Reeves and Doms, 2002). Cleavage and further processing in the Golgi  
precedes protein transportation, via cellular mechanisms, to the cell surface 
where proteins are assembled into new particles (Lever, 2005). 
The HIV gp120 SU protein contains conserved disulphide bonds, multiple 
glycosylation sites, and 5 conserved (C1-5) and variable (V1-5) domains 
(Reeves and Doms, 2002). Variable domains within HIV gp120 are 
responsible for much of the virus’ genetic diversity and are therefore an 
indispensible part of viral strategy to evade the host immune response (Watts 
et al., 2009). Non-covalent bonding associates the Envelope SU protein with 
the TM protein. The N-terminus of the HIV TM protein contains a fusion 
peptide important in entry to host cells, the central region consists of a 
membrane-spanning domain and the C-terminus contains an amphipathic 
intracellular domain (Reeves and Doms, 2002). 
The HIV genome also encodes six smaller proteins; Tat, Rev, Nef, Vif, Vpr 
and Vpu. Whilst the regulatory proteins Tat and Rev are essential for virus 
replication (see above), Nef, Vif, Vpr and Vpu are accessory proteins which, 
although not crucial in vitro, serve to enhance HIV replication (Le Rouzic and 
Benichou, 2005).  
HIV accessory proteins: Nef 
One of the first viral proteins expressed is the 27 kDa Nef (negative factor) 
protein which plays an important role in enhancing HIV pathogenicity. Nef 
binds to cellular membranes through myristylation of its N-terminus, and 
regulates the intracellular trafficking of cell surface CD4, promoting its 
endocytosis through interactions with the CD4 cytoplasmic tail (Waheed and 
Freed, 2009). Recruitment of AP-2, involved in the formation of clathrin 
coated vesicles, is also enhanced by Nef. These two activities serve to 
encourage the intracellular transport of CD4 to endosomes and finally 
lysosomes where it is degraded (Malim and Emerman, 2008). Additionally, 
Nef engineers suppression of the major histocompatibility complexes (MHCI 
and MHCII) which are important in antigen presentation on T-cells; this 
prevents T-cell activation (Waheed and Freed, 2009). Thus Nef down-
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regulates the expression of cell surface molecules important in provoking an 
immune response and thereby promotes viral survival (Malim and Emerman, 
2008). Although it remains unclear whether Nef fundamentally enhances HIV 
replication, or whether Nef itself is a pathogenic agent, deletions in Nef 
severely attenuate the pathogenicity of HIV indicating the importance of this 
factor for viral infectivity (Foster and Garcia, 2008). 
HIV accessory proteins Vpr (and Vpx) 
Viral protein R (Vpr) is a multifunctional, 14 kDa accessory protein encoded 
by HIV-1 and HIV-2. Vpr has been implicated in numerous processes within 
the virus life cycle including accurate reverse-transcription, the regulation of 
cell cycle progression, apoptosis, and permissible macrophage infection 
(Fouchier et al., 1998). Additionally, Vpr contains a nuclear localisation signal 
which permits targeting of the pre-integration complex to the nucleus. 
Although expressed during the late stages of the virus life cycle, Vpr is found 
both in virus particles and within the host cell and is therefore present for 
early stages of replication as it is released from infectious particles post-
entry. Vpr has also been isolated from the sera of AIDS patients and 
therefore may operate via a diverse range of methods (Le Rouzic and 
Benichou, 2005). Cell death results from Vpr expression, although it is 
unknown whether this is attributed to induced apoptosis, or the Vpr-mediated 
arrest of cells at the G2 stage of the cell cycle (Malim and Emerman, 2008).  
HIV-2 and SIVSMM encode both Vpr and a Vpx gene whereas HIV-1 and other 
SIVs express only Vpr (Le Rouzic and Benichou, 2005). Consequently, for 
HIV-2, the functions of Vpr in HIV-1 are shared; Vpx permits macrophage 
infection and Vpr is responsible for cell cycle arrest. It has also been 
suggested that Vpx may counteract the host defence protein TRIM5α and 
target it for destruction. Consequently, the presence of Vpx in viral cores 
means that it may be directly introduced into target cells to overcome host 
restriction factors during the early stages of infection (Malim and Emerman, 
2008).  
HIV accessory proteins: VIF 
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Vif (viral infectivity factor) is a 23 kDa protein which counteracts the antiviral 
function of the host protein APOBEC3G: a DNA-editing enzyme which can 
enter HIV virions (Harris and Liddament, 2004; Madani and Kabat, 1998). If 
incorporated into virus particles, APOBEC3G renders them non-infectious as 
it induces mutations into reverse transcribed viral DNA in subsequent cells. 
Vif suppresses APOBEC3G via two mechanisms: inhibiting translation of 
APOBEC3G mRNA and inducing proteasomal degradation of cellular 
APOBEC3G proteins [figure 23] (Stopak et al., 2003). 
 
Figure 23: Vif counteracts the antiviral activity of cellular APOBEC3G by impairing 
APOBEC3G mRNA translation and targeting APOBEC3G proteins for degradation via 
the proteasome. These mechanisms prevent APOBEC3G from becoming incorporated 
into budding virions. In the absence of Vif, APOBEC3G is incorporated into virions 
where it induces damaging mutations into the reverse transcribed viral DNA within 
subsequently infected cells. This renders APOBEC3G containing virions non-
infectious (Stopak et al., 2003). 
HIV accessory proteins: Vpu 
Vpu (Viral protein U) is an 81 AA, type 1 membrane protein produced from 
the same mRNA as the Envelope glycoproteins. Vpu is unique to HIV-1 and 
has two main roles during infectivity; facilitating the release of viral particles 
from the cell surface by sequestering tetherin and, like Nef, inducing CD4 
degradation through interactions with the CD4 cytoplasmic tail (Levesque et 
al., 2003). In this way, Vpu monitors the expression of cell surface immune 
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markers and therefore regulates viral replication and persistence. Activation 
of antiviral agents can impair HIV replication. Type 1 interferon (in particular 
IFNα) induces the restriction factor tetherin which impairs release of viral 
particles. Vpu overcomes this resistance both by suppressing immune 
activation via cell surface markers, and sequestering tetherin molecules from 
the cell surface (Malim and Emerman, 2008). As HIV-2 does not encode Vpu, 
an alternative counteractive strategy involving HIV-2 Env is employed to 
overcome host restriction by tetherin. Both HIV-1 Vpu and HIV-2 Env can 
promote removal of tetherin from the cell surface. However, HIV-1 can 
additionally mediate a reduction in the total level of tetherin within the cell; a 
factor not attributed to HIV-2 Env (Hauser et al., 2010). 
1.3.9 Retrovirus assembly, budding and maturation  
1.3.9.1 Assembly 
Retrovirus assembly results in the construction of virus particles composed of 
viral proteins and containing genomic viral mRNA. Within T-cells, viral RNA, 
Gag and Env proteins are transported on endosomes to the plasma 
membrane to form immature virions. However, in primary human 
macrophages translated Gag proteins target to intracellular multivesicular 
bodies (MVB) and are likely released via exosomal pathways. Despite 
targetting of Gag to MVB, virions are still released with high efficiency from 
macrophages (Ono and Freed, 2004). Two groups of proteins associate with 
Gag during cell trafficking; MVB and clathrin adaptor (AP) proteins. ESCRT 
(endosomal sorting complexes required for transport) recognise and sort 
ubiquitinated cargo proteins into the intralumenal vesicles of MVBs. AP 
proteins sort target proteins into clathrin coated transport vesicles (Camus et 
al., 2007).  
The major structural determinant of virion construction is the Gag polyprotein. 
In fact, if only Gag proteins are expressed they produce extracellular, virus-
like particles (VLP) which are indistinct from immature virions (Bieniasz, 
2009). Gag translation occurs on free ribosomes within the cell cytoplasm. 
Resulting Gag proteins are involved in directing budding, regulating virion 
size and packaging other virion components. The mechanism by which Gag 
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proteins travel to the cell surface is unknown. However, host proteins, such 
as Arf and the GGA proteins, have been shown to play a role in the 
intracellular transport of Gag (Joshi et al., 2008). The Gag matrix domain, 
which has an N-terminal myristate group and α-helical stalk, also facilitates 
targeting of Gag to the cellular membrane (Bieniasz, 2009). HIV-1 Gag 
proteins cannot travel to the cell surface by attachment to Golgi apparatus as 
Brefeldin A, a drug which disrupts this secretory pathway, does not disrupt 
the efficiency of Gag budding (Pal et al., 1991). It is therefore thought that 
Gag trafficking to the plasma membrane may follow the pathways used by 
cellular proteins, travelling to the plasma membrane following synthesis on 
free, cytosolic ribosomes (Coffin, J.M. et al., 1997). Additionally, it is unclear 
whether Gag monomers are singly transported or whether they co-localise to 
form multimeric proteins in the cytoplasm before encountering the plasma 
membrane at assembly sites (Bieniasz, 2009).  
HIV Gag targets the more ordered lipid raft regions of the plasma membrane 
which are abundant in cholesterol and sphingolipids. Tetherin, which restricts 
HIV particle release, is a raft-associated protein. Likewise, the raft marker 
GM1 has been shown to co-localise with HIV Gag (Waheed and Freed, 
2009). A phosphoinositide, PI(4,5)P2, resides in the plasma membrane of 
host cells. Recognition of PI(4,5)P2 by the matrix domain of Gag aids 
targeting of Gag to the plasma membrane and moreover stabilizes this 
association during assembly of virions. A bipartite motif within the matrix 
domain contains a covalently bound myristic acid and several positively 
charged amino acids. This positively charged surface is suitably placed to 
interact with the negatively charged interior of the plasma membrane. Thus 
the matrix domain helps Gag molecules to engage with the plasma 
membrane (Waheed and Freed, 2009). 
Once at the plasma membrane, Gag molecules initiate or contribute to 
already forming Gag protein shells (Bieniasz, 2009). The N-terminal matrix 
domain of Gag associates with the host cell membrane which later forms the 
membrane of the viral envelope. As the particle assembles, Gag proteins are 
radially aligned with the  N-terminals at the viral membrane and the C-
Chapter 1           Introduction 
 
46 
 
terminals pointing towards the centre of the forming virus particle [figure 24] 
(Briggs et al., 2006). 
Forming HIV virions contain two copies of positive-sense full-length genomic 
RNA (Berkhout et al., 2011). The dimerization of two viral RNA strands 
results in packaging signals positioned in close proximity. Disruption of RNA 
dimers can impair the efficiency of viral encapsidation (Kaye and Lever, 
1999). The mRNA produced during a HIV-1 infection consists of a single pool 
which is used interchangeably as both mRNA for translation and genomic 
RNA for packaging. Conversely, HIV-2 RNA is packaged primarily in cis, with 
nascent Gag proteins packaging the message from which they were 
synthesised (Paillart et al., 2002).  
 
Figure 24: A structural model of HIV Gag showing Matrix (MA), Capsid (CA), 
Nucleocapsid (NC) and p6 domains. Several possible methods of Gag monomer 
assembly contribute to the Gag shell forming at the plasma membrane [adapted from 
(Bieniasz, 2009)]. 
It is thought that the matrix domain of Gag is responsible for stimulating 
translation at low Gag concentrations. At high Gag concentrations, binding of 
Gag to the packaging signal occurs through the Gag nucleocapsid domain, 
and directs encapsidation of the genome into new virus particles. Since HIV 
mRNA serves as both a translational template and genomic RNA for 
packaging, there is competition between these processes. Consequently, 
before packaging can proceed, there must be sufficient Gag molecules 
already synthesised to produce viral particles. Additionally, this suggests that 
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the Gag protein is responsible for controlling the switch between translation 
and packaging (Anderson and Lever, 2006).  
HIV RNA contains a multipartite packaging signal; the primary packaging 
signal (Psi, Ψ) is located within the 5’ UTR of mRNA although additional 5’ 
UTR structures: DIS, poly(A), TAR and the Gag coding region have also 
been shown to contribute to optimal packaging (Paillart et al., 2002). Gag 
molecules interact with the packaging signal within the 5’ UTR of transcribed 
viral mRNA  and this drives the multimerization of Gag (Bieniasz, 2009). 
During assembly, homologous regions of Gag monomers bind, causing 
alignment and non-specific binding of their NC domain along the viral RNA in 
an RNA/NC complex. It is thought that the Gag interaction with RNA provides 
a nucleation site, allowing more Gag proteins to assemble until an immature 
viral particle is formed. Pol proteins are linked to Gag before maturation and 
therefore also become incorporated into new virions (Kaye and Lever, 1999).  
Like Gag, Env protein is targeted to lipid raft regions of the cell membrane via 
myristoylation and palmitoylation signals. Whereas Gag binds to the inner 
leaflet of the plasma membrane, Env is independently transported to the 
outer leaflet  where it is acquired by budding virus particles (Jolly and 
Sattentau, 2007). It has been proposed that Env is incorporated into forming 
virus particles via the cytoplasmic tail of gp41 which interacts with the Gag 
matrix domain (Waheed and Freed, 2009).  
Generation of virus particles commences with the formation of a protein 
sphere composed of Gag molecules. This occurs on the cytoplasmic face of 
the host cell lipid bilayer meaning that particle assembly and envelopment 
occur simultaneously [figure 25] (Bieniasz, 2009).  
The C-terminal domain of Gag, p6, contains a docking site for proteins 
associated with the ESCRT. Separation of the virion envelope from the host 
cellular membrane relies on ESCRT-associated proteins (Bieniasz, 2009). 
HIV particles budding from the membrane of host cells are immature and 
non-infectious (Briggs et al., 2006).  
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Figure 25: Assembly of HIV virions at lipid raft (red) regions of the plasma membrane 
(Waheed and Freed, 2009). 
1.3.9.2 Budding 
Following detachment of the formed virion from the host cell surface, it would 
seem that the virus particles should be free move away from the cell. 
However, a retention mechanism involving a host inhibitor, tetherin, can block 
viral release [figure 26].  
 
Figure 26: A model for tetherin retention of budding virus particles. Tetherin is an 
integral membrane protein which prevents particle release by causing virions to 
become tethered to each other and the cell membrane. Sequestering of tetherin 
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through the viral protein Vpu leads to its removal from assembly sites thereby 
allowing release of budding viral particles (Bieniasz, 2009). 
Tetherin is an integral membrane protein induced by interferon (IFN). The 
protein is composed of an N-terminal cytoplasmic tail and an extracellular 
coiled-coil held in place by a central, transmembrane anchor. The C-terminal 
also forms a glycophosphatidylinositol lipid anchor. Thus tetherin is unusual 
in that it contains two membrane anchors (Bieniasz, 2009). Consequently, 
non-permissive cells expressing tetherin can restrict the ability of HIV to 
release viral particles. However, HIV has overcome this form of resistance 
via the viral protein Vpu. The N-terminal domain of Vpu forms a 
transmembrane anchor whilst the cytoplasmic C-terminal domain contains 
two helices and a phosphorylation site. Vpu is able to sequester tetherin and 
subsequently enhance viral release by removing tetherin from viral assembly 
sites (Bieniasz, 2009). 
1.3.9.3 Maturation 
Cleavage of nascent HIV polyproteins is required for viral maturation. The 
HIV-1 dimeric aspartic Protease (PR) catalyses polyprotein processing 
(Adachi et al., 2009). However, the HIV genome only encodes one subunit of 
the HIV PR which is translated as part of the Gag-Pol polyprotein. Therefore 
dimerization of Gag-Pol (encoding PR) is first required to allow configuration 
of the PR active site and thus form an active Protease (Wan et al., 1996). 
During budding, or shortly afterwards, viral Protease cleaves Gag and Gag-
Pol polyproteins to release several viral proteins (MA, CA, NC and PR, IN, 
RT). Considerable morphological change and restructuring of the immature 
viral particle follows polyprotein cleavage resulting in capsid formation and 
maturation of the virus into an infectious particle (Briggs et al., 2006; Lever, 
2005). Within the mature virus particle, Matrix proteins remain bound to the 
membrane. The core condenses into a ribonucleoprotein (RNP) complex of 
genomic RNA bound to Nucleocapsid proteins surrounded by a shell of 
Capsid proteins (Briggs et al., 2006). The characteristic cone shape of the 
core results from the way the Capsid proteins elongate [figure 27]. 
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Figure 27: Assembly of the HIV mature core is coordinated to ensure cores of a 
homogeneous shape and size are formed. Assembly of the core initiates from a 
narrow point (1). Elongation is limited by the virion diameter (2) before growth along 
the inside of the viral envelope closes the cone (3) (Briggs et al., 2006). 
Maturation of immature virus particles by Protease cleavage and 
restructuring produces fully infectious virions which are subsequently poised 
to go on and infect naïve cells which they encounter. Viruses are obligate 
intracellular pathogens which subvert cellular replicative machinery to 
produce new progeny. Consequently, virus particles require access to 
cellular receptors on targets cells in order to bind and initiate infection. 
Classical models of virus infection focus on cell-free virus particles attaching 
to receptive target cells. However, an additional model has been proposed 
whereby some viruses, including HIV, may transition directly from host cells 
to target cells via cellular synapses. This could provide an important means 
of transmission for cells residing in close proximity to infectious cells; in 
particular, between cells of epithelial surfaces and lymphoid tissue. Likewise, 
the formation of a synapse between antigen presenting cells and T-cells is 
well characterised. Target cells may thus assist their own infection by forming 
synapses with HIV-infected cells and, moreover, provide a means for viruses 
to rapidly and covertly undergo cell-cell dissemination. This method would 
avoid complications posed by obstacles such as receptor binding, and, 
furthermore, would permit viral evasion of the antibody or complement 
aspects of the host humoral immune response (Jolly and Sattentau, 2004). 
1.4 A comparison of HIV-1 and HIV-2 
HIV-1 and HIV-2 are closely related lentiviruses which both cause AIDS. 
However, HIV-1 evolved from chimpanzee simian immunodeficiency virus 
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(SIVcpz) and was identified in 1983, whereas HIV-2 evolved independently 
from sooty mangabey SIV (SIVsmm) and was first recognised in 1985. HIV-1 is 
found globally whereas HIV-2 infection is confined to West Africa (Sleasman 
and Goodenow, 2003).  
HIV-1 is much more prevalent than HIV-2 and is the primary source of global 
AIDS cases. A causal factor is that HIV-2 is less pathogenic than HIV-1 and 
has a longer incubation stage. Both types of HIV show tropism for CD4+ T-
cells and mononuclear phagocytes (Lever, 2005). However, in vivo, lower 
viral RNA levels are seen in HIV-2 infection than HIV-1, despite similar 
proviral DNA levels, resulting in a significantly lower viral plasma load 
(MacNeil et al., 2007). 
Unlike HIV-1, HIV-2 is not transmitted vertically and, furthermore, perinatal 
transmission is less efficient (Coffin, J.M. et al., 1997). HIV-2 is also 
associated with a higher proportion of long-term non-progressors than HIV-1, 
and the average disease progression in untreated infections is a few years 
longer with HIV-2 than HIV-1, despite the establishment of a stable and 
integrated proviral infection. Infection with HIV-2 is less virulent than HIV-1 
infection and results in fewer individuals who progress to AIDS (Forsman and 
Weiss). However, once AIDS has developed the infection outcome is the 
same. Evidence suggests that a better immune response during HIV-2 
infection may control replication of the HIV-2 virus, although HIV-2 infected 
individuals who do progress to AIDS show a similar level of immune 
response activation to HIV-1 infected individuals (Forsman and Weiss; 
Leligdowicz et al., 2007). In contrast to HIV-1 infection, HIV-2 infected 
individuals can produce normal levels of CD4+ T-cells which are able to 
specifically recognise HIV, replicate, and produce IFN-γ and IL-2 (Duvall et 
al., 2006). Moreover, when CD4+ T-cell levels are equivalent, the proportion 
of CD4+ T-cells able to produce IL-2 during a HIV-2 infection is greater than 
for HIV-1 infection (Reeves and Doms, 2002). During a HIV-2 infection, a 
greater number of CD8+ T-cells are also able to maintain production of IFN-γ 
and IL-2 than during a HIV-1 infection. Consequently, this suggests a 
different immune response to HIV-1 infection than infection with HIV-2, which 
may account for the lower replication rate witnessed during HIV-2 infection. 
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However, in tissue culture, where differences in the immune system are 
irrelevant, HIV-2 also has a lower replication rate than HIV-1  suggesting that 
additional factors influence the lower replication rate of HIV-2 (Blaak et al., 
2006).  
Several distinguishing differences between infection with HIV-1 and HIV-2 
viruses are discussed below and listed in table 3. 
 HIV-1 HIV-2 
Clinical illness Majority develop AIDS 
20-25% develop AIDS, the 
remainder are LTNPs 
Plasma viral 
load 
High in acute phase and 
during disease (105-107 RNA 
copies/ml), may be 
undetectable in 
asymptomatic phase 
High in progressors (105-107 RNA 
copies/ml), undetectable in LTNPs 
CD4+ count 
Decreases during acute 
infection, returns to normal 
and then declines over time 
Normal in LTNPs, reduced count 
in progressors 
CD4+ depletion 
in gut associated 
lymphoid tissue 
Massive depletion Unknown 
Vertical 
transmission 
Up to 40% <4% 
Immune 
activation 
Elevated even when viral 
load is undetectable 
Not elevated in LTNPs, increased 
in progressors and predicts 
disease progression 
T-cell 
proliferation 
Increased CD4+ and CD8+ T 
cell turnover 
Unknown 
Thymopoiesis Reduced 
Enhanced (maintains CD4+ T-
cells) 
T-cell apoptosis Increased Lower than HIV-1 
Virus-specific 
CD8+ T-cell 
response 
Vigorous. Gag-specific 
response correlates with 
reduced virus load 
Vigorous. Magnitude and Gag 
peptide specificity inversely 
correlate to virus load 
Selection of 
cytotoxic T-cell 
escape variants 
Frequently occurs. 
Associated with clinical 
decline 
Unknown 
Virus-specific 
CD4+ T-cell 
response 
IFNγ response present 
throughout infection. IL-2 
secretion and proliferation 
correlate with LTNP status 
IFNγ response present in most 
patients, IL-2 secretion and 
proliferation correlate with LTNP 
status 
 
Table 3: A comparison of infection with HIV-1 and HIV-2 [modified from (de Silva et al., 
2008)]. 
HIV-1 and -2 have different long terminal repeats which could result in 
dissimilar expression of mRNA (de Silva et al., 2008). Alternatively, the 
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difference in production of viral mRNA suggests that HIV-2 transcription may 
be more tightly controlled than for HIV-1 (de Silva et al., 2008). The level of 
proviral DNA is comparable during a HIV-1/2 infection. Thus differences in 
viral gene expression may account for the reduced viral load associated with 
infection by HIV-2 (Reeves and Doms, 2002). In vitro, HIV-2 replicates more 
slowly and to lower titres than HIV-1. However, it is currently unknown why 
fewer viral particles are produced during a HIV-2 infection. 
Work published during the completion of this thesis has suggested that HIV-1 
and HIV-2 may have different translation strategies. In vitro, the addition of 
cap analogue inhibits translation of HIV-1 Gag but has less of an effect on 
Gag production in HIV-2. This suggests that translation of HIV-1 Gag may be 
more cap-dependent than HIV-2 (Ricci et al., 2008). HIV-2 RNA also has a 
longer 5’ UTR than HIV-1, with complex secondary structure which may 
hinder translation. Some regions of the HIV-1 and -2 genomes show 
considerable homology, whereas other regions are less homologous (Lever, 
2005). For example, the HIV-1/2 Gag-Pol coding region shows 60% 
homology whereas the Env coding region only has 30-40% homology (de 
Silva et al., 2008). The two strains also respond to differing cellular stimuli, 
indicating differences in the mechanism of gene expression (MacNeil et al., 
2007).  
It has been shown that HIV-2 is unable to bud out of yeast spheroplasts 
whilst HIV-1 can. Defective HIV-2 Gag assembly in S.cerevisiae resulted in 
the accumulation of Gag proteins at the plasma membrane but a lack of 
budding (Morikawa et al., 2007). This suggests that particle formation and 
budding could also differ between HIV-1 and -2. Additionally, HIV-2 MA does 
not bind as strongly to the plasma membrane as HIV-1 MA, which may 
contribute to a lower rate of particle production (Lever, 2005). 
Since HIV-1 infection is responsible for the globally devastating AIDS 
pandemic, whereas HIV-2 has  restricted endemicity, HIV research has 
principally focused on understanding how HIV-1 functions. Currently, a 
definitive study of the differences between the HIV-1 and HIV-2 viruses has 
not been carried out. Although differences in disease pathology, structural 
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variations and varying cellular interactions have been highlighted between 
these two viruses, it remains unclear as to the cause of the diminished 
replication levels seen during a HIV-2 infection. Identifying the underlying 
mechanisms for the failure of HIV-2 to present itself as such a severe 
pathogen, in contrast to the global dominance of the HIV-1 virus, may 
highlight a means to restrict the impact of HIV-1 through therapeutic 
intervention. Likewise, it remains to be seen whether the less effectual impact 
of the HIV-2 virus is attributable to one particular stage of the virus life cycle 
or whether it is the due to accumulative inefficiencies at various replicative 
stages. 
1.5 Project aims  
A greater understanding of the relationship between viral strategies and 
pathogenesis may provide an outlet for future therapeutic interventions, thus 
reducing the global impact of HIV. Consequently, the focus of my project lies 
in identifying and characterising the differences between HIV-1 and HIV-2 
replication at the level of gene expression, with a particular focus on the 
potential differences between translation of HIV-1 and HIV-2 RNAs. A greater 
understanding of the relationship between viral strategies, and the 
implications for pathogenesis, is an important consideration when designing 
therapeutic measures or vaccines, and may go a long way to reducing the 
global disease burden of HIV. 
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2. CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Antibodies 
Antibody Dilution 1°/ 2° Target Supplier 
Rabbit MAb anti-p24 1:2000 Primary HIV-1 p24 
NIBSC Centre 
for AIDS 
Reagents 
Sheep MAb anti-p27 1:2000 Primary HIV-2 p27 
NIBSC Centre 
for AIDS 
Reagents 
Rabbit polyclonal to 
eIF4G1 
1:1000 Primary 
eIF4G1 (220 
kDa) 
Abcam 
Purified Mouse MAb 
Anti-adaptin γ 
1:5000 Primary 
AP1α (104 
kDa) 
BD 
Transduction 
LaboratoriesTM 
Mouse monoclonal 
anti-La/SSB (22A):sc-
80655 
 
1:500 Primary 
Human cellular 
La protein (48 
kDa) 
Santa Cruz 
Biotechnology, 
Inc. 
Mouse anti-luciferase 1:2000 Primary 
Luciferase (61 
kDa) 
Sigma 
Rabbit anti-GAPDH 1:1000 Primary GAPDH Abcam 
Goat anti-rabbit IgG 
HRP 
1:5000 Secondary 
HIV-1 
p24/GAPDH 
secondary 
Santa Cruz 
Biotechnology, 
Inc. 
Rabbit-anti-sheep IgG 
HRP 
1:5000 Secondary 
HIV-2 p27 
secondary 
Santa Cruz 
Biotechnology, 
Inc. 
Goat-anti mouse IgG 
HRP 
1:5000 Secondary 
AP1 
secondary 
Sigma 
Alexa Fluor 488-
tagged goat anti-
mouse IgG 
1:500 Secondary 
AP1 
secondary 
Invitrogen 
Alexa Fluor 594-
tagged goat anti-rabbit 
IgG 
1:500 Secondary 
HIV-1 p24 
secondary 
Invitrogen 
Alexa Fluor 594-
tagged donkey anti-
sheep IgG 
1:500 Secondary 
HIV-2 p27 
secondary 
Invitrogen 
 
Table 4: The antibodies used for experiments. The protein target, dilution and supplier 
are indicated. 
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2.1.2 Plasmids 
Plasmid Description 
Digested 
with 
Source 
PJLuc 
Plasmid containing a T7 promoter and 
gene encoding firefly luciferase 
Sal1 
Emma 
Anderson 
HIV-1 MP 
HIV-1 UTR-Gag-Luc reporter plasmid 
(PJLuc) 
Nhe1 Made 
HIV-1 MA2 
MP 
HIV-1 MA2 UTR-Gag-Luc reporter plasmid 
(PJLuc) 
Nhe1 Made 
HIV-2 MP 
HIV-2 UTR-Gag-Luc reporter plasmid 
(PJLuc) 
Nhe1 Made 
SVC21ΔBgl HIV-1 Env-deleted provirus (HXB2 strain) Sal1 
Prof. 
Andrew 
Lever 
SVC21ΔBgl
MA2 
HIV-1 Env-deleted provirus (HXB2 strain) 
with the matrix region of HIV-2 (MA2) 
Sal1 
Emma 
Anderson 
SVRΔNB HIV-2 Env-deleted provirus (ROD strain) Sal1 
Prof. 
Andrew 
Lever 
PRHCVF 
Bicistronic plasmid with cap-dependent 
Renilla and Hepatitis C (HCV) IRES-driven 
firefly luciferase. 
Linearised to make bicistronic RHCVF 
RNA. 
Linearised to make cap-dependent Renilla 
luciferase RNA. 
 
 
BamH1 
Xba1 
Prof. 
Anne 
Willis 
PRHRVF 
Bicistronic plasmid with cap-dependent 
Renilla and human rhinovirus (HRV) IRES-
driven firefly luciferase. 
Linearised to make cap-dependent Renilla 
luciferase RNA. 
 
 
BamH1 
Prof. 
Anne 
Willis 
pcDNA GFP 
Plasmid encoding green fluorescent 
protein (GFP). Used as a non-specific 
translation control. 
 
Emma 
Anderson 
pcDNA GAG 
HIV Gag coding plasmid. Used as a 
specific translation control. 
 
Emma 
Anderson 
PV1 Q746 
Poliovirus 1 (PV1) IRES under the control 
of a T7 promoter. 
BamH1 
Prof. 
Richard 
Jackson 
HVPΔEC 
puroΔB14 
HIV provirus with a large deletion in Gag-
Pol and puromycin replacing Nef. 
 
Emma 
Anderson 
pT7HRV2 Used to make HRV-2 RNA. Acc65I 
Prof. Tim 
Skern 
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pcDNA3-2A 
HRV-2 2A protease (cap-dependent) in a 
pcDNA3 plasmid. 
HindIII Made 
pcDNA3-2A-
IRES 
pcDNA3 plasmid containing HRV-2 2A 
under the control of an EMCV IRES. 
 Made 
pT7Ev7ΔP1 
 
Full-length echovirus-7 with capsid genes 
removed. Encodes 2A protease to make 
2A RNA. 
Xho1 
Kym 
Lowry & 
Prof. 
David 
Evans 
pJHRV GCC 
Mutant HRV-2 IRES under the control of a 
T7 promoter. 
 
Emma 
Anderson 
PJHRV 10-
605 
HRV-2 IRES under the control of a T7 
promoter. 
BamH1 
Prof. 
Richard 
Jackson 
HIV-1ΔTAR HIV-1 MP with TAR deletion in the 5’UTR. Nhe1 Made 
HIV-1 MA2 
ΔTAR 
HIV-1 MA2 MP with TAR deletion in the 
5’UTR. 
Nhe1 Made 
HIV-2 ΔTAR HIV-2 MP with TAR deletion in the 5’UTR. Nhe1 Made 
PGEM-T 
easy 
Plasmid containing SP6 and T7 promoters 
flanking a multiple cloning site (MCS) 
within the coding region of the β-
galactosidase enzyme. Insertional 
inactivation of the α-peptide permits 
recombinant clones to be identified on 
indicator plates by colour screening. 
 
Kym 
Lowry & 
Prof. 
David 
Evans 
pTK Renilla 
Renilla luciferase under the control of a 
HSV thymidine kinase promoter. 
 
Sue 
Morris & 
Dr Keith 
Leppard. 
 
Table 5: The plasmids used for experiments. The plasmid name, content and 
restriction enzyme used for digestions are indicated alongside the plasmid source. 
2.1.3 Plasmids produced 
2.1.3.1 HIV Gag-Luc reporter plasmids 
The 5’ UTR and gag coding region from HIV-1 (SVC21ΔBgl) (primers #1, 2) 
and HIV-2 (SVRΔNB) (primers #3, 4) DNA plasmid templates were amplified 
by PCR. Sal1 restriction sites were included on forward and reverse primers, 
with the inclusion of an additional 15 nucleotide Gly(4)Ser linker on reverse 
primers. PCR products and a pJLuc plasmid encoding firefly luciferase were 
digested with Sal1 [NEB]. The pJLuc plasmid was dephosphorylated with 
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CIAP [Fermentas]. PCR products were ligated into pJLuc using T4 DNA 
ligase [NEB] and transformed into TG1 E.coli. Screening for the correct 
plasmid insert size and orientation was carried out by Sal1 and Sfo1 digests 
respectively of extracted bacterial DNA. Plasmids with the correctly 
orientated inserts were amplified by Maxiprep [Qiagen]. See appendix 1 for 
plasmid maps. 
2.1.3.2 HIV ΔTAR Gag-Luc reporter plasmids 
Forward primers were designed to bind after the TAR structure at the 5’ end 
of the HIV-1/2 5’ UTRs. Subsequently, the HIV-1 (primers #2, 16,) and HIV-2 
(primers #4, 17) 5’ UTR (ΔTAR) and gag coding region were amplified by 
PCR from HIV-1 (SVC21ΔBgl) and HIV-2 (SVRΔNB) DNA plasmid 
templates. Sal1 restriction sites were included on forward and reverse 
primers and an additional 15 nucleotide Gly(4)Ser linker included on the 
reverse primers. HIV-1 and HIV-2 ΔTAR PCR products were purified by gel 
extraction and, alongside pJLuc, digested using Sal1 [NEB]. The pJLuc 
plasmid was dephosphorylated using CIAP [Fermentas]. Following DNA 
extraction of digests, HIV-1/2 (ΔTAR) UTR-gag DNA was ligated into pJLuc 
using T4 DNA ligase [Fermentas] and ligated plasmids transformed into TG1 
E.coli. Resultant colonies were cultured by Miniprep and bacterial DNA 
isolated. Sequencing was carried out on the resulting plasmids to check the 
5’ UTR-Gag coding region was correctly inserted and affirm the deletion of 
HIV-1/2 TAR sequences. See appendix 2 for plasmid maps. 
2.1.3.3 pcDNA3-2A 
The HRV-2 2A protease was amplified by PCR (using primers #5, 6) from 
pT7HRV-2 (encoding human rhinovirus 2). The forward primer contained a 
HindIII restriction site and the reverse primer contained an XbaI restriction 
site. The PCR product and a pcDNA3 plasmid (under T7 promotion) 
[Invitrogen] were digested with HindIII and XbaI [NEB] and the plasmid 
dephosphorylated with CIAP [Fermentas]. The digested HRV-2 2A PCR 
product was ligated into pcDNA3 using T4 DNA ligase [NEB] and used to 
transform TG1 E.coli. Sequencing of DNA extracted from bacterial colonies 
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was carried out to ensure the presence of the correct insert. The resulting 
plasmid was named pcDNA3-2A. See appendix 3 for plasmid map. 
2.1.3.4 pcDNA3-2A-IRES 
Cloning was carried out to express HRV-2 2A under the promotion of an 
EMCV IRES. The encephalomyocarditis virus (EMCV) IRES (nucleotides 
1230-1840) was amplified by PCR (primers #7, 8) from a prB322 plasmid 
containing the EMCV IRES replicon [a gift from Kym Lowry and Professor 
David Evans]. The EMCV IRES PCR product was Klenow treated 
[Fermentas] according to the manufacturer’s instructions to produce blunt 
ends. Previously made pcDNA3-2A was digested with HindIII, Klenow treated 
to produce blunt ends and dephosphorylated with CIAP [Fermentas]. A blunt 
end ligation using T4 DNA ligase [NEB] was carried out to insert the EMCV 
IRES into pcDNA3-2A; the resulting plasmid was called pcDNA3-2A-IRES. 
See appendix 4 for plasmid map. 
2.1.4 Primers 
NB: Primers were used at 20 μM diluted from 100 μM stock. 
# Primer Sequence Source 
1 
Sal1 HIV-1 
(26) 
TAGCTAGTCGACGGTCTCTCTGGTT Sigma 
2 
Sal1 Linker 
Gag1 (131) 
TAGCTAGTCGACAGAGCCTCCGCCTC
CTTGTGACGAGGGGTCG 
Invitrogen 
3 
Sal1 HIV-2 
(133) 
TAGCTAGTCGACGGTCGCTCTGCGG Invitrogen 
4 
Sal1 linker 
Gag2 (132) 
TAGCTAGTCGACAGAGCCTCCGCCTC
CCTGGTCTTTTCCAAAGAG 
Invitrogen 
5 
2A protease 
FWD 
CTAGCAAGCTTATGGGCCCCAGTGACA
TG 
Invitrogen 
6 
2A protease 
REV 
CCTAGTCTAGACTATTGTTCTTCAGCA
C 
Invitrogen 
7 
EMCV IRES 
FWD 
GACCACAACGGTTTCCCT Invitrogen 
8 
EMCV IRES 
REV 
TATTATCGTGTTTTTCAAAGG Invitrogen 
9 
HIV-1 Gag 
(Pfo1) 
TCAGAAGCAGGAGCCGATAG Invitrogen 
10 
HIV-2 Gag 
(Pfo1) 
CTTGCTGCACCTCAATTCTC Invitrogen 
11 
HIV-1 T7ΔTAR 
UTR FWD 
TAGCTAATACGACTCACTATAGGGACT
GCTTAAGCCTCAATAAAGC 
Invitrogen 
12 
HIV-2 T7ΔTAR 
UTR FWD 
TAGCTAATACGACTCACTATAGGGCCA
CGCTTGCTTGCTTAAAAACC 
Invitrogen 
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13 
HIV-1 T7 UTR 
FWD 
TAGCTAATACGACTCACTATAGGGTCT
CTCTGGTTAGACCAGATC 
Invitrogen 
14 
HIV-2 T7 UTR 
FWD 
TAGCTAATACGACTCACTATAGGGTCG
CTCTGCGGAGAGGCTGGC 
Invitrogen 
15 Nhe1-Luc REV CGATGACCCTGCTGATTGGTTCGCTGA Invitrogen 
16 
Sal1 HIV-
1ΔTAR 
TAGCTAGTCGACACTGCTTAAGCCTCA
ATAAAGC 
Invitrogen 
17 
Sal1 HIV-
2ΔTAR 
TAGCTAGTCGACCCACGCTTGCTTGCT
TAAAAACC 
Invitrogen 
18 GAPDHf TCTCCTCTGACTTCAACAGCGAC Invitrogen 
19 GAPDHr CCCTGTTGCTGTAGCCAAATTC Invitrogen 
20 Pre-GAPDHf CCACCAACTGCTTAGCACC Invitrogen 
21 Pre-GAPDHr CTCCCCACCTTGAAAGGAAAT Invitrogen 
22 Gag1_1412f GGCAAGAGTTTTGGCTGAAG Invitrogen 
23 Gag1_1584r CACATTTCCAACAGCCCTTTT Invitrogen 
24 Gag2_1457f AAGCTTGAGGGCAGAACAAA Invitrogen 
25 Gag2_1651r AGGGCCTCTGCCATTAATCT Invitrogen 
26 
H2 spliced 
FWD 
ACTAGCAGTCGCCGC Invitrogen 
27 
H2 spliced 
REV 
TGCCACTAGATGTCTCCGCAC Invitrogen 
28 
H2 unspliced 
FWD 
CCTCTTAATAAAGCTGCCAGTTAG Invitrogen 
29 
H2 unspliced 
REV 
ACTCAGCGGTATATGGGTGTAG Invitrogen 
30 Renilla FWD ATGATAACTGGTCCGCAGTG Invitrogen 
31 Renilla REV GCGCTACTGGCTCAATATGT Invitrogen 
32 
T7 Sequencing 
primer 
TAATACGACTCACTATAGGG 
Bo Meng & 
Prof. Andrew 
Easton 
 
Table 6: Primer names and primer sequences used for experiments. The primer 
number and source are shown. 
2.2 Methods 
2.2.1 Tissue culture 
HeLa and COS-1 cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FCS at 37ºC/5% CO2. When confluent, 
HeLa were split 1/10 and COS-1 split 1/5 twice weekly. Jurkat cells were 
grown in suspension at 37ºC/5% CO2 in Roswell Park Memorial Institute 
medium (RPMI) supplemented with 10% FCS and split 1/10 twice weekly. 
BSRT7 cells were grown alternatively in Glasgow minimum essential medium 
(GMEM) and GMEM-G418 (supplemented with Geneticin, G418) at 37ºC/5% 
CO2. In both cases media was supplemented with FCS (5%), glutamine 
(0.25%), Penstrep (0.25%), and cells were split 1/6 when confluent. 
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2.2.2 Plating out cells (for transfection) 
Confluent BSRT7, COS-1 or HeLa cells were washed in PBS and extracted 
from flasks by incubation with 3 ml trypsin-EDTA at 37ºC/5% CO2 for 5 min. 
Trypsin reactions were quenched with 7 ml media. Cell suspensions were 
diluted 1/8 (HeLa), 1/4 (COS-1) in DMEM and seeded into 6-well (2 ml per 
well) or 12-well (1 ml per well) plates and incubated overnight at 37ºC/5% 
CO2. 
Jurkat cells grown in suspension were centrifuged at 1,500 rpm for 5 min. 
The supernatant was discarded and the remaining cell pellet resuspended in 
10 ml RPMI. 10 μl cells were stained with 10 μl Trypan blue [Sigma] and the 
cell concentration determined by counting using a haemocytometer. Cells 
were plated at a concentration of 0.8-1.6 x 106 cells/ml diluted in RPMI and 
grown overnight at 37ºC/5% CO2. 
2.2.3 Transfection of cells 
Cells at 70% confluency were transfected with DNA or RNA via a lipid 
transfection system. LipofectamineTM2000 [Invitrogen] was diluted 1/50 
(BSRT7, COS-1, HeLa) or 1/25 (Jurkat cells) in OPTIMEM and incubated for 
20 min with nucleic acid also diluted in OPTIMEM. Cell media was replaced 
before the nucleic acid/Lipofectamine/OPTIMEM suspension was added to 
cells. Transfected cells were incubated at 37ºC/5% CO2. Conventionally, 
DNA transfections were harvested after 24 h and RNA transfections after 6 h 
and RNA or protein extracted for downstream expression analysis. 
Actinomycin D treatment: Cellular transcription was shut down by substituting 
cell media for media containing 5 μg/ml actinomycin D [Sigma] at 24 h post-
transfection. 
Leptomycin B treatment: To shut down CRM-1-dependent nuclear export, 
cell media was supplemented with 15 nM leptomycin B [Sigma-Aldrich] at 24 
h post-transfection. 
Poliovirus infections: For shutdown of cap-dependent translation, HeLa cells 
were infected with poliovirus diluted to a concentration of 3.8 x 106 pfu/well in 
DMEM (with 10% FCS) for 1 h prior to transfections (at an m.o.i of 10). Media 
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containing poliovirus was removed and cells were washed twice with 1 ml 
PBS before new media was replaced onto cells and transfection carried out. 
Saquinavir treatment: For some transfections, HIV Protease cleavage of Gag 
was inhibited by supplementing the media of treated cells with 1 μM 
saquinavir. 
siRNA treatment: Where stated, cells were treated with either 50 nM AP-1 
siRNA or 50 nM negative control siRNA [Ambion] by transfection with 
LipofectamineTM2000 [Invitrogen]. 
2.2.4 Protein extraction from transfected cells 
Following incubation at 37ºC, media was removed from transfected BSRT7, 
COS-1 or HeLa. Cells were washed with PBS before adding 200 µl 1x PLB 
[Promega] and lysing cells on a Luckham R100 Orbital Shaker for 20 min. 
Lysed cells were centrifuged for 2 min at 13,000 rpm. The supernatant, 
containing total cellular protein, was removed to a fresh Eppendorf and 
stored at -20ºC. Jurkat cells grown in suspension were first centrifuged at 
2,000 rpm for 1 min to pellet cells. Cell pellets were washed with 200 µl PBS 
and centrifuged again at 2,000 rpm for 1 min, before discarding the 
supernatant and lysing cells by adding 50 µl 1x PLB. 
2.2.5 Sub-cellular fractionation of cells for qPCR 
At stated time points, the media was removed from cells and the monolayer 
washed in PBS. 200 µl Trypsin-EDTA was added for 5 min at 37°C. Cells 
were dislodged, transferred to an Eppendorf and rinsed in 1 ml DMEM (10% 
FCS). After centrifugation at 4000 rpm for 5 min, the supernatant was 
discarded and cell pellet washed in 1 ml PBS. Following further centrifugation 
for 3 min at 4,000 rpm, the cell pellet was either resuspended in 200 μl ice-
cold PBS for total RNA extraction, or further processed for nucleus/cytoplasm 
separation. 
Cell pellets for nucleus/cytoplasm separation were resuspended in 1 ml RSB 
(10 mM Tris pH 7.5, 10 mM NaCl, 10 mM MgCl2) and incubated on ice for 3 
min. After centrifugation at 4,000 rpm for 3 min, the cell pellet was 
resuspended in 200 µl RSBG40 (10 mM Tris pH 7.4, 10 mM NaCl, 3 mM 
Chapter 2       Materials & Methods 
 
63 
 
MgCl2, 10% glycerol, 0.5% NP40, 0.5 mM DTT, 4000U RNase inhibitor) and 
centrifuged at 7,000 rpm for 3 min. 200 µl of the supernatant was removed to 
a new Eppendorf for cytoplasmic RNA extraction. Excess supernatant was 
discarded and the pellet vortexed slowly in 100 µl RSBG40 with 1/10 
detergent mix (3.3% wt/wt sodium deoxycholate, 6.6% Tween40). After 
incubation on ice for 5 min, the pellet was centrifuged at 7,000 rpm for 3 min 
and the supernatant discarded before resuspension in 100 µl RSBG40. After 
centrifuging at 10,000 rpm for 5 min, the pellet was resuspended in 200 µl for 
nuclear RNA extraction. RNA was extracted from total, nuclear and 
cytoplasmic samples using Trizol. 
2.2.6 RNA isolation from cells: Trizol extraction 
After vortexing in 1 ml Tri Reagent® [Sigma-Aldrich], samples were 
incubated for 5 min at rt. 200 µl chloroform was added and samples were 
shaken by hand for 15 sec before leaving for 2 min (rt). After centrifuging at 
12,000 g (10 min), the aqueous phase containing RNA was removed into 0.5 
ml isopropanol, mixed by inverting, and placed at -20ºC overnight to 
precipitate RNA. Following centrifugation at 12,000 g (10 min), the 
supernatant was discarded and the pellet washed with 1 ml 75% ethanol. 
After vortexing and re-pelleting the sample at 12,000 g (5 min), the 
Eppendorf lid was left open to air dry the pellet for 10 min. Pelleted RNA was 
re-suspended in 30 µl DEPC-treated H2O. 
2.2.7 RNA isolation: phenol extraction 
Nuclease-free water was added to nucleic acid samples to produce a total 
volume of 150 µl or 200 µl. An equal volume of phenol/chloroform/isoamyl 
alcohol (25:24:1) [Fisher BioReagents] was added to each sample. Following 
vortexing and centrifugation for 2 min (13,000 rpm), the aqueous phase 
containing nucleic acid was removed to a fresh Eppendorf. An equal volume 
of isopropanol was added before overnight precipitation at -20ºC. Following 
overnight precipitation, the sample was centrifuged for 8 min at 13,000 rpm 
and the pellet resuspended in 20 µl nuclease-free H2O. 
Alternatively, RNA was extracted using an RNeasy Mini Kit [Qiagen] as per 
the manufacturer’s instructions. 
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2.2.8 DNase treatment 
RNA samples were treated with 2 μl DNaseI (2 U/μl) in 50 μl 1x DNase1 
Buffer [Ambion] to remove template DNA. Reactions were incubated at 37°C 
for 30 min, before phenol extraction of DNA. 
2.2.9 DNA isolation: phenol extraction 
DNA products were purified by phenol/chloroform extraction and ethanol 
precipitation. Reaction volumes were adjusted to 200 μl with nuclease-free 
H2O and an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) mix 
[Fisher BioReagents] was added to each sample prior to vortexing and 
centrifugation at 13,000 g for 2 min. The upper aqueous phase was removed 
to a fresh Eppendorf and DNA precipitated overnight at -20°C in 1/10 3 M 
NaOAc and 2.5 vol. 100% ethanol. The next day, samples were centrifuged 
at 13,000 rpm for 8 min and the supernatant discarded. The remaining DNA 
pellet was resuspended in 20 μl nuclease-free H2O. 
Alternatively, DNA reactions were cleaned up using the MinElute Reaction 
Cleanup Kit [Qiagen] according to the manufacturer’s instructions. 
2.2.10 Determining the concentration of nucleic acids 
A Nanodrop 1000 Spectrophotometer [Thermo Scientific] was used to 
determine the concentration of DNA or RNA preparations. 
2.2.11 In vitro DNA transcription (mMESSAGE mMACHINE® T7 kit) 
1 μg linearised DNA was transcribed into capped RNA using a mMESSAGE 
mMACHINE® T7 kit [Ambion] for 2 h at 37°C. Capped RNA was 
polyadenylated using a Poly(A) Tailing kit [Ambion] and template DNA was 
degraded by incubation with TURBO DNase [Ambion mMESSAGE 
mMACHINE® T7 Kit] at 37°C for 30 min before extraction of capped and 
polyadenylated RNA by phenol extraction. Reactions were carried out 
according to the manufacturer’s instructions. 
To produce uncapped RNA, the cap-NTP mix contained in the mMESSAGE 
kit was exchanged for 7.5 mM NTPs, preventing the addition of a cap-
structure to the mRNA. 
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2.2.12 In vitro DNA transcription (MAXIscript® kit)  
The Ambion MAXIscript® kit was used to make radiolabelled RNA from 1 μg 
linearised DNA plasmids. Reactions were incubated with 1x Transcription 
Buffer, 0.5 mM ATP, 0.5 mM CTP, 0.5 mM GTP, 0.05 mM UTP, 20 μCi α-32P 
UTP (10 μCi/μl) [Perkin Elmer] and enzyme mix as per the manufacturer’s 
instructions at 37°C for 1 h. Subsequent TURBO DNase [Ambion 
mMESSAGE mMACHINE® T7 Kit] treatment removed template DNA. 
Radioactive RNA was isolated using the RNeasy Mini Kit [Qiagen]. 
2.2.13 In vitro DNA transcription (biotinylated RNA) 
Biotinylated RNA was produced for RNA affinity chromatography. 1 μg of 
linearised DNA was used in a reaction with 2 μl of Biotin RNA Labelling mix 
[Roche Applied Science], 1x Transcription Buffer and 2 μl RNA T7 
polymerase [Ambion]. Samples were incubated at 37°C for 2 h before DNase 
treatment at 37°C for 15 min. Biotinylated RNA was extracted using 
phenol/chloroform. To make radioactively labelled biotin RNA, 2 μl α-32P UTP 
(10 μCi/μl) [Perkin Elmer] was added to transcription reactions. 
2.2.14 In vitro DNA transcription/translation (TnT) 
100 ng of DNA plasmid was used in an in vitro TnT Quick Coupled 
Transcription/Translation system [Promega] with 35S-methionine (0.01 μCi). 
Reactions were carried out at 30°C for 1.5 h according to manufacturer’s 
instructions. Proteins produced were used for luciferase assays or in a SDS-
PAGE; gels were vacuum dried and exposed to KODAK™ Biomax® MR 1 
Film [Perkin Elmer]. 
2.2.15 In vitro RNA translation (rabbit reticulocyte lysate) 
800 ng RNA was translated in a Flexi® Rabbit Reticulocyte Lysate System 
[Promega] supplemented with amino acid (minus methionine) [Promega], 60 
mM or 100 mM KCl, 1/10 HeLa S100 extract and 35S-methionine (0.01 μCi). 
Reactions were incubated for 1.5 h at 30°C before 10 μl RNase STOP 
solution (50 μg/ml RNase A, 10 mM EDTA pH 7.5) was added and the 
reactions incubated at 37°C for a further 15 min before heating to 85°C for 10 
min. 2.5 μl radioactively labelled proteins were used in a luciferase assay or 
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added to 2x SDS sample buffer and used in a SDS-PAGE; gels were vacuum 
dried and exposed to KODAK™ Biomax® MR 1 Film [Perkin Elmer]. 
2.2.16 Luciferase assays 
The amount of firefly and Renilla luciferase in 5 μl of extracted protein 
sample, or 2.5 μl TnT reaction, was quantified using a Dual-Luciferase® 
Reporter (DLRTM) Assay System [Promega]. 25 μl of luciferase assay 
reagent II (LARII) was added to each sample in a 96-well, flat-bottomed, 
white plate [Greiner Bio-One] and the luminescent signal read on a 
Luminoskan Ascent luminometer [Thermo Labsystems]. After firefly 
luciferase quantification, the reaction signal was quenched, and the Renilla 
luciferase simultaneously activated, by adding 25 μl Stop & Glo® Reagent 
[Promega] to each sample. Renilla luciferase luminescence was quantified by 
once more reading the plate on the luminometer. 
2.2.17 SDS-PAGE and western blotting 
Protein samples were diluted in 2x SDS sample buffer (100 mM Tris Cl pH 
6.8, 4% SDS, 20% glycerol, 0.2% bromophenol blue, 5% β-mercaptoethanol) 
and heated at 100ºC for 5 min before loading onto a 10% SDS-PAGE gel 
(composed of a 5% stacking layer and 10% resolving layer). 10 μl of a 
PageRulerTM Plus Prestained Protein Ladder [Fermentas] was run alongside 
samples for sizing. Samples were separated at 30 mA in 1x protein gel 
running buffer (0.1% SDS, 0.03% Tris, 1.44% Glycine) for 2 h. A 
nitrocellulose filter was used for western blotting of resolved protein gels, 
sandwiched between layers of 3 mm Whatman® Chromatography Paper, at 
400 mA for 2 h. Western blotting was carried out in 1x transfer buffer (0.3% 
Tris, 2.88% glycine, 20% methanol) at 4ºC. 
2.2.18 Immunoprobing 
After western blotting, nitrocellulose filters were blocked overnight in 5% 
dried milk Marvel TBS-T (0.1% Tween). The filter was probed with primary 
antibody diluted in 5% Marvel TBS-T for 1 h and secondary antibody diluted 
in 5% Marvel TBS-T for 1 h. After each incubation, 3x 10 min washes were 
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carried out using TBS-Tween. The filter was developed using an ECLTM 
Advance Kit [Amersham] according to the manufacturer’s instructions. 
2.2.19 Gel staining and vacuum drying 
Gels were stained by immersion in Coomassie Brilliant Blue for 2 min 
followed by destain (10% acetic acid, 10% methanol, H2O). Gels for mass 
spectrometry were stained with Instant BlueTM [Expedeon] according to the 
manufacturer’s instructions. The Silver Stain Plus kit [Biorad] was used to 
stain RNA affinity chromatography SDS-PAGE gels. Staining was carried out 
according to the manufacturer’s instructions. After staining, the gels were 
placed onto two layers of 3 mm Whatman® Chromatography Paper and 
covered with cling film before vacuum drying at 80°C for 1 h on a Slab Gel 
Dryer Sr. SE1160 [Hoefer Scientific Instruments]. Dried gels were exposed to 
photographic Fuji Medical X-Ray Film [Fujifilm] or KODAK™ Biomax® MR 1 
Film [Perkin Elmer] for the stated exposure time before developing films 
using a Curix60 Developer [AGFA]. 
2.2.20 Mass spectrometry 
Instant Blue stained gel pieces were excised, cut into smaller segments using 
a scalpel and placed into 200 μl H2O. Mass spectrometry was carried out by 
the Warwick/Waters Centre for Biomedical Mass Spectrometry and 
Proteomics facility within the School of Life Sciences, University of Warwick. 
The gel sample was processed and digested by trypsin according to the 
MassPrep robotic protein handling system manufacturer’s instructions. 
Peptides extracted from each sample were analysed by nanoLC-ESI-MS/MS 
using the NanoAcquity/Synapt HDMS instrumentation and a 45 minute LC 
gradient. Data was corrected for mass drift using reference data from the 
Human [Glu1]-Fibrinopeptide B [Sigma] sampled for each minute of data 
collection. Resulting data was used to interrogate the UniProt databases 
(http://www.ebi.ac.uk/integr8) using ProteinLynx Global Server v2.4. Proteins 
identified from the database search were presented in an Excel document. 
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2.2.21 Confocal microscopy 
Prior to transfection, HeLa cells were seeded into 12-well plates containing 
16 mm glass cover-slips. Following transfection, cell media was removed and 
cells were fixed for 10 min with 10% (v/v) liquid formalin diluted in PBS and 
permeabilised with 0.5% (v/v) NP40 in PBS for 10 min. Non-specific binding 
was blocked by treating cells with 10 mg/ml BSA in PBS for 1 h. Cells were 
washed in PBS before incubation with primary antibody for 1 h diluted 1:500 
in 1% BSA PBS. Following washes in PBS, cells were incubated for 1 h with 
a secondary Alexa Fluor® antibody [Invitrogen] diluted 1:500 in PBS with 1% 
BSA. Incubation steps were repeated with subsequent primary and 
secondary antibodies to target additional proteins. DAPI nuclear stain 
[Sigma] at 1 µg/ml in PBS was applied for 5 min. Slides were mounted using 
Vectashield® Mounting Medium [Vector Laboratories] and sealed using clear 
nail varnish before viewing on a SP2 confocal microscope [Leica 
Microsystems]. 
2.2.22 Reverse transcription: making cDNA 
For qPCR experiments, between 2-4 μg of Trizol extracted RNA was DNase 
treated to remove template DNA. cDNA was produced from 500 ng RNA 
using the High Capacity RNA-to-cDNA kit [Applied Biosystems] according to 
the manufacturer’s recommendations. Reactions were carried out in a TC-
3000 Personal 25-well Thermal Cycler [Techne] with the following conditions: 
60 min at 37°C, 5 min at 95°C, reactions held at 4°C. 
2.2.23 PCR 
For PCR, 50 ng plasmid template DNA or 1 µl of cDNA were amplified by 30 
cycles of PCR  using 20 μM forward and reverse primers and 2x Biomix 
[Bioline]. Reactions were carried out in a TC-3000 Personal 25-well Thermal 
Cycler [Techne] with the following conditions: denaturation for 2 min at 96°C, 
30 cycles of: 1 min at 96°C, 1 min at 55°, 2 min at 72°C and a final extension 
at 72°C for 10 min. 
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2.2.24 Quantitative real-time PCR (qPCR) 
qPCR master mixes were prepared in a MicroAmp® Optical 96-well Reaction 
Plate [Applied Biosystems] with 2x Fast SYBR® Green Master Mix [Applied 
Biosystems] according to the manufacturer’s recommendations. Plates were 
sealed with an Optical Adhesive Cover [Applied Biosystems]. Master mixes 
contained 20 μM forward and reverse primers and 2 μl reverse transcribed 
cDNA template in a total reaction volume of 20 μl. Amplification of cDNA was 
carried out by real-time quantitative PCR and detected using an ABI 7000 
Sequence Detection System [Applied Biosystems]. Gene expression was 
normalised to housekeeping genes and samples were run alongside RT 
negative cDNA (produced without reverse transcriptase) and H2O controls. 
Data was evaluated using 7500 Fast System SDS Sequence Detection 
Software (version 1.4) [Applied Biosystems] with a threshold bar setting of 
1.00; results were exported into an Excel document for further analysis. 
2.2.25 Denaturing RNA gel electrophoresis 
Denaturing gels were prepared using 1% nuclease-free Agarose-LE 
[Ambion], 6% formaldehyde and 10x MOPS gel running buffer [Ambion] 
diluted to a total volume of 20 ml in DEPC-treated water. Samples were 
added to 3x loading dye [Ambion] (with 10% β-mercaptoethanol) and heated 
to 65°C for 15 min before loading onto the gel. A 5x ssRNA Millenium marker 
[Ambion] was loaded alongside samples for sizing. Electrophoresis was 
carried out at 30 mA in 1x MOPS running buffer [Ambion]. 
2.2.26 DNA agarose gel electrophoresis 
Unless otherwise stated, agarose gels were prepared using 0.75% agarose 
[Gibco-BRL] in 1x TBE buffer with 0.02% ethidium bromide [Sigma]. Samples 
to be separated by gel electrophoresis were mixed with 6x DNA loading dye 
(0.625% SDS, 62.5% glycerol, 0.125% bromophenol blue) and loaded onto 
the gel. Electrophoresis was carried out at 30 mA in 1x TBE buffer and gels 
were visualised using UV illumination. A 1 kb DNA ladder [Invitrogen] was 
used to size fragments.  
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2.2.27 Gel extraction of DNA and purification of restriction digests 
The correct fragment on a 0.75% agarose gel was viewed on a 
Transilluminator 4000 UV light box [Stratagene], excised with a scalpel and 
purified using a QIAquick Gel Extraction Kit [Qiagen] according to the 
recommended procedure.  
2.2.28 Restriction enzyme digests  
PCR DNA digestion: 25 µl of PCR product was digested with a restriction 
enzyme for 2 h according to the manufacturer’s instructions. DNA was 
isolated by phenol extraction. 
Plasmid digestion and dephosphorylation: 5 µg of plasmid was typically 
digested with 2 µl restriction enzyme for 2 h according to the manufacturer’s 
instructions. After 2 h, an additional 2 µl of enzyme was added and the 
reaction incubated for a further 2 h. Plasmids digested for use as vectors in 
ligation reactions were dephosphorylated to prevent self-ligation by treatment 
of the entire restriction digest volume with 1 µl calf intestinal alkaline 
phosphatase (CIAP) in 10x NEBuffer 3 [NEB] at 37°C for 15 min, according 
to the manufacturer’s instructions. DNA was isolated by phenol extraction. 
2.2.29 Ligation 
Restriction digested inserts and plasmids were ligated at a molar ratio of 3:1 
insert: vector with T4 DNA ligase [NEB] at 16°C overnight in accordance with 
the manufacturer’s instructions. 
2.2.30 Transformation of E.Coli and purification of bacterial DNA 
50 µl of E.coli TG1 competent bacteria were transformed with 5 µl ligation 
reaction or 1 µl plasmid DNA. Reactions were incubated on ice for 20 min 
before heat-shock at 42°C for 45 sec followed by placement on ice for 1 min. 
200 µl SOC was added to each sample and the bacteria incubated for 1 h at 
37ºC. 200 µl bacteria were plated onto selective LB plates containing 
ampicillin at 100 µg/ml and incubated at 37ºC overnight. 
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Provirus DNA was transformed into TOP10F cells according to the 
manufacturer’s recommendations  [Invitrogen] and plates incubated at 30ºC 
for 24 h. 
2.2.31 Sequencing 
250 ng DNA samples were sequenced in a 10 μl reaction volume with 5.5 
pmol T7 primer. Sequencing was carried out in house on a PRISM 3130XL 
Genetic Analyser [Applied Biosystems]. 
2.2.32 DNA Miniprep 
Resulting colonies from transformations were grown up in 2 ml LB-medium 
supplemented with 100 μg/ml ampicillin. After growth overnight at 37°C in an 
Orbital Incubator [Gallenkamp], each culture was decanted into a 1.5 ml 
Eppendorf and centrifuged for 2 min at 13,000 rpm. The supernatant was 
discarded and bacterial DNA extracted using reagents from the Plasmid Maxi 
Kit [Qiagen]: the pellet was resuspended in 100 μl P1, 100 μl P2 and 100 μl 
P3 sequentially, inverting the Eppendorf after each addition. DNA was 
extracted using phenol/chloroform. 
2.2.33 DNA Maxiprep 
For large scale plasmid preparation, transformed bacterial colonies were 
isolated and initially incubated for 5 h in 2 ml LB-medium supplemented with 
100 µg/ml ampicillin before transferring 50 µl of the resulting culture into a 1 
litre conical flask, containing 250 ml LB-medium with 100 µg/ml ampicillin, 
and incubating overnight. Incubations were carried out at 37°C in an Orbital 
Incubator [Gallenkamp] or 30°C for amplification of provirus DNA in TOP10F 
cells. Cultures were centrifuged for 10 min at 5,000 rpm in a JA10 Rotor 
[Beckman] to pellet bacterial cells and bacterial DNA was purified using the 
Plasmid Maxi Kit [Qiagen] according to the manufacturer’s instructions. 
Centrifugation steps were carried out with a JA20 Rotor [Beckman] and DNA 
was eluted in 400 µl H2O and stored at -20ºC. 
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2.2.34 Making HeLa cell extract 
HeLa S10 extract [a gift from Professor Richard Jackson] was adjusted to 0.5 
M KCl by dropwise addition. Following 30 min incubation on ice, the extract 
was layered onto a 5 ml glycerol cushion (25% glycerol, 0.5 M KCl, 20 mM 
MOPS pH 7.2, 6 mM Mg(OAc)2, 2 mM EGTA, 2 mM DTT). After 
centrifugation for 3.5 h at 28,000 rpm, 4°C, in a Beckman XL-70 
Ultracentrifuge with a SW40Ti rotor [Beckman], extract was dialyzed in 3 ml 
(10K) Slide-A-Lyzer G2 Dialysis Cassettes [Thermo Scientific] against H100 
buffer (20 mM HEPES pH 7.5, 100 mM KCl, 2 mM DTT) overnight at 4°C. 
The resulting HeLa S100 extract was stored at -80°C. 
2.2.35 UV cross-linking 
The MW of HIV RNA binding proteins were determined by UV cross-linking. 
Each 10 μl reaction was incubated for 15 min at 30ºC in a 96-well, U-Bottom, 
Flexible Plate [BD FalconTM] with 2 µl HeLa S100 extract, 1 mg/ml tRNA, 0.1 
M KCl and 2 μl α-32P UTP labelled RNA in binding buffer (at a final 
concentration of 10 mM HEPES pH 7.5, 3 mM MgCl2, 5% glycerol, 1 mM 
DTT). Non-specific, specific or unlabelled RNA competitors were added at 
specified molar excess ratios. Samples were kept on ice and cross-linked by 
exposure to UV light at 3x 0.800 J/cm2 using a UV cross-linker CL-E508 
[Uvitec]. Unbound RNA was degraded with 4 μl of RNase mix: 10 mg/ml 
RNaseA and Cobra venom RNase V1  [Ambion] diluted 1/30 in buffer (at a 
final concentration of 10 mM Tris/HCl pH 7.8, 1 mM MgCl2, 100 mM KCl) for 
15 min at 37°C. 15 μl 2x SDS sample buffer was added and samples boiled 
at 100°C for 5 min. Protein-RNA complexes were separated by 10% SDS-
PAGE alongside 10 μl of PageRuler PlusTM Prestained Protein Ladder 
[Fermentas]. The resolved gel was Coomassie stained and destained before 
vacuum drying at 80°C for 1 h. Protein-RNA complexes were identified by 
autoradiography and sized by comparison to the protein marker. 
2.2.36 UV cross-linking and La immunoprecipitation (Protein G 
agarose) 
UV cross linking was carried out using HeLa S100 extract, followed by La 
immunoprecipitation. 400 μl NET Buffer (50 mM Tris pH 7.6, 150 mM NaCl, 
Chapter 2       Materials & Methods 
 
73 
 
0.01% NP40) and 1 μl La antibody [Santa Cruz Biotechnology, Inc.] were 
added to each UV cross-linking reaction and incubated for 1 h at 4°C. 
Precipitated proteins were pelleted by centrifugation at 8,000 rpm for 2 min. A 
50% slurry of hydrated Protein G agarose beads [Sigma] washed in 1 ml 
NET buffer (150 mM NaCl, 1 mM EDTA, 50 mM Tris pH 8) was added to 
each sample and incubated on a Spiramix 5 tube rotator [Denley] for 20 min 
at 4°C. Beads were centrifuged at 13,000 rpm for 1 min; the supernatant was 
discarded and the pellet was washed 3 times with RIPA buffer (1% NP40, 
0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris pH 7.8). 
The pellet was resuspended in 25 μl 2x SDS sample buffer before heating at 
100°C for 5 min. Precipitated proteins were separated by SDS-PAGE; the gel 
was subsequently Coomassie stained, destained, vacuum dried at 80°C for 1 
h and exposed to Fuji Medical X-Ray Film [Fujifilm]. 
2.2.37 La immunoprecipitation (Dynabeads) 
La immunoprecipitation was carried out using recombinant La [Prospec-Tany 
Technogene Ltd] and HeLa cell extract. 1.5 mg of magnetic Dynabeads® 
Protein G [Invitrogen] were removed from solution by placing on a 
MagnaRackTM [Invitrogen] and used in a binding assay with 2 μg mouse anti-
La antibody [Santa Cruz Biotechnology, Inc.] at rt, for 10 min with rotation on 
a Spiramix 5 tube rotator [Denley]. Beads were placed on the magnet and the 
supernatant discarded. The remaining bead-antibody complex was washed 
by gentle pipetting in 200 μl PBS with (0.02%) Tween (PBS-T) followed by 2 
washes in 200 μl conjugation buffer (20 mM sodium phosphate, 0.15 M 
NaCl). The supernatant was discarded by placing the beads on a magnet 
and beads resuspended in 250 μl 5 mM BS3 (bis[sulfosuccinimidyl] suberate) 
[Thermo Scientific] at rt, for 30 min with rotation. 12.5 μl Quenching buffer (1 
M Tris HCl pH 7.5) was added for 15 min at rt with rotation, before washing 
beads 3x with 200 μl PBS-T; beads were placed on the magnet and the 
supernatant discarded each time. Antigen samples: 10 μl HeLa S100 extract 
or 1 μg Recombinant Human La protein [Prospec-Tany Technogene Ltd] in 
200 μl PBS were added to the beads and incubated at rt for 30 min to allow 
antigen-antibody binding. The bead-Ab-Ag complex was washed 3x in 200 μl 
PBS; the supernatant was separated by magnet and discarded between 
Chapter 2       Materials & Methods 
 
74 
 
each wash. 100 μl PBS was added to each sample, which was removed to a 
clean Eppendorf for elution. After discarding the supernatant, 20 μl 2x SDS 
sample buffer was added to samples which were heated to 100°C for 5 min. 
Eluted protein samples were separated from beads using magnetism and 
resolved by SDS-PAGE. 
Additionally, UV cross-linking reaction samples were used for La 
immunoprecipitation. Following UV cross-linking, and prior to the addition of 
SDS, samples were, instead, diluted in 200 μl PBS and added as antigen 
samples to this stage of the immunoprecipitation protocol. 
2.2.38 RNA affinity chromatography (RAC) 
Magnetic Dynabeads® M-280 Streptavidin [Invitrogen] were vortexed and 
placed on a MagnaRackTM [Invitrogen] to allow aspiration of the supernatant. 
Beads were prepared for RNA binding by washing in twice the bead volume 
of Binding & Washing buffer (10 mM Tris HCl pH 7.5, 1 mM EDTA, 2 M NaCl) 
for a total of 3 washes, Solution A (0.1 M NaOH, 0.05 M NaCl) for a total of 2 
washes and Solution B (0.1 M NaCl) for 2 washes. Solution B was removed 
from the beads which were then resuspended in twice the bead volume of 
Binding & Washing buffer. Beads were incubated with an equal volume of 
diluted biotin RNA (2 pmol RNA/µl beads) for 1 h at rt on a Spiramix 5 tube 
rotator [Denley]. The supernatant was removed by placing the sample on the 
magnet. Biotinylated RNA coated beads were washed 2 times with Binding & 
Washing buffer and added to a protein binding reaction containing 2 μl HeLa 
extract S100, Binding buffer (at a final concentration of 10 mM HEPES pH 
7.5, 3 mM MgCl2, 5% glycerol, 1 mM DTT), 1 mg/ml tRNA and 0.1 M KCl. 
Protein binding was carried out for 1 h at 30°C. Beads were washed with 
increasing concentrations of NaCl in PBS to elute RNA-bound proteins. After 
each wash, biotin RNA-bead-protein complexes were isolated by placing 
samples on the magnet and the supernatant wash fraction removed to a 
clean tube. After several washes, the beads were resuspended in 20 μl 2x 
SDS sample buffer to elute any remaining RNA-bound proteins. 10 μl wash 
fractions were added to 10 μl SDS, heated at 100°C for 5 min, and resolved 
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by SDS-PAGE, or fractions were used in UV cross linking to identify RNA 
binding proteins. 
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3. CHAPTER 3: TRANSCRIPTION AND NUCLEAR 
 EXPORT OF HIV GAG-POL MRNA 
3.1 Introduction 
Various stages of the viral life cycle may differ between HIV-1 and HIV-2 and 
thus contribute to the lower rate of replication witnessed for HIV-2. This 
chapter addresses the potential differences in HIV-1/2 transcription and the 
export of full-length viral RNA from the nucleus to the cytoplasm. Both of 
these steps, if attenuated, may prove rate-limiting for the production of viral 
particles; lowered mRNA synthesis and inefficient mRNA export would result 
in a limited supply of viral RNA in the cytoplasm for the translation of viral 
proteins and genome packaging. Consequently, we wanted to address 
whether HIV-2 has a reduced transcription rate or inefficient export when 
compared to HIV-1.  
Firstly, this chapter discusses already noted differences between the HIV-1 
and HIV-2 viruses which may account for transcriptional or export variations. 
Considerations of potential HIV RNA degradation pathways, affecting both 
nuclear and cytoplasmic viral RNA levels, are made. Actinomycin D and 
leptomycin B are introduced as investigative tools to shutdown transcription 
and RNA export respectively, to examine HIV-1/2 RNA degradation rates. 
Finally, quantitative real-time RT-PCR results are presented showing a 
comparison of HIV-1/2 mRNA levels in total cell lysate, nuclear and 
cytoplasmic fractions in order to assess the level of HIV-1/2 mRNA 
transcription and export. 
3.1.1 HIV-1/2 transcription 
Although it is recognized that individuals infected with the HIV-2 virus exhibit 
significantly slower disease progression, the mechanisms responsible for this 
attenuated pathogenicity remain unclear. The level of viral RNA in the blood 
is much lower during a HIV-2 infection compared to HIV-1. However, both 
HIV-1 and HIV-2 are able to establish stable integration of proviral DNA. 
Consequently, this suggests that the production of viral mRNA may be 
attenuated for HIV-2 (MacNeil et al., 2007). 
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There are several features of HIV-2, which differ from HIV-1 and, moreover, 
which could potentially affect the way in which it undergoes transcription. The 
HIV-1 long terminal repeat (LTR) contains two binding sites for the 
transcriptional enhancer NFкB (nuclear factor kappa B) whereas the 
equivalent region of the HIV-2 LTR contains only one conserved NFкB 
binding site. T-cell activation signals were shown to initiate a better response 
from the HIV-1 LTR than for HIV-2 due to the qualitative difference in LTR 
transcriptional enhancer regions (Tong-Starksen et al., 1990). Thus the 
immediacy of transcriptional activation may differ between HIV-1 and HIV-2. 
HIV transcription is regulated by both the interaction of cellular factors with 
the HIV LTR and binding of the viral trans-activator protein Tat to the TAR 
structure, also found within the HIV LTR. HIV-1 and HIV-2 Tat bind with 
similar efficiency to their respective TAR structures. Additionally, both HIV-
1/2 Tat proteins have been shown to bind interchangeably with HIV-1/2 TAR 
structures (Dillon et al., 1990). However, HIV-2 Tat is a weaker activator of 
the HIV-1 TAR than HIV-1 Tat. Consequently, the binding properties of HIV-1 
and HIV-2 TAR may differ, and thus their interactions with cellular 
transcription factors may also differ. Subsequently, there are apparent 
differences in the mechanisms by which HIV-1 and HIV-2 Tat assert their 
trans-activation functions (García-Martínez et al., 1995). 
HIV-1 TAR extends from nucleotides 1-59 of the HIV-1 5’ UTR whereas HIV-
2 TAR presents an extended structure which occupies nucleotides 1-123 of 
the HIV-2 5’ UTR. Essentially, HIV-2 TAR appears to be a duplication of the 
HIV-1 TAR structure; each HIV-2 TAR stem-loop consists of a bulge and 6 
nucleotide conserved loop similar to the HIV-1 TAR [figure 28] (García-
Martínez et al., 1995).  
Transcriptional activation of HIV-1 relies on Tat interactions with the 
nucleotide bulge of HIV TAR RNA, and the additional binding of cellular 
factors; TAK and TRP-185. The role of TAK (consisting of CyclinT1 and 
CDK9 components) in Tat-activated transcription is discussed in detail in 
Chapter 1. TRP-185 is a TAR-RNA binding protein which regulates binding of 
RNA polymerase II to TAR during transcription (Wu, F. et al., 1991). TRP-185 
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has been shown to interact with the CUGGGA loop sequence (nucleotides 
30-35) of the HIV-1 TAR structure. Loop sequences (CUGGGA and 
CUGGGU) within the HIV-2 TAR structure closely resemble the HIV-1 
CUGGGA loop sequence and therefore TRP-185 may also bind to HIV-2 
TAR. Differences in the trans-activation of HIV-1 and HIV-2 may be further 
enhanced by variations in associations with TRP-185, RNA polymerase II or 
additional elongation factors (García-Martínez et al., 1995). 
 
Figure 28: The stem-loop structures of HIV-1 and HIV-2 TAR showing regions of 
similarity regarding the loop and bulge sequences. HIV-2 TAR appears to be a 
duplication of the HIV-1 TAR structure (García-Martínez et al., 1995). 
An assessment of the transcriptional rate of both HIV-1 and HIV-2 can be 
undertaken by proviral transfection. This negates rate-limiting stages such as 
virus entry, reverse transcription and integration which occur prior to 
transcription in the virus life cycle and could also affect the overall rate of 
mRNA production post-infection. The level of viral RNA can be easily 
quantified using real-time RT-PCR (qPCR) which is both a sensitive and 
accurate means of measuring gene expression. Many qPCR detection 
methods have been developed, although the most commonly used non-
specific detection dye is SYBR® Green. SYBR® Green intercalates with 
dsDNA and emits fluorescence. The amount of fluorescence from 
incorporated dye is directly proportional to the amount of DNA and therefore 
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provides an indication of the number of DNA copies. Changes in SYBR® 
Green fluorescence can thus be monitored using a thermocycler detector, 
and the number of cycles taken to reach a threshold fluorescence level 
provides a measure of the starting cDNA level.  
To measure RNA levels a two-step reaction is required, whereby all RNA is 
first reverse transcribed into cDNA before carrying out qPCR using specific 
primers for the target gene. During each PCR cycle, the amount of DNA is 
doubled. Therefore an exponential increase in products is observed until one 
of the reaction reagents becomes limiting, whereupon a plateau is reached. 
Comparing the number of cycles (Ct) taken to reach a threshold level of 
fluorescence (within the exponential range) provides a means to compare the 
starting levels of cDNA. The more abundant a target is, the quicker it is 
amplified to the threshold level; this is reflected by a lower Ct value. As the 
target DNA is amplified exponentially, a cycle difference of a single Ct 
therefore corresponds to a two-fold difference in DNA quantity 
[http://www.eurogentec.com/uploads/qPCR-guide.pdf]. Overall qPCR 
provides a system whereby the HIV-1/2 RNA levels within cells can be 
quantified and compared in an environment which reflects the natural 
progression of gene expression during an actual infection. 
3.1.2 Nuclear export of full-length HIV-1/2 mRNA 
Early HIV transcripts are spliced by cellular machinery. The majority of 
cellular mRNAs are very efficiently spliced. However, splicing of HIV 
transcripts is less efficient and results in alternative splicing of viral mRNA. 
Many of the HIV transcripts contain introns which, for cellular mRNA, would 
usually be spliced. The presence of introns would normally preclude 
nucleocytoplasmic transport of HIV mRNA or incorrect splicing would target 
these mRNAs for degradation via the exosome. However, HIV expresses a 
regulatory factor, Rev, which functions to prevent degradation of incompletely 
spliced viral transcripts such as the full-length, viral RNA. Virally encoded 
Rev is translated from multiply-spliced viral mRNA in the cytoplasm, and 
imported into the cell nucleus. Here it binds to the Rev response element 
(RRE) which is present on all intron-containing HIV transcripts. Binding of 
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Rev to the RRE stabilises viral mRNA and facilitates its transport to the 
cytoplasm via the CRM-1 export pathway (see Chapter 1) (Blissenbach et al., 
2010; Malim and Cullen, 1993).  
The HIV-1 RRE is a 334 nucleotide region present within the env coding 
region. A similar RNA structure is present within HIV-2 env. Multiply-spliced 
HIV mRNAs no longer contain the RRE, which is necessary for export of 
unspliced or partially spliced transcripts. The HIV-1 Rev protein is able to 
interact with both the HIV-1 and HIV-2 RRE. However, the same is not true 
for HIV-2 Rev which can only function with the HIV-2 RRE. Nonreciprocal 
Rev-RRE binding results from the HIV-2 Rev protein, which is unable to 
stably interact with the HIV-1 RRE. The phosphorylation level of HIV-1 Rev is 
higher than for HIV-2 Rev although it remains unclear as to whether this 
influences the Rev-RRE interaction as Rev phosphorylation is not thought to 
correlate with Rev function (Dillon et al., 1990). Consequently, differences in 
the HIV-1/2 Rev-RRE interaction may affect the efficiency with which viral 
mRNAs are exported from the nucleus. 
3.1.3 HIV-1/2 mRNA degradation 
The level of viral RNA within the cell is not merely a product of mRNA 
synthesis. In order to assess the level of HIV transcript synthesis it is 
important to consider other factors which may alter mRNA levels such as 
RNA degradation. mRNA degradation is important in regulating gene 
expression and therefore is a prevalent part of normal gene expression. 
Transcribed precursor mRNA is subject to processing and extensive quality 
control checks before nucleus-cytoplasm transport occurs. Both viral and 
cellular mRNA undergoes capping, polyadenylation and splicing to remove 
introns; if any of these stages produce erroneous mRNA, the mRNA is 
degraded.  
The nucleus contains an exosome which is responsible for inducing the 
degradation of mRNAs (Raijmakers et al., 2004). Additionally, spliceosome 
associated mRNAs which have failed to splice correctly are retained in the 
nucleus by Mlp1 and subsequently degraded by the nuclear exosome. 
Furthermore, the exosome core, in conjunction with Rrp6p, prevents mRNAs 
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lacking, or with an excessive poly(A) tail from undergoing nuclear export 
(Raijmakers et al., 2004). 
In the cytoplasm, incorrectly spliced mRNAs may contain a premature stop 
codon and therefore undergo nonsense mediated decay (NMD); Upf1 
recruits these mRNAs to the cytoplasmic exosome where they are 
sequestered into mRNA turnover pathways in order to inhibit their translation. 
Successfully produced mRNAs are translated several times before they, too, 
are directed for degradation (Raijmakers et al., 2004). The normal mRNA 
turnover pathway induces 3’-5’ removal of the mRNA poly(A), which 
stabilises mRNA, and degradation by exoribonucleases within the exosome. 
Additionally, removal of the 5’ cap structure by hydrolysis permits subsequent 
5’-3’ mRNA degradation by the exoribonuclease hXrn1. Lsm1 is also 
important in transcript degradation following shortening of the poly(A) tail, 
and recruitment of the decapping enzyme (Slomovic et al., 2010). 
HIV-1 infection also stimulates cellular mRNA degradation although it is 
unknown whether HIV proteins directly function as nucleases or whether they 
induce degradation through activation of cellular ribonucleases. SIV infected 
cells do not activate cellular mRNA degradation. As HIV-2 is more closely 
related to SIV, it is therefore possible that this feature of HIV-1 infection is not 
present during a HIV-2 infection. Thus HIV-1 infection may promote 
preferential translation of its own, viral mRNA by inducing degradation of 
competitive, cellular mRNAs whereas HIV-2 may not be able to enhance 
translation of its own mRNA via the same mechanism (Agy et al., 1996). 
The transcriptional inhibitor, actinomycin D (actD), provides an approach to 
studying mRNA degradation. ActD is an antibiotic typically used in the 
treatment of cancer. It non-specifically inhibits cellular proliferation by binding 
to deoxyguanosine within dsDNA. DNA-actD complexes prevent transcription 
by inhibiting DNA-primed RNA synthesis by RNA polymerase (Imamichi et 
al., 2005). It has also been reported that actD can produce single-strand 
breaks within DNA which disrupts transcription (Kang and Park, 2009). The 
inhibitory activities of actD make it a useful tool for observing the cellular 
effects of transcriptional shutdown. Likewise, it provides a means to quantify 
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RNA degradation levels without interference from continued mRNA 
synthesis. 
Previous experiments have utilised actD to assess the effect of this drug on 
HIV virion mRNA levels. Treating HIV-1 infected Jurkat (T-lymphocyte) cells 
with actD results in a decrease in the level of virion RNA, reflecting the 
decline in cytoplasmic mRNA levels resulting from transcriptional shutdown. 
Following HIV-2 infection of Jurkat cells, viral mRNA levels were shown to be 
more stable even at higher concentrations of actD although the level of virion 
mRNA still reflected the cytoplasmic level of viral mRNA. This suggests that 
HIV-2 mRNA may be more stable than HIV-1 mRNA (Dorman and Lever, 
2000). 
Shutting down CRM-1 dependent nuclear export also provides a means to 
assess viral RNA degradation. Leptomycin B (lepB) is often used as a means 
to do this. LepB is an antibiotic metabolite derived from Streptomyces. 
Typically, lepB is used in the treatment of tumours. It was shown that treating 
HIV-1 infected Jurkat cells with lepB lowered the levels of both viral and 
cellular cytoplasmic mRNA. However, HIV-2 infected cells treated with lepB 
maintained a relatively constant level of cytoplasmic mRNA, even when the 
dosage of lepB was doubled. Consequently, HIV-2 Rev-dependent export 
may not be susceptible to inhibition by lepB (Dorman and Lever, 2000). 
Further work is necessary to quantify and characterise the potential 
differences between the export of HIV-1/2 RNA. 
It remains unknown as to the extent to which HIV-1/2 mRNA degradation 
influences the life cycles of these viruses. Any differences in mRNA stability, 
or the inadvertent activation of mRNA degradation machinery, may have a 
substantial impact on gene expression. With regard to this, any differences in 
transcript stability and consequential degradation may, therefore, contribute 
to the differing replicative capacity of these viruses. Likewise, to effectively 
compare the transcription rates of the HIV-1 and HIV-2 viruses, it is 
necessary to control for mRNA degradation. 
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3.2 Results 
3.2.1 Primer testing: Gag primers 
Primers targeting HIV gag genes were designed by Cyril Barbezange. HIV-1 
gag forward (1077-1096n) and HIV-1 gag reverse (1230-1249n) primers 
amplified a 172n region of gag. HIV-2 gag forward (912-931n) and HIV-2 gag 
reverse (1087-1106n) primers amplified a 194n gag product. To test these 
primers, HeLa cells were transfected with 580 ng HIV-1/2 provirus in a 6-well 
plate and total, cytoplasmic and nuclear RNA extracted at 24 h post-
transfection. cDNA was produced from reverse transcription of extracted 
RNA, and used in a PCR with HIV-1 gag (primer #22, 23) and HIV-2 gag 
(primer #24, 25) primers. PCR products were run on an agarose gel [figure 
29]. 
 
Figure 29: PCR to test HIV gag primers. HIV gag was amplified by RT-PCR from RNA 
extracted from HIV-1, HIV-2 and HIV-1 MA2 provirus transfections. HIV-1 MA2 is a 
chimeric provirus with the HIV-1 5’ UTR/Gag coding region and the matrix region of 
HIV-2 (marked with a *). Primers to HIV-1 and HIV-2 gag were used on cDNA samples 
produced from total (T), cytoplasmic (C) and nuclear (N) RNA. 
HIV-1 and HIV-2 gag primers produced the expected fragment sizes (172n 
and 194n) following RT-PCR. Gag mRNA could be detected in total, nucleus 
and cytoplasmic RNA samples for both primer sets. Furthermore, HIV-1/2 
gag primers did not amplify product from a negative control of untransfected 
HeLa cell RNA (data not shown). This indicates that these primers are, firstly, 
amplifying the correct products and, secondly, are sensitive enough to use in 
a comparison of HIV-1 and HIV-2 gag RNA expression levels following sub-
cellular fractionation. 
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3.2.2 Primer testing: housekeeping primers 
Detection of differential gene expression can be accurately determined by 
qPCR. However, it is necessary to control for any experimental variations 
which may arise from reagent disparities, dissimilar RNA extraction levels or 
pipetting error. Consequently, control ‘housekeeping’ (HK) genes are 
frequently used to normalize the expression levels of qPCR gene expression 
data (Barber et al., 2005). Cellular GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) is frequently used as a housekeeping gene. Spliced GAPDH 
mRNA can act as an endogenous, cytoplasmic marker within the cell. 
Additionally, the unprocessed precursor to GAPDH  (pre-GAPDH) provides a 
nuclear marker (Blissenbach et al., 2010). qPCR results were thus 
normalised to housekeeping genes; pre-GAPDH for nuclear samples and 
GAPDH as a cytoplasmic control. 
Primers were initially designed by Cyril Barbezange. Forward (947-969n) and 
reverse (1051-1072n) primers targeting cytoplasmic GAPDH produced a 
126n GAPDH fragment. Forward (2833-2851n) and reverse (3019-3039n) 
primers targeting pre-GAPDH (the unspliced precursor to GAPDH) produced 
a PCR product of 207n. It was necessary to, firstly, ensure that the 
housekeeping genes in the nucleus and cytoplasm did not overlap in their 
detection and, secondly, ensure that the primers were only amplifying the 
target gene in the correct cell fractions. The expression of GAPDH and pre-
GAPDH in total, nuclear and cytoplasmic RNA samples was thus compared. 
HeLa cells were subjected to sub-cellular fractionation and RNA extracted 
from total, nucleus and cytoplasm samples. cDNA, produced from extracted 
RNA, was amplified by PCR using primers to GAPDH (primer #18, 19) and 
pre-GAPDH (primer #20, 21) and gene expression detected by running PCR 
samples on an agarose gel [figure 30].  
GAPDH was only detected in the cytoplasm and pre-GAPDH was only 
detected in the nucleus [figure 30]. This indicates that the targets of GAPDH 
and pre-GAPDH primers were distinct and therefore the primers did not 
cross-react. These results also confirmed successful sub-cellular 
fractionation and isolation of separate nuclear and cytoplasmic RNA pools. 
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Figure 30: An agarose gel of PCR products showing the expression of GAPDH and 
pre-GAPDH in RNA extracted from total (T), cytoplasmic (C) and nuclear (N) HeLa cell 
fractions. 
Pre-GAPDH primers did not detect pre-mRNA from total RNA samples. This 
may be because the levels of pre-mRNA, as a percentage of the total RNA 
fraction, may be below the detection threshold. 
Since GAPDH and pre-GAPDH primers successfully amplified discrete 
products from the nucleus and cytoplasm, they were suitable for using as 
housekeeping gene controls for subsequent qPCR experiments. 
3.2.3 Optimisation: RT negative samples 
For a comparison of HIV-1 and HIV-2 gene expression, cells were 
transfected with HIV provirus and cellular RNA extracted for qPCR. To 
accurately compare HIV-1 and HIV-2 transcription, it was necessary to 
ensure that HIV primers were only detecting cDNA reverse transcribed from 
viral RNA, and not amplifying the transfected provirus DNA template. 
DNase treatment of extracted RNA was optimised to ensure that template 
DNA was not amplified by PCR. 2-4 μg of total, nuclear or cytoplasmic HIV-1 
RNA samples were treated with DNase prior to reverse transcription. This 
ensured removal of contaminating, transfected proviral DNA. A PCR was 
carried out using RT+ve and RT-ve (made with/without reverse transcriptase) 
cDNA samples and primers to HIV-1 gag. Products were run on an agarose 
gel [figure 31]. 
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Figure 31: An agarose gel showing pairs of alternate RT–ve (odd # lanes) and RT+ve 
(even # lanes) cDNA from an RT-PCR of HIV-1 transfection RNA. RNA cellular 
fractions were used from an actD HeLa cell transfection timecourse. T=0 represents 
24 h post-proviral transfection when some cells were treated with actD. Only lanes 1+2 
shown were treated with actD. Lanes 1+2: T=0, total RNA (actD), lanes 3+4: T=0, total 
RNA, lanes 5+6: T=0 cytoplasmic RNA, lanes 7+8: T=0 nuclear RNA, lanes 9+10: T=2 
total RNA, lanes 11+12: T=4 total RNA, lanes 13+14: T=6 total RNA, lanes 15+16: T=8 
total RNA. 
Bands were not detected from RT-ve samples indicating that DNase 
treatment of extracted RNA was effective at removing transfected plasmid 
templates. Thus only synthesised RNA was detected in subsequent qPCR 
experiments. 
3.2.4 A comparison of HIV-1 and HIV-2 total RNA levels 
HIV-1 and HIV-2 transcription was compared by quantifying the amount of 
HIV-1/2 gag RNA transcribed from transfected proviral DNA over a time 
course. HeLa cells were transfected with 580 ng of HIV-1 or HIV-2 provirus 
for 6, 12, 24 and 48 h and total RNA harvested. Following DNase treatment 
and reverse transcription, the same quantity of cDNA was used in a qPCR 
with primers to HIV-1 or HIV-2 gag, in triplicate. Gene expression was 
normalised to the GAPDH housekeeping gene. qPCR data was analysed by 
calculating ΔCt. This was done by subtracting the sample Ct from the 
housekeeping gene Ct produced from the same cDNA (ΔCt = Ct sample – Ct 
HK). Results were subsequently plotted by raising 2 to the power of ΔCt 
(2ΔCt) which accounts for the 2-fold increase in RNA quantity relative to each 
decrease in Ct. Experiments were repeated twice and graphs were plotted in 
Excel showing relative HIV-1 and HIV-2 gag RNA levels (as 2ΔCt) in total RNA 
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for 6, 12, 24 and 48 h time points [figure 32]. Error bars were calculated as 
the standard error. 
 
Figure 32: The relative expression levels of HIV-1 gag (blue) and HIV-2 gag (orange) in 
total RNA (expressed as 2
ΔCt
) quantified by qPCR from samples extracted following 6, 
12, 24 and 48 h HIV-1/2 provirus transfection. Error bars represent the standard error 
of the mean (SEM) 
Both HIV-1 and HIV-2 gag levels steadily increased between 6 and 48 h 
although HIV-1 gag total RNA levels were higher than HIV-2 gag RNA across 
the time course. The difference in HIV-1/2 gag RNA levels was particularly 
noticeable by 48 h where HIV-1 gag RNA levels were 7-fold higher than HIV-
2 gag RNA levels, indicating a much higher level of HIV-1 gag mRNA 
synthesis. These results suggest that HIV-1 transcription is more efficient 
than HIV-2 as gag mRNA was produced more quickly from transfected HIV-1 
provirus. 
3.2.5 A comparison of HIV-1 and HIV-2 gag RNA levels in the 
nucleus and cytoplasm 
The level of HIV-1 and HIV-2 gag RNA in the nucleus and cytoplasm was 
compared at various times post-transfection to assess how quickly gag 
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mRNA is exported from the nucleus for HIV-1 and HIV-2. HeLa cells were 
transfected with 580 ng HIV-1 or HIV-2 provirus for 6, 12, 24 and 48 h. After 
sub-cellular fractionation of harvested cells, RNA was isolated from the 
nuclear and cytoplasmic fractions. The level of HIV-1/2 gag RNA in each 
fraction was quantified, in duplicate, by qPCR using primers to HIV-1/2 gag 
RNA. Results were normalised to a GAPDH housekeeping gene for 
cytoplasmic fractions and pre-GAPDH for nuclear fractions and RNA levels 
expressed as 2ΔCt [figure 33]. Experiments were repeated twice and error 
bars plotted as the standard error. 
There was a noticeable difference in the scale of results from the nucleus 
and cytoplasm [figure 33]. This is due to expressing viral RNA levels relative 
to different housekeeping genes; pre-GAPDH RNA (at very low levels) in the 
nucleus and GAPDH RNA levels (at levels comparable to viral RNA) in the 
cytoplasm. 
In the nucleus, HIV-1 gag RNA levels increased rapidly between 6 h and 12 h 
post-transfection, before decreasing between 12 h and 48 h [figure 33]. This 
indicates efficient transcription of HIV-1 mRNA before nuclear export 
commences to reduce nuclear gag mRNA levels at 12 h post-transfection. 
HIV-2 gag RNA levels in the nucleus increased more slowly between 6 and 
12 h, before decreasing slightly after this time. The 12 h peak in nuclear HIV-
2 gag RNA levels was also noticeably lower (by 3.5-fold) than for HIV-1 gag 
RNA. This suggests that HIV-2 exhibits a slower rate of gag mRNA 
transcription. In the cytoplasm, HIV-1 gag RNA levels increased steadily 
across the time course and were consistently higher (by up to 3.8-fold) than 
HIV-2 gag RNA levels. HIV-2 RNA levels steadily increased in the cytoplasm, 
although not as rapidly as HIV-1 gag RNA levels. Consequently, HIV-2 
mRNA export may be slower than for HIV-1. 
Overall, these results suggest that HIV-1 gag RNA builds up more rapidly in 
the nucleus, and then transitions more quickly from the nucleus to the 
cytoplasm than HIV-2 gag RNA i.e. HIV-1 transcription and export is more 
efficient than for HIV-2. 
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(A)  
 
 
(B)  
 
Figure 33: qPCR data showing the relative expression of HIV-1 (blue) and HIV-2 
(orange) gag RNA (expressed as 2
ΔCt
) in the nucleus (A) and cytoplasm (B) at 6, 12, 24 
and 48 h post-proviral transfection. Gag RNA levels are expressed as 2
ΔCt
 with results 
normalised to pre-GAPDH (nucleus) and GAPDH (cytoplasm) housekeeping genes. 
Error bars represent the SEM. 
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The nucleus:cytoplasm ratio of HIV-1/2 RNA was calculated using the 
following method: 
 ΔCt : sample data was normalised to housekeeping genes by 
calculating ΔCt; the nucleus/cytoplasm Ct value was subtracted from 
the pre-GAPDH/GAPDH housekeeping gene Ct (ΔCt = Ct sample – Ct 
HK) 
 ΔΔCt: calculated by subtracting the cytoplasm ΔΔCt from the nucleus 
ΔΔCt (ΔΔCt = ΔCt nucleus – ΔCt Cytoplasm) 
 Ratio N:C (2ΔΔCt): the nucleus to cytoplasm ratio (N:C ratio) was 
calculated by raising 2 to the power of ΔΔCt (2ΔΔCt) which accounts for 
the 2-fold increase in RNA quantity relative to each decrease in Ct. 
Comparing the N:C ratio of HIV-1 and HIV-2 over time provides an indication 
of the rate of RNA export from the nucleus to the cytoplasm [figure 34]. A 
higher N:C ratio value reflects a larger level of HIV RNA in the nucleus and a 
lower RNA level in the cytoplasm. A decrease in the N:C value represents 
less RNA in the nucleus and an increase in RNA in the cytoplasm. 
 
Figure 34: The N:C ratio (expressed as 2
ΔΔCt
) of HIV-1 and HIV-2 gag RNA at 6, 12, 24 
and 48h post-proviral transfection of HeLa cells. 
The HIV-1 N:C ratio decreased very slightly between 6 and 12 h before 
dropping dramatically after 12 h. This suggests that initially HIV-1 mRNA was 
slowly exported from the nucleus. However, after 12 h, HIV-1 mRNA export 
was more rapid resulting in the dramatic decrease in N:C ratio. Alternatively, 
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the HIV-2 N:C ratio increased between 6 and 12 h, suggesting nuclear export 
was slow to initiate. After 12 h the HIV-2 N:C ratio decreased, indicating 
nuclear export of mRNA, albeit less rapidly than HIV-1. The N:C ratio of HIV-
2 did not drop to the same level as HIV-1 even by 48 h. This suggests that 
HIV-1 gag RNA is exported more quickly to the cytoplasm than HIV-2 gag 
RNA. 
3.2.6 A comparison of HIV-1 and HIV-2 Gag RNA stability 
A lower level of HIV-2 RNA in total cell lysate may have been caused by less 
efficient transcription, increased mRNA degradation, or a combination of the 
two. Similarly, a lower level of HIV-2 RNA in the cytoplasm may have been 
caused by inefficient export or an enhanced rate of mRNA degradation. To 
assess whether differences in RNA stability contribute to lower total and 
cytoplasmic levels of HIV-2 RNA, a comparison of HIV-1/2 gag RNA stability 
was made using actD. ActD inhibits mRNA synthesis and therefore provides 
a means to assess the decline in existing RNA pools due to degradation. 
HeLa cells were transfected with 580 ng HIV-1/2 provirus and, after 24 h, 
transcription was shut down by treating cells with 5 μg/ml actD. HIV gag RNA 
levels from total cell lysate were assayed over a time course 0, 2, 4, 6 and 8 
h post-actD treatment (T=0) to assess the rate at which HIV gag RNA levels 
dropped (i.e. RNA was degraded) in the absence of ongoing RNA synthesis. 
cDNA was produced from RNA extracted at various time points and qPCR 
was carried out to quantify viral RNA levels using primers to HIV-1/2 gag and 
HK genes. Data was normalised to HK genes and 2ΔCt was calculated for 
each sample [figure 35]. 
In the absence of actD, HIV-1 gag RNA levels increased slightly over the 
time course whereas HIV-2 gag RNA levels remained constant over the 8 h 
time course [figure 35]. This reflects the enhanced transcriptional rate of HIV-
1. Shutdown of transcription using actD resulted in a decrease, after 2 h, of 
both HIV-1 and HIV-2 gag RNA levels over the time course as existing RNA 
was degraded.  
For the 2 h period after actD treatment (T=0), HIV-1 and HIV-2 Gag RNA 
levels did not change significantly [figure 35]. During this period it is likely that  
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 (A)  
 
 
(B)  
 
Figure 35: qPCR results quantifying HIV-1/2 total gag RNA levels (expressed as 2
ΔCt
) 
over a time course (0, 2, 4, 6, 8 h) starting 24 h post-provirus transfection (T=0) in the 
absence (A) or presence (B) of 5 μg/ml actD. Error bars represent the SEM. 
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transcription was still occurring and the cells were transitioning from a state 
of being transcriptionally active to transcriptional shutdown. Thus it appears 
that actD takes a while to exert its effect on the cells resulting in this lag 
phase.  
To compare the decline in HIV-1/2 RNA levels relative to starting levels of 
RNA, the results were expressed as a percentage of 2 h data [figure 36]. This 
was because prior to 2 h, when actD treatment was still taking effect, RNA 
may still have been synthesised. 
 
Figure 36: A comparison of total HIV-1/2 RNA levels at each time point after actD 
treatment expressed as a percentage of the 2 h value. 
Both HIV-1 and HIV-2 gag RNA levels declined at a similar rate by 8 h 
relative to the starting level of RNA. This suggests that HIV-2 RNA is not 
degraded more rapidly and therefore the higher level of HIV-1 RNA is likely 
due to more efficient transcription. 
The degradation rate of HIV-1/2 gag RNA in the cytoplasmic fraction was 
also studied to determine whether export differences or degradation rates 
were responsible for the slower accumulation of HIV-2 gag RNA in the 
cytoplasm. HIV-1/2 provirus (580 ng) was transfected into HeLa cells for 24 
h, prior to the addition of actD. Cells were harvested and fractionated at 0, 2, 
4, 6 and 8 h after actD treatment. The level of cytoplasmic HIV gag RNA at 
each time point, with and without actD treatment, was examined by qPCR. 
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Data were normalised to the GAPDH HK gene and RNA expression levels 
calculated as 2ΔCt [figure 37].  
(A)  
(B)   
Figure 37: qPCR results quantifying HIV-1/2 cytoplasmic RNA levels (expressed as 
2
ΔCt
) over a time course (0, 2, 4, 6, 8 h) starting 24 h post-provirus transfection (T=0) in 
the absence (A) or presence (B) of 5 μg/ml actD. Error bars represent the SEM. 
Cytoplasmic HIV-1/2 gag RNA levels did not change significantly over the 
time course in HeLa cells without actD treatment [figure 37A] although HIV-1 
gag RNA levels were consistently higher than HIV-2 gag RNA levels. When 
transcription was shutdown via actD treatment, both HIV-1 and HIV-2 
cytoplasmic gag RNA levels decreased steadily after an initial delay of 2 h 
[figure 37B]. This suggests that following transcriptional shutdown, both HIV-
1 and HIV-2 RNA levels were not maintained (i.e. were degraded) in the 
cytoplasm. 
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A comparison of the rate of HIV-1/2 RNA degradation was made by 
comparing the level of gag RNA, at each time point after actD treatment, to 
the starting value of HIV-1/2 RNA [figure 38]. 
 
Figure 38: A comparison of the HIV-1/2 cytoplasmic RNA levels at each time point 
after actD treatment expressed as a percentage of the 2 h value. 
Both HIV-1 and HIV-2 RNA levels dropped at an equivalent rate over the time 
course comparative to their respective starting RNA levels. These results 
suggest that the rate of HIV-1/2 mRNA degradation is similar, and, 
consequently, that the slower accumulation of HIV-2 gag RNA in the 
cytoplasm is due to slower export from the nucleus rather than faster 
degradation in the cytoplasm. 
Leptomycin B (lepB) was also used as a tool to investigate the effect of 
export shutdown on the stability of cytoplasmic HIV-1/2 gag RNA levels (data 
not shown). HeLa cells were transfected with HIV-1/2 provirus for 24 h before 
treating cells with lepB (T=0) to shutdown export. Cells were subsequently 
harvested at 0, 2, 4, 6, and 8 h post-lepB treatment and total and cytoplasmic 
RNA isolated. Real-time RT-PCR was carried out using primers to HIV-1 and 
HIV-2 gag. However, there was very little effect of lepB on cytoplasmic HIV-2 
gag RNA levels suggesting that lepB was unable to shut down HIV-2 gag 
RNA export from the nucleus. HIV-1 gag RNA levels in the cytoplasm did 
decrease over the time course as expected (Dorman and Lever, 2000). Due 
to the discrepancy of the effect of lepB on HIV-1/2 gag RNA export, it was not 
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possible to compare the rate of RNA degradation between these viruses 
using lepB. 
3.3 Discussion 
3.3.1 HIV-1 and HIV-2 transcription 
Following HIV-1/2 provirus transfection into HeLa cells, the level of cellular 
HIV-1 gag mRNA produced was greater than for HIV-2 at all time points. This 
suggests that HIV-1 provirus DNA was transcribed into gag mRNA more 
efficiently than for HIV-2. Consequently, a reduced availability of HIV-2 
mRNA during infection may limit the rate of HIV gene expression and 
therefore contribute to the lower rate of particle production observed during a 
HIV-2 infection. 
Transcription was shut down using actD to assess the stability of existing 
HIV-1/2 gag RNA in total pools after this time. The levels of HIV-1/2 gag 
mRNA, relative to each starting level, decreased comparably indicating that 
the degradation rates of HIV-1/2 mRNA were equivalent. Therefore the 
higher level of cellular HIV-1 gag mRNA observed is most likely due to a 
higher rate of HIV-1 transcription rather than a result of accelerated HIV-2 
gag mRNA degradation. 
3.3.2 HIV-1 and HIV-2 gag RNA export 
To investigate the rate at which HIV-1/2 gag mRNA is synthesised and 
transitions from the nucleus to the cytoplasm, the level of HIV-1/2 gag mRNA 
in the nucleus and cytoplasm was compared by sub-cellular fractionation 
post-provirus transfection. At 6 h and 12 h post-transfection HIV-1 gag RNA 
levels in the nucleus were higher than HIV-2, reflecting the faster rate of 
transcription seen for HIV-1. Between 12 and 48 h, the level of HIV-1 gag 
RNA decreased. Expression of the viral Rev protein promotes increased 
export of unspliced HIV-1 gag mRNA by enhancing Rev/RRE dependent 
export of HIV RNA from the nucleus. Consequently, as more Rev is 
expressed during the viral life cycle, gag mRNA is more efficiently exported 
from the nucleus. Therefore the decrease in HIV-1 gag mRNA in the nucleus 
after 12 h likely reflects efficient export of full-length HIV-1 gag RNA to the 
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cytoplasm via the Rev-RRE pathway. To complement this, the level of HIV-1 
viral RNA in the cytoplasm increased over the time course, reflecting the 
export of synthesised HIV-1 gag RNA from the nucleus. 
The amount of HIV mRNA remaining in the nucleus is relative to both the rate 
of transcription (producing nascent mRNA) and the rate of mRNA export from 
the nucleus to the cytoplasm (removing mRNA from the nucleus). Assuming 
the rate of transcription and mRNA degradation are constant over time, if the 
rate of export is lower than the rate of mRNA transcription (T>E), then mRNA 
levels in the nucleus will increase, albeit at a lower rate than previous to 
export commencing. If the rate of mRNA synthesis is equivalent to the rate at 
which it is exported (T=E), the level of mRNA in the nucleus will remain 
relatively constant, whereas if the rate of mRNA export exceeds the rate of 
mRNA transcription (T<E), RNA levels in the nucleus will drop (summarised 
in figure 39). 
 
Figure 39: The effect of differing export rates (E) on the level of RNA in the nucleus 
(blue line) assuming a constant level of transcription (T). 
Thus HIV-1 export appears to have been occurring very efficiently as the 
level of overall RNA in the nucleus dropped after 12 h indicating that HIV-1 
Gag RNA export was occurring at a greater rate than Gag RNA synthesis 
(T<E). 
HIV-2 Gag mRNA accumulated much more slowly in the nucleus indicating 
less efficient transcription. After 12 h, the level of HIV-2 RNA in the nucleus 
only decreased slightly, rather than decreasing rapidly like HIV-1. This 
suggests that HIV-2 mRNA was undergoing export at a similar, or only 
slightly higher, rate to the rate at which it was being synthesised (T=E). The 
level of HIV-2 transcription was shown to be less efficient than HIV-1. 
Chapter 3                       Transcription & nuclear export of HIV gag-pol mRNA 
 
98 
 
Therefore, as the export rate was not vastly different to the transcription rate 
for HIV-2, this suggests that export is equally inefficient for HIV-2 and, 
additionally, less efficient than for HIV-1. 
The N:C ratios for HIV-1 and HIV-2 support these observations. The HIV-1 
N:C ratio remained similar 6-12 h post-transfection. During this period the 
rate of mRNA increase in the nucleus and cytoplasm was the same i.e. 
mRNA synthesised matched the mRNA export rate (T=E). As HIV-1 
transcription was shown to be very efficient, HIV-1 mRNA export must have 
been reasonably efficient to match the mRNA synthesis rate during this time. 
The N:C rate for HIV-1 dropped rapidly after 12 h indicating that HIV-1 mRNA 
was exported more efficiently from the nucleus after this time (T>E). As 
replication progressed, the presence of more Rev RNA in the nucleus may 
have served to accelerate the rate of HIV-1 gag mRNA export producing the 
observed drop in N:C ratio. 
The HIV-2 N:C ratio increased initially from 6-12 h indicating that mRNA 
levels were increasing in the nucleus (via synthesis) but the rate of HIV-2 gag 
mRNA in the cytoplasm was not increasing by an equivalent amount. This 
suggests that HIV-2 export was slow to initiate as mRNA transcription levels 
were greater than the mRNA export rate (T>E). As overall HIV-2 transcription 
was shown to be inefficient, HIV-2 mRNA export must have been very 
inefficient (or not occurring) between 6-12 h to result in an increase in HIV-2 
mRNA in the nucleus during this time. By 24 h, the HIV-2 N:C ratio started to 
decrease (T<E), but not to the same extent as for HIV-1, indicating that 
cytoplasmic HIV-2 RNA levels were not increasing as quickly for HIV-2 as for 
HIV-1. Consequently, these results suggest that the rate of gag RNA export 
appears to be much slower for HIV-2. 
Increased HIV-2 mRNA instability in the cytoplasm could have resulted in the 
lower levels of HIV-2 gag mRNA observed. ActD was successfully used to 
shut down mRNA synthesis and thereby compare the rate at which existing 
HIV-1/2 mRNA in the cytoplasm was degraded. There was a detectable 
decrease in the level of both HIV-1/2 viral mRNA in the cytoplasm post-actD 
treatment indicating degradation. However, following the shutdown of mRNA 
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synthesis, HIV-1/2 cytoplasmic gag mRNA levels fell by an equivalent rate 
suggesting that the rate of gag mRNA degradation was the same for both 
viruses. 
It is likely that depletion of nuclear viral RNA occurred via transport to the 
cytoplasm following transcription shutdown. This may account for the 
increase in cytoplasmic RNA levels for both HIV-1 and HIV-2 in the 2 h post-
actD treatment. As HIV-1 transcription is more efficient than HIV-2, one can 
hypothesise that more HIV-1 RNA may have been present in the nucleus at 
the point of transcriptional shutdown. This is reflected by the greater peak in 
HIV-1 RNA appearing in the cytoplasm at T=2; potentially due to export of a 
larger quantity of HIV-1 RNA from the nucleus. If anything, these results 
therefore suggest that HIV-1 RNA may be degraded more quickly in the 
cytoplasm than HIV-2 to result in more similar levels by 8 h. Either way, these 
findings indicate that a greater rate of HIV-2 gag RNA degradation does not 
cause the lowered cytoplasmic levels of HIV-2 gag RNA seen in the 
cytoplasm. Consequently, we put forward the idea that HIV-2 export is much 
less efficient than HIV-1 export and, in conjunction with a lowered rate of 
HIV-2 transcription, accounts for the reduced levels of HIV-2 gag RNA found 
in the cytoplasm. 
Overall, results indicate that both HIV gag mRNA transcription and export are 
less efficient for HIV-2 than for HIV-1. Inefficiencies within mRNA 
transcription and export may thus contribute to the lower rate of viral particle 
production observed for HIV-2 infected individuals by limiting the rate of gene 
expression and thus the availability of components required for virion 
assembly.  
3.3.3 Controls and drawbacks 
Despite normalising qPCR data to a generic control, even common 
housekeeping genes such as GAPDH show variations in expression levels. 
As a result, although normalising to housekeeping genes can improve the 
accuracy of gene expression date, no perfect control to validate data exists 
(Barber et al., 2005). 
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However, further work could be carried out to improve the accuracy of current 
experiments. The actual number of HIV-1/2 RNA copies could be calculated 
by comparing qPCR values to a standard curve of known RNA concentration. 
This would provide a more accurate reading of differences in HIV-1/2 RNA 
levels in sub-cellular fractions and thereby provide a means to quantify 
differences in HIV-1/2 transcription and export rates. Better controls are also 
required to affirm that HIV-1/2 gag mRNA primers bind with equal efficiency 
to their target RNAs. 
qPCR is highly sensitive and therefore results are susceptible to 
contamination. A study by Blissenbach et al. (2010) was carried out to 
compare pre-mRNA levels in nuclear and cytoplasmic extracts following sub-
cellular fractionation. Extracted cytoplasmic RNA was shown to contain 3% of 
RNA derived from the nucleus. Assuming that pre-mRNA is exclusively 
present in the nucleus, this indicates that, during processing, cytoplasmic 
RNA fractions can be contaminated with nuclear RNA. This highlights a 
possible factor which may affect the consistency of qPCR data from samples 
which have undergone sub-cellular fractionation (Blissenbach et al., 2010). 
Measuring the level of pre-mRNA expression in nuclear RNA samples and 
comparing this to the level of pre-mRNA in cytoplasmic RNA samples by 
qPCR would identify the extent of this error. 
Furthermore, difficulties in normalising qPCR results occur when cells are 
treated with inhibitory agents such as actD or lepB. Shutting down cellular 
transcription or export not only affects the target genes of interest, but also 
alters cellular mechanisms. This could prove detrimental to the cell and also 
alter the expression of housekeeping genes which are used as controls for 
these experiments. For example, inhibiting cellular transcription can block 
GAPDH synthesis and, additionally, interfere with the production of 
spliceosome, export or exosome-associated proteins necessary for the 
successful nuclear processing and export of GAPDH mRNA. All of these 
additional factors will affect the qPCR data produced concerning overall viral 
RNA levels. Consequently, it is very difficult to precisely isolate one stage of 
gene expression within a biological system without inadvertent consequence 
to other processes.  
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As an alternative to RNA degradation, viral RNA may, additionally, have been 
removed from the cytoplasm by packaging of gag mRNA into viral particles 
as genomic RNA. Our assay does not account for the deficit of viral RNA in 
the cytoplasm which may be induced by RNA incorporation into viral 
particles. However, Dorman et al. (2000) reported that the amount of viral 
RNA in the cytoplasm is proportional to the rate at which it is packaged 
(Dorman and Lever, 2000). HIV-2 does not demonstrate more efficient 
particle production than HIV-1 (Popper et al., 2000) and our experiments 
have shown that HIV-2 RNA is inefficiently transcribed (limiting the supply of 
cytoplasmic RNA). In view of this, it is unlikely that enhanced packaging of 
viral RNA contributes to the lower HIV-2 cytoplasmic RNA levels observed. 
3.3.4 Future work 
Overall, the results presented in this chapter suggest that HIV-1 gag RNA is 
transcribed with greater efficiency than HIV-2 gag RNA. Additionally, the 
export of HIV-2 gag RNA is less efficient than HIV-1 gag RNA export. The 
culmination of these results is that a lower level of HIV-2 gag RNA is 
observed in both the nucleus and cytoplasm following proviral transcription. 
The factors prompting more efficient HIV-1 transcription and mRNA export 
remain unclear. Future work will look to elucidate the factors enhancing HIV-
1 or restricting HIV-2 transcription. Likewise, inhibition of export by 
leptomycin B appeared to affect HIV-1 export to a greater extent than HIV-2 
export. This suggests that HIV-2 gag RNA export may require alternative 
pathways to HIV-1 gag RNA or, instead, may rely on factors that are not 
affected by leptomycin B-induced export inhibition. Therefore, further work is 
required to determine the mechanisms of HIV-1/2 export and examine how 
these differ to limit the rate of HIV-2 mRNA export. 
Recent research has shown that the HIV-2 5’ UTR contains a 142 nucleotide 
intron which, when spliced, removes part of the 5’ UTR spanning from 
halfway through TAR to the C-box region and including the entire poly (A) 
signal [figure 40] (Strong et al., 2009). HIV-2 transcripts lacking the 5’ UTR 
intron showed a 5’ fold increase in translation efficiency. Spliced mRNA was 
not found to be incorporated into virus particles as it lacks a packaging 
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signal. The transition between translation and packaging may therefore be 
controlled by the presentation of the packaging signal on unspliced 5’ UTR 
mRNA (Strong et al., 2009). 
 
 
 
Figure 40: The HIV-2 5’ UTR (A) can undergo splicing to remove a 142 nucleotide 
intron which includes part of TAR, all of the poly(A) signal and the C-box region (B) 
(Strong et al., 2009). 
Although both spliced and unspliced HIV-2 mRNA variants have been 
identified within infected cells, the sub-cellular localisation and relative 
abundance of these transcript variants has not been determined. Identifying 
whether HIV-2 spliced transcripts are exported more quickly from the nucleus 
may provide an indication of the temporal regulation of gene expression for 
HIV-2. Furthermore, quantifying the contribution of spliced HIV-2 mRNA to 
the overall mRNA pool in both the nucleus and cell cytoplasm may suggest a 
role for these variants in the regulation of HIV-2 gene expression. 
Future work will therefore look to quantify the contribution of spliced and 
unspliced HIV-2 mRNAs in total, nuclear and cytoplasmic cellular fractions, 
as well as assessing the stability of spliced and unspliced transcripts. 
Quantifying the relative level of HIV-2 mRNAs in sub-cellular fractions will 
allow us to see whether there is any difference in the export of spliced and 
unspliced transcripts. We detected both spliced and unspliced variants of 
HIV-2 gag RNA in a PCR of cDNA from HIV-2 provirus transfections [figure 
41]. 
Using a primer spanning the splice site, or primers solely within the intron, 
would allow specific detection of spliced or unspliced HIV-2 gag transcripts 
respectively. Work is underway to design and verify such primers, and use 
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them in qPCR experiments to assess the levels of spliced and unspliced HIV-
2 gag RNAs in provirus-transfected cells. 
 
 
Figure 41: RT-PCR of total RNA extracted from HIV-2 provirus transfected HeLa cells. 
Primers at the start of the HIV-2 5’ UTR and within gag were used to amplify both 
spliced and unspliced HIV-2 transcript variants. The sample was halved and run in 
duplicate on the gel. 
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4. CHAPTER 4: HIV GAG TRANSLATION 
4.1 Introduction 
In this chapter an overview of eukaryotic translation is presented. Cap-
dependent and IRES-driven translation are introduced, followed by a 
discussion on how the 5’ UTR structure affects translation, and an overview 
of the translational attributes of HIV-1 and HIV-2. Finally, the factors 
regulating HIV translation are discussed before presenting results. My work 
establishes translational differences between HIV-1 and HIV-2 both in vitro 
and in cells. Translation of both HIV-1 and HIV-2 Gag is shown to be cap-
dependent with little evidence of IRES activity. However, HIV-1 appears to be 
more reliant on cap-dependent translation than HIV-2, indicating that 
differences in translational initiation mechanisms may effect variations in the 
rate of HIV-1/2 translation. Based on the composition of Gag, we propose 
that elongation rates between HIV-1/2 Gag are likely to be similar. We 
suggest that the extended HIV-2 5’ UTR, and the intrinsic level of structure, is 
likely to contribute to translational initiation differences between HIV-1/2. 
Attempts to characterise the origins of translational differences between HIV-
1 and HIV-2 are discussed. 
4.1.1 Eukaryotic translation: cap-dependent initiation 
HIV mRNA hijacks the host translational machinery and is therefore 
translated in the same way as eukaryotic cellular mRNA. Translation can be 
separated into three stages: initiation, elongation and termination. The 
efficiency with which eukaryotic mRNA is translated is dependent on the rate 
of translation initiation. mRNA has several structural features, including a 5’ 
cap and a 50-300 nucleotide 3’ poly(A) tail, which enhance translation 
initiation (Mathews et al., 2007). Additionally, at least 12 initiation factors 
(eIFs) are involved in translation initiation in eukaryotes (Mathews et al., 
2007). Although important for translation initiation, in the absence of a 5’ cap 
structure, translation initiation can still commence in a 5’ end dependent 
manner and, like cap-dependent translation, is reliant on the scanning 
mechanism of the 40S ribosomal subunit. Highly stable secondary structures, 
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such as those found within the HIV 5’ UTR, can impair ribosomal scanning 
and thus decrease the rate of translation initiation (Mathews et al., 2007).  
During translation initiation, the mRNA poly(A) tail is bound by poly(A) 
binding protein (PABP) which interacts with the eIF4F cap-binding complex 
[figure 42] (Mathews et al., 2007). Binding of eIF4F (a eukaryotic initiation 
factor composed of eIF4E, eIF4A and eIF4G) to the m7GpppN cap structure 
located at the 5’ end of mRNA initiates formation of an mRNA complex 
(Mathews et al., 2007). eIF4E is the cap-binding component of the eIF4F 
complex and is therefore necessary for cap-dependent translation (López-
Lastra et al., 2005). eIF4A is a member of the DEAD-box family and functions 
as an ATPase and RNA helicase to unwind RNA secondary structure. This 
requires ATP (Lamphear et al., 1993). The RNA helicase activity of eIF4A is 
enhanced more than 20-fold by its incorporation into the eIF4F complex 
(Mathews et al., 2007). Both eIF4G and a RNA-binding protein, eIF4B, can 
stimulate the weak helicase activity eIF4A. Scaffold proteins eIF4GI and 
eIF4GII (referred to commonly as eIF4G) direct construction of the translation 
initiation complex which culminates in associating mRNA with the 
translational machinery (López-Lastra et al., 2005). 
 
Figure 42: A (closed loop) model of translation initiation. The eIF4F complex 
(comprised of eIF4G, eIF4A and eIF4E) associates with the 5’ mRNA cap (m
7
GpppN) 
via eIF4E, the poly(A) tail via PABP and the 40S ribosomal subunit via eIF3 [adapted 
from (López-Lastra et al., 2005)]. 
Formation of a 43S pre-initiation complex occurs when eIF2 recruits Met-
tRNAi
Met to the P site located on the 40S ribosomal subunit. Thus the P site 
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of the 40S ribosomal subunit carries a methionyl-transfer RNA (Met-
tRNAi
Met)-eIF2-GTP complex to start translation (López-Lastra et al., 2005). 
The 43S complex associates with the 5’ end of the mRNA with the help of 
eIF2 and eIF3 (Lapointe and Brakier-Gingras, 2003). The 40S ribosomal 
subunit associates with eIF3, which in turn interacts with the eIF4G subunit of 
eIF4F, and facilitates attachment of 40S to the 5’ end of the mRNA. Binding 
of the 43S pre-initiation complex to mRNA results in a 43S-mRNA complex 
which is ready to undergo ribosomal scanning [figure 43].  
 
Figure 43: Initiation of translation in eukaryotes (López-Lastra et al., 2005). 
Further factors, eIF1 and eIF1A, bind to mRNA and facilitate 5’-3’ directional 
transport of the 43S complex along the mRNA to the initiation codon. eIF4F-
dependent binding of mRNA to the 43S pre-initiation complex is enhanced by 
eIF1A. Subsequently, 40S commences scanning along the mRNA until it 
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reaches an AUG start codon. This requires energy provided by ATP. 
Translation initiation is optimal when the AUG start codon is in the context of 
a flanking Kozak sequence: GCC(A/G)CCAUGG (with key nucleotides 
shown in bold). Deviations at the -3 and +4 positions can result in leaky 
scanning and the use of alternative, suboptimal start codons. Lower 
efficiency initiation can occur at codons CUG, GUG and UUG, and is reliant 
on flanking sequences (Weill et al., 2010). Additionally, the presence of a 
downstream 12-15 nucleotide hairpin structure can enhance translation 
initiation by stalling scanning of the 40S ribosomal subunit (Mathews et al., 
2007). 
Once the 43S complex encounters an initiation codon, eIF1 promotes base-
pairing of the initiator tRNA anticodon to the AUG start codon, forming a 48S 
complex which primes translation. The initiator tRNA anticodon is usually the 
CAU anticodon of eIF2-associated Met-tRNAi
Met located in the 40S ribosome 
P site (López-Lastra et al., 2005). Following base-pairing of Met-tRNAi
Met and 
the AUG start codon, eIF5 promotes the hydrolysis of GTP within the 
initiation complex. This facilitates the release of eIF2 and other associated 
initiation factors from the ribosomal 40S subunit; a necessary step to allow 
joining of the ribosomal subunits (Das, S. and Maitra, 2001). eIF5B is a 
GTPase which promotes binding of the 60S ribosomal subunit to 40S (Lee et 
al., 2002). The resulting 80S ribosome forms an active translation complex 
which can undergo elongation (Mathews et al., 2007).  
4.1.2 IRES-driven translation initiation 
An alternative to cap-dependent translation is internal initiation. Ribosomes 
may be recruited to an internal site in the 5’ UTR of mRNA, independently of 
the 5’ end, usually by a structured RNA element called an internal ribosome 
entry site (IRES) (Buck et al., 2001; Lapointe and Brakier-Gingras, 2003). 
IRES were first discovered in picornaviruses (Jang et al., 1988; Pelletier and 
Sonenberg, 1988) and subsequently in a number of other viruses such as 
cricket paralysis virus, hepatitis C virus and classical swine fever virus 
(Pestova et al., 1998; Wilson et al., 2000) as well as retroviruses (Brasey et 
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al., 2003; Buck et al., 2001; Herbreteau et al., 2005; Miele et al., 1996; 
Ohlmann et al., 2000) and cellular mRNAs (Komar and Hatzoglou, 2005).  
An IRES is thought to form a stable structure that is recognised by the 40S 
ribosomal subunit and/or associated initiation factors. Binding of IRES trans-
acting factors (ITAFs) may stabilise the IRES structure or provide protein 
interaction sites for 40S or initiation factors (Vallejos et al., 2011). It has been 
shown that mutations which disrupt the IRES structure dramatically reduce 
IRES function (Mathews et al., 2007). 
Internal initiation allows ribosomes to by-pass some of the requirements for 
cap-dependent translation, such as components of the eIF4F complex, 
enabling translation of mRNAs with long, structured 5’ UTRs, or upstream 
AUG codons (Mathews et al., 2007). Several viruses shut down cellular, cap-
dependent translation e.g. by cleavage of eIF4G (Glaser et al., 2003) but 
maintain viral protein synthesis via internal initiation. Similarly, many of the 
cellular IRES-containing mRNAs are expressed under conditions where cap-
dependent translation is unfavourable such as during the G2/M phase of the 
cell cycle (Buck et al., 2001) during nutrient limitation, apoptosis, mitosis or 
hypoxia (Komar and Hatzoglou, 2011).  
4.1.3 Eukaryotic translation: elongation 
During translation, the ribosome functions to decode genetic information into 
a polypeptide chain. This process occurs in a 5’-3’ direction along the mRNA 
and requires continual processing of amino-acyl tRNAs by the ribosome 
active site, which catalyses the formation of a peptide bond between 
associated peptides [figure 44]. Amino-acyl tRNAs carry amino acids defined 
by the anticodon they present. The order of amino acids incorporated into the 
nascent polypeptide chain is defined by the sequence of triplet nucleotide 
codons within the mRNA (Rospert et al., 2005).  
The accuracy of translation is important to limit errors in the synthesised 
protein product. Events such as amino acid misincorporation (Zaher and 
Green, 2009), frameshifting, and read through of stop codons can lead to 
errors in translation (Proud, 1994). Cellular factors such as elongation factor-
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1 (eEF1) assist translation. eEF1 is composed of two subunits; eEF1α and 
eEF1β. In the presence of GTP, eEF1α binds to amino-acyl tRNAs forming a 
ternary complex of eEF1α-GTP and amino-acetyl tRNA.  
Initially, a tRNA carrying methionine (initiator Met-tRNAi
Met) binds loosely to 
the mRNA start codon (AUG) in the ribosome P site [figure 44A]. 
 
Figure 44: An overview of translation initiation and elongation [Image adapted from 
http://www.nobelprize.org/educational/medicine/dna/a/translation/elongation.html]. 
Subsequently, amino-acyl tRNAs, carrying specific anticodon-determined 
amino acids enter the ribosome A site [figure 44B]. If the amino-acyl tRNA 
anticodon is complementary to the mRNA codon, a peptide bond is catalysed 
between the amino acid on the incoming peptidyl tRNA and the amino acid of 
the previous peptidyl tRNA now in the ribosome P site [figure 44C]. The 
peptidyl transferase activity of the ribosome catalyses this reaction. Once the 
peptide it is carrying has been incorporated into the nascent polypeptide 
chain, the empty tRNA relocates to the ribosome P site, freeing the A site for 
incoming peptidyl tRNAs. This occurs simultaneously with the ribosome 
advancing 3 nucleotides (one codon) along the mRNA each time, moving the 
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uncharged tRNA out of the P site into the E site (Proud, 1994). Cyclical 
repetition of amino-acyl tRNA positioning at the A site [figure 44D], peptide 
bond formation and ribosome shifting along the mRNA results in stepwise 
addition of amino acids to the emerging polypeptide chain [figure 44E]. 
eEF1α-GTP is hydrolysed during elongation resulting in eEF1α-GDP. 
Consequently, a guanine nucleotide exchange factor converts eEF1α-GDP to 
eEF1α-GTP to allow recycling of eEF1α-GTP for continued elongation. 
4.1.4 Eukaryotic translation: termination 
The final stage of translation, termination, is triggered by the presence of an 
in-frame stop codon (UAA, UAG or UGA) in the ribosome A site (Sund et al., 
2010). Eukaryotic release factors (eRF) and GTP are important in 
termination. eRF1 recognises stop codons within mRNA and induces 
activation of the ribosome peptidyl centre (RPC). The RPC triggers release of 
the newly synthesised peptide by hydrolysing the ester bond linking it to the 
terminal tRNA. As part of this mechanism, eRF1 occupies the A site of the 
ribosome where it functions as a tRNA. A GTPase, eRF3, enhances eRF1 
function (Moreira et al., 2002). Termination is catalysed by ribosomal RNA 
and results in the release of the completed, nascent peptide (Rospert et al., 
2005). Following termination, the translational machinery disassembles and 
can reform to initiate translation on other mRNAs. Several ribosomes can 
simultaneously synthesise protein from the same mRNA by temporal binding 
and initiation. Multiple ribosomes translating the same mRNA are called 
polysomes; the number of bound ribosomes determines the polysome size 
(Zouridis and Hatzimanikatis, 2007). 
4.1.5 Eukaryotic translation: regulation 
The rate of translation can be regulated by many factors such as the 
availability of nutrients, stress, cell cycle adjustments and viral infection (Gale 
et al., 2000). Control of gene expression is achieved on a cellular level by 
modulating the assembly of components involved in the mRNA cap-binding 
complex. Thus, the expression of mRNAs can be regulated by 
phosphorylation or dephosphorylation of translation factors (Lapointe and 
Brakier-Gingras, 2003). Likewise, binding of eukaryotic mRNAs to various 
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cytoplasmic proteins can mediate nuclear export, alter mRNA stability, 
promote sub-cellular localisation or bring about translational repression 
(Mathews et al., 2007). Changes to the cellular environment can also affect 
the mechanism of translation utilised, and thus cause a switch between 
translation initiation mechanisms (Ricci et al., 2008). For example, during 
infection viral proteins produced may alter translation rates. The human 
rhinovirus 2 (HRV-2) genome encodes a cysteine protease, 2A, which is self-
processed by autocatalytic cleavage from the HRV-2 viral polyprotein VP1. 
2A has been shown to cleave both isoforms of eIF4G in rabbit reticulocyte 
lysate (RRL). Since eIF4G forms part of the eIF4F complex which is involved 
in recruiting capped mRNAs to the 40S ribosomal subunit, HRV-2 infection 
shuts down cap-dependent translation. Likewise, poliovirus also encodes a 
2A protease which cleaves eIF4G directly, as well as indirectly via the 
activation of cellular proteases (Glaser et al., 2003). 
Non-standard translation events such as alternative initiation events (IRES-
driven translation, ribosomal shunting and leaky scanning), frameshifting, 
stop codon read-through and re-initiation can also regulate protein synthesis. 
Secondary structure within mRNA can affect ribosomal scanning and induce 
non-standard translation events thus reducing the rate of protein synthesis.  
The intrinsic properties of translated genes can also affect the rate of 
elongation. The genetic code is degenerate therefore amino acids can be 
encoded by more than one codon. However, within the human genome, 
some codons are rarer than others resulting in the concept of codon bias. 
The presence of rare codons can cause ribosomal stalling due to the low 
abundance of corresponding amino-acyl tRNAs. Likewise, translation 
elongation is also affected by the orientation of codons. Adjacent amino acids 
can be encoded by up to 36 synonymous codon pairs, with some codon pairs 
being more frequently used than others. This is called the codon pair bias. It 
is unknown why some codons are represented more frequently than others, 
although the fact that some codon pairings are more common means that 
codon, and codon pair, arrangements within a gene may also affect 
translational rates (Coleman et al., 2008). 
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The structural features of RNA affecting translation are summarised in table 
7. 
 
Table 7: The structural features of mRNA which influence translational control (Gale et 
al., 2000). 
4.1.6 HIV translation 
4.1.6.1 Structure within the HIV 5’ UTR 
Transcribed HIV mRNA contains a considerable level of RNA structure which 
can affect translation. The presence of pseudoknots, frameshift elements, 
packaging signals, IRES and other regulatory motifs provides a means for 
the ssRNA genome to direct multiple aspects of the viral life cycle. Due to its 
extensive structure, HIV RNA therefore plays a role in initiating reverse 
transcription and transcription, directing nuclear export, altering reading 
Structural 
feature 
Effect on translation 
5’ UTR length Influences scanning. A long 5’ UTR may impede translation. 
5’ UTR and 
coding region 
secondary 
structure 
Complex 5’ UTR structures may impede scanning. IRES 
structures promote cap-independence and allow the ribosome to 
largely avoid scanning. Pseudoknot structures promote 
frameshifting and recoding. Structure may also mediate binding 
with trans-acting factors. 
Sequence 
context of the 
initiation codon 
Imparts ribosome selectivity for first AUG codon. ‘Weak’ AUG 
codons promote leaky scanning. 
M7G Cap 
Promotes mRNA stability and interaction with eIF4F. Facilitates 
the translation of most cellular mRNAs. Accessibility to initiation 
factors may influence translational efficiency. 
uORF 
Upstream open reading frames (uORFs) may impede ribosome 
scanning to downstream cistrons. 
Poly(A) tail 
Length imparts stability and translational efficiency to mRNA. 
Interaction with PABP mediates association with cap-binding 
complex on the mRNA. 
3’ UTR 
Mediates the closed-loop translation complex via PABP 
interaction. Structural complexity may influence translational 
efficiency and interaction with trans-acting factors. 
Codon usage 
Use of non-abundant tRNAs may impede elongation. Influences 
frameshifting and recoding. 
Trans-acting 
factors 
Specific RNA sequence and/or structural motifs promote 
interaction with RNA-binding proteins, which may influence 
translational efficiency. 
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frame usage, promoting genome dimerization and regulating packaging. 
However, although evolutionarily conserved, many structural components of 
the HIV genome remain uncharacterised (Watts et al., 2009).  
Transcription of the HIV provirus produces capped and polyadenylated RNA 
with terminal 5’ and 3’ untranslated regions (UTR) [figure 45]. The 5’ UTR is 
the most conserved region of the HIV genome and is responsible for directing 
various stages of the HIV life cycle (Abbink and Berkhout, 2003). 
 
 
Figure 45: HIV proviral DNA is flanked by long terminal repeats (LTR) containing U3, R 
and U5 regions and reverse transcription signals: the primer binding site (PBS) and 
polypurine tract (ppt). Transcription of HIV DNA produces capped and polyadenylated 
RNA with terminal 5’ and 3’ untranslated regions (UTR). The TAR and poly(A) hairpin 
are present in both the 5’ and 3’ UTRs (Das, A.T. et al., 1997). 
 
Several structural features within the HIV 5’ UTR play an important role in 
directing gene expression and viral assembly [figure 46]. Trans-activation 
response element (TAR) is a highly conserved, secondary (stem-loop) 
structured region comprised of a loop of 6 unpaired nucleotides, and a 
partially base-paired stem containing a tripyrimidine bulge (Braddock et al., 
1993; Strong et al., 2009). The HIV-1 TAR structure is 59 nucleotides long 
and contains 1 stem-loop, compared to a 123 nucleotide TAR, with 3 stem-
loops, for HIV-2 (Strong et al., 2009). TAR interacts with the viral protein Tat 
to up-regulate transcription of viral genes (see Chapter 1). 
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  (A)  
  
  
(B)      
 
Figure 46: The functional domains of the HIV-1 5’ leader showing TAR, the poly(A) 
hairpin, the primer binding site (PBS), the dimer initiation site (DIS), the major splice 
donor (SD), the RNA packaging signal (ψ) and the AUG hairpin loop (with the start 
codon shown as a black box) (A) and the folded structure of the HIV-1 5’ UTR (B) 
[adapted from (Berkhout et al., 2011; Brasey et al., 2003)]. 
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The HIV 5’ UTR has been shown to inhibit translation from downstream 
cistrons as a result of the TAR stem-loop structure it contains. In HeLa cells, 
TAR stem-loop translational inhibition was less than in RRL. This suggests 
that a factor present in HeLa cell extracts (and missing from RRL) may 
mitigate translational inhibition by TAR. The La autoantigen is a possible 
candidate as it is abundant in HeLa cell extracts (Svitkin, Y.V et al., 1994). 
Cellular TAR binding proteins have been identified in extracts from 
mammalian cells. These include loop binding proteins (LBP); p68, TRP-1 and 
TRP-185 and bulge binding proteins (TRP-2) (Braddock et al., 1993; Svitkin, 
Y.V et al., 1994). Other proteins binding to the TAR stem have been 
reported; PKR, SBP and TAR RNA-binding protein (TRBP) (Svitkin, Y.V et 
al., 1994). 
TAR also alters the rate of translation initiation by inhibiting or activating PKR 
(a dsRNA-dependent protein kinase). At low concentrations, HIV TAR can 
activate PKR which phosphorylates eIF2α to decrease translation initiation. 
At higher TAR concentrations, TAR inhibits PKR by blocking PKR 
dimerization (important for functional PKR). Inactivated PKR cannot 
phosphorylate eIF2α therefore permitting translation initiation (Cole, 2007).  
Downstream of TAR is the poly(A) hairpin. A polyadenylation signal 
(AAUAAA) within the single-stranded loop of the poly(A) hairpin is 
responsible for production of a poly(A) tail at the 3’ end of HIV genomic RNA 
(Berkhout and van Wamel, 2000). The stem-loop structure of poly(A) in the 5’ 
UTR obstructs the polyadenylation signal and therefore suppresses its 
function (Kasprzak et al., 2005). Two important reverse transcription signals; 
the PAS (primer activation signal) and PBS (primer binding site), are located 
in U5 - a structural domain downstream of the R region (Abbink and 
Berkhout, 2003). Newly synthesised RNA is single-stranded, although within 
viral particles genomic HIV RNA exists as a non-covalent dimer (Watts et al., 
2009). Dimerization of genomic RNA is a unique feature of retroviruses and 
is coordinated by the DIS (dimer initiation site) found adjacent to the PBS. A 
6 nucleotide complementary sequence (usually GCGCGC or GUGCAC) self-
anneals to make a hairpin DIS loop. A base pairing interaction between the 
DIS structure of two adjacent HIV mRNAs results in the formation of a 
Chapter 4        HIV Gag translation 
 
116 
 
‘kissing loop’ complex which initiates dimerization (Kasprzak et al., 2005). 
Only unspliced, genomic RNA retains the dimerization element and therefore 
only full-length, genomic RNA undergoes dimerization (Baudin et al., 1993). 
The major splice donor site (SD), the packaging signal (Psi, ψ) and the start 
codon (AUG) hairpin are equally essential downstream structures within the 
HIV 5’ UTR (Abbink and Berkhout, 2003).  
During translation of newly synthesised viral mRNA, the highly structured 5’ 
UTR is the first region encountered by scanning ribosomes. Consequently, 
the length and structure of the HIV-1 5’ UTR have been shown to limit the 
rate of HIV-1 translation by impeding ribosomal scanning and cap 
accessibility (Svitkin, Y.V. and Sonenberg, 2004). The organisation of the 
HIV-1 5’ UTR resembles that of HIV-2. Therefore, it is likely that the rate of 
HIV-2 translation is also regulated by its 5’ UTR. However, the HIV-2 5’ UTR 
(545 nucleotides) is significantly longer than the HIV-1 5’ UTR (335 
nucleotides) and contains a higher level of structure (Strong et al., 2009).  
4.1.6.2 Evidence for cap-dependent translation  
Current literature on the mechanism of HIV-1/2 translation initiation remains 
controversial. Both ribosomal scanning and internal initiation have been 
observed in different experimental settings. Consequently, cap-dependent 
translation and IRES-driven translation have both been proposed to account 
for Gag translation (Berkhout et al., 2011).  
HIV Gag is translated from viral mRNA which is produced analogously to 
host cell mRNA. Consequently, HIV viral mRNA is both capped and 
polyadenylated and proposed to undergo cap-dependent translation in an 
equivalent manner to cellular mRNA. Several experiments have highlighted 
the role of cap-dependence in HIV Gag translation. Insertion of additional, 
upstream AUG codons within the HIV-1 5’ UTR resulted in a decrease in 
translation from the native HIV-1 AUG codon and translation, instead, of the 
introduced ORF. These results confirmed the presence of ribosomal 
scanning throughout the HIV-1 5’ UTR. Likewise, a putative HIV-1 5’ UTR 
IRES did not disrupt translation from upstream AUGs suggesting that internal 
initiation was not occurring (Berkhout et al., 2011). 
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A high level of RNA secondary structure within the HIV-1/2 5’ UTR has been 
shown to be inhibitory to ribosomal scanning and therefore limits the 
efficiency of cap-dependent translation. Nevertheless, the presence of a 5’ 
cap structure and evidence for the involvement of ribosomal scanning in Gag 
translation are both consistent with cap-dependent translation (Miele et al., 
1996). Furthermore, the HIV-1 5’ leader sequence was unable to promote 
translation when it was cloned into a dicistronic construct with a downstream 
reporter gene. This suggests that the HIV-1 5’ UTR is unable to undergo 
internal initiation via an IRES, also favouring cap-dependent translation from 
the Gag AUG (Miele et al., 1996). 
Recent work by Ricci et al. (2008) suggests that translation of full-length, 
HIV-1 p55 Gag occurs via a cap-dependent mechanism. Ricci et al. (2008) 
used a cap-analogue, which competes for eIF4E, and FMDV-encoded L-
protease, which cleaves eIF4G, to shut-down cap-dependent translation in 
an in vitro RRL system. Translation of HIV-1 p55 was inhibited within this 
system whereas HIV-2 p57 translation was not. Thus Ricci et al. (2008) 
propose that HIV-1 p55 Gag relies on cap-dependent translation whereas 
HIV-2 p57 Gag may employ alternative translation initiation mechanisms.  
4.1.6.3 Evidence for IRES-dependent translation 
Evidence for HIV-1 IRES activity: 
Brasey et al. (2003) used foot and mouth disease virus (FMDV) L-protease to 
shut down cap-dependent translation in an in vitro RRL system. Surprisingly, 
and in contrast to the work by Ricci et al. (2008), HIV-1 mRNA translation 
was able to continue within this system. A potential IRES element was 
identified within the 5’ leader of HIV-1, spanning 232 nucleotides (between 
nucleotides 104 to 336) and overlapping with the RNA packaging signal (ψ) 
(Brasey et al., 2003).  
An additional IRES within the gag ORF has also been suggested for HIV-1. 
Buck et al. (2001) report the finding of an IRES region within the HIV-1 gag 
ORF which allows translation of the Gag precursor (Pr55gag) and a 40 kDa N-
terminally truncated Gag isoform. Experiments were carried out using 
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poliovirus-infected cells to shut down cap-dependent translation by viral 2A 
protease cleavage of eIF4G and cleavage of PABP by viral 2A and 3C. HIV 
Gag translation was not severely impacted when cap-dependent translation 
was inhibited whereas translation of a cap-dependent control was greatly 
reduced. The gag 5’ UTR was also shown to be dispensable for IRES activity 
within the gag ORF. Furthermore, Buck et al. (2001) suggest the presence of 
the HIV-1 5’ UTR is unnecessary, and even slightly detrimental to the 
translational capability of the gag ORF. 
The data presented by Buck et al. (2001) and Brasey et al. (2003) suggest 
the presence of two HIV-1 IRESs; one within the 5’ leader sequence and 
another within the gag ORF. Subsequent to IRES binding, 5’ to 3’ ribosomal 
scanning would be expected to occur although this may not be necessary 
depending on the location of the IRES. One of the reported HIV-1 IRESs is 
located downstream of the gag ORF and therefore translocation of the 40S 
ribosomal subunit, in a 3’-5’ direction would need to occur in order for 
recognition of the upstream gag start codon (Brasey et al., 2003). It remains 
unclear, however, as to whether 40S ribosomal recruitment to the gag mRNA 
can occur from backscanning in a 3’-5’ direction from the gag ORF IRES 
(Buck et al., 2001), or whether traditional 5’-3’ scanning can promote 
translation initiation from the 5’ leader IRES (Brasey et al., 2003). The HIV-1 
5’ UTR contains secondary structures which can inhibit cap-dependent 
translation by blocking access of the translation initiation complex (eIF4F) to 
the 5’ cap. Thus, the presence of HIV-1 IRESs may provide a mechanism by 
which the ribosome can bypass the structural obstacles hindering cap-
dependent translation, and allow translation to proceed via direct ribosome 
recruitment to the gag ORF (Buck et al., 2001). 
Ventoso et al. (2001) observed that HIV-1 Protease can cleave eIF4G, thus 
shutting down cap-dependent translation. However, in vitro translation of 
HIV-1 mRNA was increased by 4-fold when eIF4G was cleaved by HIV-1 
Protease. This suggests not only that eIF4G cleavage enhances the rate of 
HIV-1 mRNA translation, but that HIV-1 mRNA is also able to undergo 
translation in a cap-independent manner. Consequently, HIV-1 IRES activity 
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is proposed to permit translation of HIV mRNAs when cap-dependent 
translation is shut down (Ventoso et al., 2001).  
Evidence for HIV-2 IRES activity: 
Herbreteau et al. (2005) demonstrated IRES activity in the HIV-2 gag ORF in 
a dicistronic assay in both RRL and HeLa cells. Translation from the HIV-2 
Gag AUG, and two internal AUG codons, occurred when the matrix region of 
the gag ORF was present in the intercistronic region of reporter constructs. 
However, the presence of the HIV-2 5’ UTR reduced IRES activity. 
Weill et al. (2010) and Locker et al. (2011) have extended this work to show 
that transcripts containing the first 420 nt of the HIV-2 gag ORF without the 5’ 
UTR are able to recruit translation initiation complexes directly (Locker et al., 
2011). 
SIVmac, which is closely related to HIV-2, has been reported to contain an 
IRES in its 5’ UTR (Ohlmann et al., 2000). However, it has also been 
postulated to contain an IRES similar to HIV-2 in its gag ORF (Weill et al., 
2010). 
Compelling arguments exist for both cap-dependent and IRES initiated 
translation. Ostensibly, HIV mRNA is structured to undergo translation in a 
cap-dependent fashion alongside cellular mRNA. However, several stages of 
the viral life cycle appear to result in unfavourable conditions for cap-
dependent translation. Cleavage of eIF4G by HIV PR, or cellular arrest at the 
G2/M stage of the cell cycle by viral Vpr, both inhibit cap-dependent 
translation. Likewise, during assembly, the HIV 5’ UTR may become blocked 
by binding of Gag proteins to the HIV genome, inhibiting cap-dependent 
translation (Anderson and Lever, 2006). Although cap-dependent translation 
of viral mRNA may be favourable, more complex initiation mechanisms may 
have developed to ensure that the important step of translation initiation is 
not disregarded due to cellular circumstance. It may be that under certain 
conditions IRES activity permits HIV translation or, alternatively, other 
regulatory factors or pathways may serve to sustain cellular HIV translation. 
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Currently the manner and conditions under which HIV Gag translation is 
initiated are not fully understood and further work is required to elucidate HIV 
translational mechanisms. Likewise, it remains unknown whether HIV-1 and 
the less studied HIV-2 virus use comparative or distinctive translational 
methods. 
4.1.6.4 Regulation of translation of HIV Gag 
The mechanism of switching between cap-dependent and IRES-driven 
translation, and what determines this switch, are unknown, but an 
involvement of the Gag protein has been suggested (Ricci et al., 2008). 
Investigation into the effect of Gag concentration on protein synthesis has 
shown that at high concentrations, p55 Gag inhibits protein synthesis of viral 
RNA, whereas at low concentrations, p55 Gag stimulates synthesis 
(Anderson and Lever, 2006). Binding of p55 Gag protein to the 5’ UTR of its 
mRNA following synthesis may prevent adherence of scanning ribosomes 
thus triggering a switch to IRES driven translation (Ricci et al., 2008). 
Consequently, an additional role for the Gag protein may be to control the 
rate of viral translation. 
Additionally, two variant HIV-2 Gag transcripts have been identified which are 
translated with differing efficiencies. The removal of a 142 nucleotide intron 
from the HIV-2 5’ UTR results in a spliced version of HIV-2 Gag RNA which is 
translated with a 5-fold increased efficiency. It is thought that the removal of 
secondary structure by splicing may promote more efficient ribosome 
scanning (Strong et al., 2009). Likewise, splicing removes a C-box/G-box 
long range interaction within the HIV-2 RNA; removal of the C-box region has 
been shown to enhance translation rates (Brasey et al., 2003). Thus different 
HIV-2 transcripts may facilitate regulation of HIV-2 Gag translation. 
Further work is necessary to assess whether translation differs between HIV-
1 and HIV-2 and, moreover, develop a clearer picture as to the translational 
mechanisms employed by these viruses. As translation is such an important 
regulatory step within the HIV life cycle, variations in translational efficiency 
may thus impart differences in the overall replicative capacity of these viruses 
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and provide an answer as to why HIV-1 is a more voracious pathogen than 
HIV-2. 
4.2 HIV-1/2 Gag translation 
4.2.1 HIV Gag RNA reporters 
Initial work focused on comparing Gag translation between HIV-1 and -2. The 
binding affinity of HIV-1 and HIV-2 Gag-specific antibodies may vary, so 
western blotting or immunoprecipitation cannot be used to compare Gag 
protein synthesis directly. Consequently, capped and polyadenylated RNA 
reporters were generated from T7 promoter-driven transcription of HIV Gag-
Luc reporter plasmids. RNA reporters contained the 5’ UTR and gag coding 
region from HIV-1 or HIV-2 linked to the coding sequence for firefly luciferase 
to provide a common basis for assay [figure 47].  
 
Figure 47: Capped and polyadenylated RNA reporters produced from T7-driven 
transcription of reporter plasmids. Reporter RNA contained the 5’ UTR and gag 
coding region from HIV-1 or -2 linked, via a Gly(4)Ser linker, to a gene encoding firefly 
luciferase.  
Translation of these RNA reporters produces a fusion protein of Gag and 
luciferase, detectable by luciferase assay. In this way, translation is isolated 
from transcription and splicing. Consequently, the luciferase activity of the 
HIV-1/2 RNA reporters can be used as a measure of Gag translation and, 
thus, these reporters can be used to compare the rate of translation between 
HIV-1 and HIV-2. 
4.2.2 In vitro HIV-1/2 Gag-Luc expression 
The size and functionality of the Gag-Luc fusion protein was tested by in vitro 
transcription and translation of HIV-1/2 Gag-Luc reporter plasmids in a TnT 
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rabbit reticulocyte lysate (RRL) system [Promega] using radioactively labelled 
35S-methionine. The proteins produced were detected by SDS-PAGE and 
autoradiography [figure 48A] or by luciferase assay [figure 48B]. 
(A)  
(B)  
Figure 48: In vitro transcription and translation of 
35
S-methionine labelled HIV-1/2 Gag-
Luc DNA SDS-PAGE and autoradiography (A) and luciferase assay results to verify 
luciferase functionality (B). Fluorescence of Gag-Luc in terms of relative light (RL) 
units was used as a measure Gag translation.  
The size of proteins produced from HIV-1 and 2 Gag-Luc reporters was 
shown to be ~120 kDa, which is the expected size of the Gag-Luc fusion 
proteins (HIV-1 Gag = 55 kDa, HIV-2 Gag = 57 kDa, Luc = 65 kDa). Several 
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bands were produced from translation of reporters. This is likely to be due to 
alternative translation initiation at internal Gag AUG codons producing 
different Gag isoforms. Previously identified Gag isoforms include two HIV-2 
Gag isoforms (p50 and p44) which would produce Gag-Luc fusion proteins of 
115 kDa and 109 kDa, and a single HIV-1 isoform (p40) which would result in 
a fusion protein of 105 kDa (Ricci et al., 2008). As expected, the HIV-2 Gag-
Luc fusion proteins have a larger MW than HIV-1 Gag-Luc fusion proteins. 
However, several additional HIV-1 bands were produced potentially 
representing unknown N-terminally or C-terminally truncated HIV-1 Gag 
isoforms. 
The functionality of the Gag-Luc fusion protein was tested by carrying out a 
luciferase assay [figure 48B]. This showed that firefly luciferase within the 
Gag-Luc fusion protein was functional and, furthermore, could be detected by 
this method. Consequently, the Gag-Luc fusion proteins could be used as a 
suitable means to assess the level of HIV-1/2 Gag translation. In vitro 
transcription and translation from HIV-1/2 Gag-Luc reporter plasmids 
suggested that HIV-1 Gag was expressed 1.8-fold better than HIV-2 Gag. 
However, this may have been due to more efficient HIV-1 transcription (see 
Chapter 3) so it was necessary to isolate translation by using RNA reporters 
in order to directly compare HIV-1/2 translation rates. 
4.2.3 HIV-1/2 Gag translation in cells 
Comparing the rate of translation between HIV-1/2 may indicate whether this 
is a rate limiting stage of replication responsible for the lower level of viral 
particle production observed during a HIV-2 infection. HIV-1 and HIV-2 Gag 
translation was compared in several cell types; HeLa (human cervical 
carcinoma cell line), COS-1 (African green monkey kidney cell line) and 
Jurkat (human T-lymphocyte cell line). All these cell lines support HIV 
replication, with Jurkat cells being the most closely related to the cells 
infected in a natural HIV infection. 
Capped and polyadenylated HIV-1/2 Gag-Luc reporter RNAs [figure 47] were 
generated by in vitro transcription and varying concentrations of RNA were 
used to transfect HeLa [figure 49], COS-1 [figure 50] and Jurkat [figure 51] 
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cells before harvesting protein after 6 h. Renilla luciferase RNA was co-
transfected as a control for transfection efficiency. The quantity of Gag-Luc 
fusion protein translated from HIV-1/2 reporters was measured using a Dual-
Luciferase® Reporter Assay System [Promega] and normalised to Renilla 
luciferase. Each transfection was conducted in duplicate and results shown 
are the average of 3 experiments. Error bars represent the SEM. 
 
 
Figure 49: Translation of HIV-1/2 RNA reporter constructs in HeLa cells. Fluorescence 
of Gag-Luc in terms of relative light (RL) units was used as a measure Gag translation. 
Results were normalised to the Renilla transfection control.  
 
Figure 50: Translation of HIV-1/2 RNA reporter constructs in COS-1 cells. 
Fluorescence of Gag-Luc in terms of relative light (RL) units was used as a measure 
Gag translation. Results were normalised to the Renilla transfection control.  
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Figure 51: Translation of HIV-1/2 RNA reporter constructs in Jurkat cells. 
Fluorescence of Gag-Luc in terms of relative light (RL) units was used as a measure 
Gag translation. Results were normalised to the Renilla transfection control.  
HIV-2 Gag was translated to a much lower level than HIV-1 for varying 
concentrations of RNA and in several different cell lines. In HeLa cells, HIV-1 
Gag was translated up to 6.9-fold more efficiently than HIV-2 Gag [figure 49]; 
in COS-1 cells HIV-1 Gag was translated up to 11.9-fold more efficiently than 
HIV-2 Gag [figure 50] and in Jurkat cells HIV-1 Gag was translated up to 3.2-
fold more efficiently than HIV-2 Gag [figure 51]. Overall, these data indicates 
that HIV-2 Gag translation is much less efficient than HIV-1 Gag translation in 
a variety of cell types. It is interesting to note that in Jurkat cells, the most 
physiologically relevant cell type, the lowest fold difference in HIV-1/2 
translation rates occurred. 
4.2.4 HIV-1/2 RNA reporter stability 
In cells, HIV-1 Gag RNA is translated more efficiently than HIV-2 Gag RNA. 
However, HIV-1/2 translation rates may be altered by differences in HIV-1/2 
RNA stability. Thus it was necessary to confirm that the observed differences 
in HIV-1/2 Gag-Luc fusion protein production were due to translational 
differences rather than RNA degradation. HeLa cells were transfected with 
60 ng of HIV-1/2 Gag-Luc reporter RNA and the level of RNA remaining in 
the cells after 3 h and 6 h was quantified by harvesting total cell RNA and 
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carrying out real-time RT-PCR (qPCR). Primers to HIV-1 (primer #22, 23) 
and HIV-2 (primer #24, 25) Gag were used for the qPCR, with results 
normalised to a GAPDH housekeeping gene (amplified using primers #18, 
19). Reactions were carried out in duplicate. 2ΔCt was calculated for each 
sample and expressed as a percentage of the largest 2ΔCt RNA value to 
permit scaled averaging of results from two experiments [figure 52]. 
 
Figure 52: A comparison of HIV-1/2 Gag-Luc reporter RNA stability at 3 h and 6 h post-
transfection. Gag RNA levels were quantified by qPCR and normalised to a GAPDH 
housekeeping gene. To compensate for scale, RNA levels are shown as 2
ΔCt
 
expressed as a percentage of the largest 2
ΔCt
 RNA value, averaged for two 
experiments. Error bars represent the SEM. 
Transfected HIV-1 and HIV-2 reporter RNA levels were similar at 3 h and 6 h. 
Neither HIV-1 nor HIV-2 Gag-Luc RNA levels decreased between 3 h and 6 h 
indicating that no observable RNA degradation occurred during the 
experiment. Therefore the reporter RNAs were reasonably stable following 
transfection and enhanced HIV-2 reporter RNA degradation was not 
responsible for the lower rate of HIV-2 Gag translation observed in cells. 
4.2.5 HIV-1/2 Gag translation in the presence of proviral DNA 
The presence of viral proteins may affect the level of HIV-1 or HIV-2 
translation differently. Consequently, HeLa cells were transfected with 30 ng 
of HIV-1 or HIV-2 provirus for 24 h to produce viral proteins, before 
transfection of 60 ng of HIV-1/2 reporter RNAs [figure 47] for 6 h. Gag 
translation in the presence/absence of provirus (and thus viral proteins) was 
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assayed by a luciferase assay of harvested protein [figure 53]. 60 ng of 
Renilla luciferase RNA was co-transfected as a control for translation 
efficiency. 30 ng of two DNA controls was also used: pcDNA GFP expressing 
GFP protein was used as a control for non-specific translation competition, 
and pJHRV (containing a non-mammalian promoter) was used to control for 
any effect of plasmid presence on translation levels. Reactions were carried 
out in duplicate and the results shown are the average of 3 experiments. 
 
Figure 53: Luciferase assay results showing the translation of HIV-1/2 Gag-Luc RNA 
reporters in the presence of HIV-1 provirus, HIV-2 provirus, pcDNA GFP plasmid or 
pJHRV plasmid co-transfections. Gag translation is expressed in relative light (RL) 
units as a percentage of Gag translation levels from isolated HIV-1/2 RNA reporter 
transfections. Error bars represent the SEM. 
In the presence of either HIV-1 or HIV-2 viral proteins, HIV-1/2 Gag 
translation decreased by a similar level. A comparable effect was observed 
when HIV-1/2 Gag translation was monitored in the presence of non-specific 
GFP translation (from pcDNA GFP). This indicates that, in the presence of 
proviral plasmids, competition for translational machinery was likely effecting 
a reduction in the levels of HIV-1/2 Gag translation. For this reason, it is 
unlikely that proviral plasmids effected a specific reduction in translation 
attributable to the presence of translated viral proteins.  
The presence of a generic plasmid, pJHRV, did not alter HIV-1/2 Gag 
translation levels significantly. As a similar decrease in HIV-1/2 Gag 
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translation was observed in the presence of HIV-1/2 provirus, it appears that 
viral proteins do not differently affect HIV-1/2 translation rates. 
4.3 HIV-1/2 Gag translation initiation: cap-dependent or 
IRES-dependent? 
4.3.1 Transfection of HRV-2 RNA 
HIV-1/2 translation initiation strategies may differ. This may account for the 
lowered HIV-2 Gag translation rate observed in vitro and in cells. We 
therefore wanted to assess the reliance of HIV-1/2 gag mRNA on cap-
dependent translation initiation. Inhibition of cap-dependent translation can 
be achieved using human rhinovirus (HRV-2) which encodes a 2A protease. 
2A cleaves eIF4G, an initiation factor involved in cap-mediated translation 
initiation, thus inhibiting cap-dependent translation. HRV-2 can therefore be 
used as a tool to specifically inhibit cap-dependent translation. 
HeLa cells were transfected with 250 ng HRV-2 RNA (encoding 2A) for 16 h 
to shut down cap-dependent translation, before transfection for 6 h with 60 
ng either HIV-1 or HIV-2 reporter RNA constructs [figure 47]. All reactions 
were carried out in duplicate. Further dicistronic RNA controls [figure 54] 
were transfected alongside reporter RNAs to assess whether HRV-2 RNA 
transfections had an effect on IRES-dependent translation. 
 
Figure 54: Cap-dependent Renilla luciferase and (HCV/HRV) IRES-dependent firefly 
luciferase dicistronic RNA controls. 
The dicistronic RNAs have an upstream cap-dependent region encoding 
Renilla luciferase and a downstream region expressing firefly luciferase 
under the control of an internal ribosome entry site (IRES) from either 
hepatitis C virus (HCV) or human rhinovirus (HRV). Thus Renilla luciferase 
translation is cap-dependent whereas firefly luciferase translation is IRES-
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dependent. Consequently, these dicistronic controls were used as a positive 
control for both IRES activity and to assess the inhibition of cap-dependent 
translation by HRV-2 2A. After 6 h transfection, cells were harvested and 
total cell protein extracted before carrying out a luciferase assay to quantify 
the levels of HIV-1/2 translation and that of the dicistronic controls [figure 55]. 
Results shown are the average of 3 experiments. 
 
(A)      (B) 
(C)  
Figure 55: Translation of HIV-1 and HIV-2 RNA reporters in the presence and absence 
of HRV-2. Gag-Luc fusion protein translation was quantified by firefly luciferase 
fluorescence measured in terms of relative light (RL) units (A) and expressed as a 
percentage of ‘No HRV-2’ values (B). Translation of cap-dependent Renilla luciferase 
and IRES-driven firefly luciferase from RHRVF and RHCVF were compared in the 
presence and absence of HRV-2. Renilla and firefly luciferase translation was 
measured in RL units and expressed as a percentage of ‘No HRV-2’ values (C). Error 
bars represent the SEM. 
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In the presence of HRV-2 RNA a significant decrease in HIV-1 Gag 
translation, by 22.5-fold, and HIV-2 Gag translation, by 12.2-fold, was 
observed [figure 55]. This suggests that both HIV-1 and HIV-2 Gag 
translation relies on cap-dependent initiation. 
Translation of cap-dependent Renilla within the dicistronic controls 
decreased by 5.2-fold for RHRVF and 5.0-fold for RHCVF in the presence of 
HRV-2. This suggests that HRV-2 RNA transfections shut down cap-
dependent translation. However, IRES-driven firefly translation also 
decreased by 4.3-fold for RHRVF and 2.6-fold for RHCVF in the presence of 
HRV-2. Although this decrease was not to the same extent as for Renilla, it 
was expected that eIF4G cleavage would stimulate IRES activity within the 
dicistronic controls. As this was not the case, eIF4G may not have been fully 
cleaved and therefore cap-dependent translation may not have been fully 
shut down. If eIF4G was not fully cleaved, ongoing cap-dependent translation 
may have competed for translational machinery and therefore prevented an 
increase in IRES-driven translation. Alternatively, the transfection of lots of 
HRV-2 RNA may have had a cytopathic effect on the cells, thus also effecting 
a reduction in IRES-dependent translation. 
4.3.2 Expression of 2A protease 
Non-specific effects of the HRV-2 virus may have been contributing to 
translational inhibition of HIV-1 and HIV-2 Gag. To isolate 2A induced shut 
down of cap-dependent translation, HRV-2 2A, rather than the full-length 
HRV-2 genome, was cloned into pcDNA3. However, expression of pcDNA3-
2A did not inhibit cap-dependent translation of a Renilla RNA control in vitro 
or in HeLa cells [not shown].  
It was thought that HRV-2 2A may have been inhibiting its own cap-
dependent translation through eIF4G cleavage. Consequently, HRV-2 2A 
was cloned into pcDNA3 downstream of an encephalomyocarditis virus 
(EMCV) IRES to promote better 2A protein expression. Both IRES-driven 2A 
expression (from pcDNA3-2A IRES) and cap-dependent 2A expression (from 
pcDNA3-2A) were tested in an in vitro transcription/translation TnT system 
[Promega] [figure 56]. 
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Figure 56: An SDS-PAGE of 
35
S-methionine labelled 2A from an in vitro 
transcription/translation in a TnT system. Lane 1: IRES-driven 2A expression from 
pcDNA3-2A IRES, Lane 2: Cap-dependent 2A expression from pcDNA3-2A, Lane 3: 
protein expression from a pcDNA3 control plasmid (with no 2A). 
Expression of 2A from both pcDNA3-2A and pcDNA3-2A-IRES was low, only 
producing a faint band at around 16 kDa following an in vitro 
transcription/translation [lanes 1+2, figure 56]. 
To verify whether cap-dependent or IRES-dependent expression of 2A 
affected HIV-1/2 Gag translation, 1.5 μg of pcDNA3-2A or pcDNA-2A-IRES 
DNA was used to transfect HeLa cells for 16 h to express 2A. Reactions 
were carried out in duplicate. As a comparison, cells were also not 
transfected, mock transfected or transfected with pcDNA3 (which does not 
encode 2A). After 16 h, 60 ng of HIV-1/2 reporter RNA reporters was 
transfected into HeLa cells for 6 h before harvesting total cellular protein for 
use in a luciferase assay [figure 57]. Renilla luciferase RNA was co-
transfected with HIV-1/2 RNA reporters as a control for 2A inhibition of cap-
dependent translation, and to account for variations in transfection efficiency. 
Results shown are the average of 2 experiments. 
Both cap-dependent and IRES-driven 2A expression had very little effect on 
the translation rate of the cap-dependent Renilla luciferase control [not 
shown]. This suggests that cap-dependent translation was not efficiently shut 
Chapter 4        HIV Gag translation 
 
132 
 
down. Unsurprisingly, the very low level of 2A expressed therefore had little 
effect on either HIV-1 or HIV-2 Gag translation levels [figure 57].  
 
Figure 57: Luciferase assay results from HeLa transfection of 2A plasmids (pcDNA3-
2A and pcDNA3-IRES-2A) for 16 h, followed by HIV-1/2 RNA reporters for 6 h. Gag-Luc 
translation is expressed in relative light (RL units), normalised to the Renilla control. 
HIV-1/2 Gag translation was compared in the presence of no transfection, mock 
transfection and pcDNA3 transfection controls. Error bars represent the SEM. 
To check whether 2A protein expressed from either pcDNA3 2A or pcDNA3-
2A IRES was cleaving eIF4G, protein samples were used in a western blot 
with an antibody to eIF4G [figure 58]. 
 
Figure 58: A western blot of HIV-1 (H1) and HIV-2 (H2) transfection protein with an 
antibody to eIF4G. Harvested protein was used from cells not transfected (-), mock 
transfected, transfected with pcDNA3 (without 2A), pcDNA3-2A (with cap-dependent 
2A) and pcDNA3-IRES-2A (with IRES-driven 2A). 
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As expected, no transfection, mock transfection and pcDNA3 transfection 
controls showed inact eIF4G. There was also no difference in 2A expression 
between the controls and cap-dependent 2A (expressed from pcDNA3-2A) 
transfection cell protein [lanes 8+9, figure 58]. Likewise, IRES-driven 2A 
expression (from pcDNA3-2A IRES) did not affect the cleavage pattern of 
eIF4G [lanes 9+10, figure 58]. As neither cap-dependent HRV-2 2A nor 
IRES-driven HRV-2 2A was able to promote complete cleavage of eIF4G, 
cap-dependent translation was, therefore, not shut down. 
As an alternative approach, pT7EV7∆P1, which encodes a poliovirus 2A 
protease, was tested as a means to inhibit cap-dependent translation via 
eIF4G cleavage. 5 μg of poliovirus 2A RNA (transcribed from pT7EV7∆P1) 
was used to transfect HeLa cells for 18 h in duplicate. 5 μg of HRV-2 2A RNA 
(produced from both pcDNA3-2A and pcDNA3-IRES-2A) was also used to 
transfect HeLa cells for 18 h as a comparison. After 18 h, HeLa were 
transfected with 120 ng of cap-dependent Renilla luciferase RNA for 6 h and 
total cell protein harvested. Renilla luciferase translation was quantified by 
luciferase assay to see whether poliovirus 2A was able to shut down cap-
dependent translation [figure 59]. 
 
Figure 59: A luciferase assay of protein harvested from cap-dependent Renilla 
luciferase RNA transfections in mock (no 2A), pcDNA3-2A (cap-dependent 2A), 
pcDNA3-IRES-2A (IRES-driven 2A), and pT7EV7ΔP1 RNA (poliovirus 2A) transfected 
cells. 
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Whereas cap-dependent and IRES-driven HRV-2 2A failed to shut down cap-
dependent translation, expression of poliovirus 2A reduced the level of cap-
dependent translation. Although the reduction in cap-dependent translation 
was fairly small, poliovirus 2A RNA transfection also resulted in some 
cleavage of eIF4G [figure 60].  
 
 
 
Figure 60: Western blot showing eIF4G cleavage in protein cell extracts from 
poliovirus 2A (polio 2A) transfections. Cells were transfected with: poliovirus 2A RNA 
(lane 1) from pT7EV7ΔP1, IRES-driven 2A RNA (lane 2) from pcDNA3-IRES-2A, cap-
dependent 2A RNA (lane 3) from pcDNA3-2A and no RNA (lane 4).  
Partial eIF4G cleavage was detected in cells transfected with poliovirus 2A 
RNA, shown by a band at 140 kDa [figure 60, lane 1], in contrast to cells 
transfected with cap-dependent or IRES-driven HRV-2 2A [figure 60, lane 
2+3] where no eIF4G cleavage was detected. However, eIF4G cleavage with 
pT7EV7∆P1 was incomplete, shown by a residual band at 220 kDa [figure 
60, lane 1] signifying uncleaved eIF4G. Consequently, cap-dependent 
translation may not have been completely inhibited. However, it appeared 
that poliovirus 2A was more efficient than HRV-2 2A at cleaving eIF4G and 
knocking down cap-dependent translation. 
Chapter 4        HIV Gag translation 
 
135 
 
4.3.3 HIV-1/2 Gag translation initiation: cap-dependence (poliovirus 
infections)  
As poliovirus appeared to be more efficient at inhibiting cap-dependent 
translation, HeLa cells were infected with poliovirus (PV) type 1 at a 
multiplicity of infection (m.o.i) of 10 to shut down cap-dependent translation. 
PV infection was carried out, rather than using the less reliable transfection 
method, to ensure that each cell was targeted with PV. After 1 h, infected 
cells were transfected with 60 ng HIV-1/2 RNA reporters and controls 
(dicistronic RHCVF, RHRVF and Renilla RNA) for 6 h before harvesting 
protein to quantify expression of the controls [figures 61 and 62] and Gag 
[figure 64] via a luciferase assay. Transfections were carried out in duplicate 
with the results shown as the average of 3 experiments. 
 
Figure 61: Translation of Renilla and firefly luciferase from dicistronic controls 
(RHRVF and RHCVF) in the presence/absence of poliovirus (PV) infection. The level of 
Renilla (blue) and firefly (orange) luciferase translation is expressed in relative light 
(RL) units as a percentage of ‘no PV’ transfections. Error bars represent the SEM. 
Dicistronic poliovirus infection controls behaved as expected in the presence 
and absence of poliovirus 2A. When poliovirus was present, 2A cleavage of 
eIF4G resulted in a decrease in the level of upstream cap-dependent Renilla 
translation (by 88% for RHRVF and 87% for RHCVF), whilst downstream 
IRES-driven firefly luciferase translation was strongly enhanced; 4-fold for 
RHRVF and 2.2-fold for RHCVF [figure 61] (López de Quinto et al., 2002). 
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The cap-dependent Renilla RNA control also showed a 77% decrease in 
translation in the presence of poliovirus infection [figure 62]. 
     
Furthermore, a western blot of transfection protein with an eIF4G antibody 
showed that complete cleavage of eIF4G occurred in poliovirus infected cells 
[figure 63]. 
 
Figure 63: A western blot of protein extracts from poliovirus infected and mock 
infected (no poliovirus) cells. Cells were infected with poliovirus (or mock) for 1 h 
followed by 6 h transfection of RNA: Renilla luciferase, HIV-1/2 Gag-Luc RNA 
reporters, a HIV-1 MA2 chimera reporter (containing HIV-1 Gag with the matrix domain 
from HIV-2) and dicistronic RHRVF/RHCVF RNA controls. eIF4G cleavage, shown by a 
band ~140 kDa is seen in poliovirus infected cells but not in the mock infected 
(control) cells. 
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Figure 62: Translation of cap-dependent 
Renilla luciferase RNA in the 
presence/absence of poliovirus (PV) 
infection. Renilla translation is expressed 
in RL units as a percentage of translation 
levels in the absence of poliovirus (no PV). 
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HeLa cells infected with poliovirus were shown to have complete cleavage of 
eIF4G, producing a band of around 140 kDa [lanes 1-6, figure 63], in contrast 
to uninfected cells where intact eIF4G, producing a band around 220 kDa 
[lanes 7-12, figure 63], was detected. 
Poliovirus infection resulted in complete cleavage of eIF4G and thus allowed 
a comparison of the rate of HIV-1/2 Gag RNA translation when cap-
dependent translation was shutdown [figure 64]. 
 
Figure 64: Translation of Renilla RNA and HIV-1/2 Gag-Luc RNA reporters in the 
presence and absence of poliovirus (PV) infection. Reactions were carried out in 
duplicate and averaged over 3 experiments. Values are normalised to ‘no poliovirus’ 
for each reporter to allow for a direct comparison of translation knockdown. Error 
bars represent the SEM. 
In the presence of poliovirus infection, when cap-dependent translation was 
shut down by eIF4G cleavage, translation of both HIV-1 Gag and HIV-2 Gag 
RNAs decreased significantly by 91% and 83% respectively [figure 64]. 
Likewise, translation of the cap-dependent Renilla RNA control also 
decreased by 83% in poliovirus transfected cells. These results strongly 
suggest that both HIV-1 and HIV-2 Gag translation rely on cap-dependent 
initiation. Both of these RNAs are poorly translated when cap-dependent 
translation is shut down and, additionally, both RNAs behave comparably to 
the cap-dependent Renilla RNA control. The Renilla control solely relies on 
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cap-dependent translation; both HIV-1/2 Gag RNA translation decreased by 
a similar level to the cap-dependent Renilla RNA control suggesting that 
alternative translation initiation mechanisms are also inefficient under these 
conditions. This suggests that any cap-independent mechanism of translation 
that HIV-1/2 Gag RNAs may undergo is not able to compete with the 
poliovirus IRES for translational machinery.  
4.3.4 HIV-1/2 Gag translation initiation: cap-dependence (uncapped 
RNA)  
Inhibiting cap-dependent translation may have resulted in off-target cellular 
effects. As an alternative method to determine the importance of the 5’ cap to 
HIV-1/2 Gag translation, uncapped HIV-1/2 reporter RNAs [figure 47] were 
produced. Transfection of 60 ng of both capped and uncapped HIV-1/2 RNA 
reporters, in duplicate, alongside a Renilla RNA control was carried out for 6 
h in HeLa. Total cell protein was extracted and used in a luciferase assay to 
quantify translation of the Gag-Luc fusion protein from HIV-1/2 
capped/uncapped RNA reporters [figure 65].  
. 
Figure 65: Luciferase assay of HIV-1/2 Gag translation expressed in relative light (RL) 
units from capped and uncapped RNA reporters. Results are normalised to a co-
transfected Renilla luciferase RNA control and expressed as a percentage of ‘capped 
RNA’ data. 
0 
20 
40 
60 
80 
100 
120 
Renilla HIV-1 HIV-2 
G
a
g
:L
u
c
 t
ra
n
s
la
ti
o
n
 (
%
 R
L
 u
n
it
s
) 
RNA 
Capped 
Uncapped 
Chapter 4        HIV Gag translation 
 
139 
 
Removal of the 5’ cap structure resulted in a considerable decrease in both 
the level of HIV-1 Gag translation (81%) as well as translation of the cap-
dependent Renilla control (61%). Uncapped HIV-2 RNA showed a slight 
decrease (21%) in translation although not to the same extent as HIV-1 
[figure 65]. These results suggest that translation of HIV-1 Gag is highly cap-
dependent. Alternatively, whilst HIV-2 Gag translation still requires intact 
eIF4G, it depends less on the presence of a cap structure than for HIV-1 
translation. However, these results could also mean that uncapped HIV-2 
RNA is more stable in cells than uncapped HIV-1 RNA. Further work is 
required to check the stability of uncapped HIV-1/2 RNA and determine 
whether a greater degradation rate of uncapped HIV-1 RNA may have 
contributed to the lower HIV-1 translation level. 
4.3.5 Use of internal AUG codons 
Full-length Gag is reportedly produced from cap-dependent translation, 
whereas internal initiation from additional AUG sites is proposed to produce 
Gag isoforms (Ricci et al., 2008). To determine whether alternative 
translational strategies are employed by HIV-1/2, the use of internal AUG 
codons was examined. However, the anti-capsid antibody typically used to 
visualise HIV-1/2 Gag detects capsid-containing products from the proteolytic 
cleavage of Gag, and not primarily full-length Gag. Consequently, to observe 
full-length Gag and thus visualise translational isoforms of the Gag precursor, 
it was necessary to prevent HIV Protease cleavage of Gag. Saquinavir (SQ) 
is a HIV Protease inhibitor and was therefore used to specifically inhibit HIV 
Protease cleavage of Gag.  
HeLa cells were transfected with 580 ng of HIV-1/2 provirus DNA for 24 h in 
the presence/absence of saquinavir (+/- SQ) before harvesting cellular 
proteins. Western blotting and immunoprobing with antibodies to the HIV Gag 
capsid region (p24 for HIV-1, p27 for HIV-2) allowed visualisation of Gag 
precursors and cleavage products [figure 66].  
In the absence of SQ, HIV-1 full-length p55 Gag and Gag cleavage products: 
the processing intermediate p41 (Matrix/Capsid, p17/p24) and p24 Capsid 
protein, were identified [lane 1, figure 66]. In the presence of SQ, an 
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additional 160 kDa band was identified [lane 2, figure 66] representing HIV-1 
Gag-Pol in addition to full-length p55 Gag, whereas the p41 processing 
intermediate and Capsid p24 were no longer detectable. Likewise, both HIV-
2 p57 Gag and cleaved p27 Capsid were detectable in the absence of SQ 
[lane 3, figure 66] whereas only full-length p57 Gag was detected when SQ 
was present [lane 4, figure 66]. This indicates that SQ successfully inhibited 
HIV-1/2 Protease cleavage. 
 
Figure 66: Western blot with antibodies to the capsid region of HIV-1/2 Gag. 
Expression of HIV-1 and HIV-2 Gag (p55/p57) precursors, the HIV-1 p41 Matrix/Capsid 
(MA/CA) processing intermediate and both HIV-1/2 Capsid (p24/p27) proteins are 
shown from transfected provirus in the presence/absence of saquinavir (SQ).  
Furthermore, the p40 HIV-1 Gag isoform and a potentially new HIV-1 Gag 
isoform around 48 kDa were detected [lanes 1+2, figure 66] in addition to the 
HIV-2 p50 and p44 Gag isoforms [lanes 3+4, figure 66].  
Ricci et al. (2008) have suggested that translation of these Gag isoforms may 
be driven by internal initiation from one or several HIV IRES. PV infection 
was therefore used to shut down cap-dependent translation (via eIF4G 
cleavage) and monitor whether internal AUG translation initiation was able to 
promote translation of the Gag isoforms. HeLa cells were transfected with 
580 ng of HIV-1/2 provirus DNA for 24 h in the presence/absence of 
saquinavir (+/- SQ) before infecting cells with poliovirus (PV) for 1 h (+/- 
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saquinavir). Cells were subsequently left for 6 h (+/- saquinavir) before 
harvesting cellular protein for use in a western blot with antibodies to HIV-1/2 
Gag p24/p27 [figure 67]. 
(A)   
(B)   
Figure 67: Western blot of transfection protein with antibodies for HIV-1 Gag (p24) (A) 
and HIV-2 Gag (p27) (B). Provirus transfections were carried out for 24 h with/without 
saquinavir (+/- SQ). Cells were then infected with/without poliovirus (+/- PV) for 1 h (+/-
SQ) and then incubated for 6 h (+/- SQ) before harvesting total cell protein.  
In cells infected with poliovirus, the level of HIV-1/2 Gag precursors, p41 
processing intermediates and Capsid proteins were lower than for uninfected 
cells. This was represented by fainter bands on the gel [lanes 1+2 for HIV-
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1/2, figure 67] indicating that the shutdown of cap-dependent translation via 
eIF4G cleavage was preventing HIV Gag translation. A western blot of 
samples with an antibody to eIF4G showed that complete eIF4G cleavage 
was detected in all samples infected with poliovirus (+/- SQ) (data not 
shown). This indicates that cap-dependent translation was shut down in 
poliovirus infected cells. Likewise, this confirmed that SQ was not inhibiting 
the activity of the poliovirus 2A protease and its activity was therefore specific 
to the HIV Protease. 
It was unknown whether SQ treatment was necessary at every stage of the 
experiment to prevent Gag precursor cleavage, or whether SQ treatment 
would interfere with the success of PV infection on shutting down cap-
dependent translation. The presence of SQ throughout the experiment 
successfully prevented cleavage of the Gag precursor into either processing 
intermediates or Capsid. This was evident from the lack of lower molecular 
weight bands and an increase in the intensity of the Gag precursor band for 
samples fully treated with SQ [lanes 5, 6, 9+10 for HIV-1/2, figure 67]. 
Samples which were only treated with SQ for partial stages of the experiment 
produced some Gag cleavage products [lanes 3, 4, 7+8 for HIV-1/2, figure 
67], albeit to a lesser extent than cells not treated with saquinavir. This 
indicates that some Gag cleavage was able to occur at stages of the 
experiment where SQ was not present. 
It was thought that when cap-dependent translation was shut down, IRES-
driven translation, utilising internal Gag AUG codons, may have been 
enhanced due to reduced competition for translational machinery by cap-
dependent RNAs. However, in cells treated with both PV and SQ, whereby 
cap-dependent translation was inhibited and Gag precursor cleavage 
prevented, no additional translation of HIV-1/2 Gag isoforms was identified 
[lanes 5, 9+10 for HIV-1/2, figure 67]. 
Furthermore, eIF4G cleavage has been shown to enhance IRES activity 
(Dobrikova et al., 2006). Therefore, if IRES-driven activity from internal Gag 
AUG codons was stimulated by eIF4G cleavage (in PV infected cells) it was 
expected that stronger bands around 40 kDa (HIV-1) and 44 kDa/50 kDa 
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(HIV-2) would be apparent for protein samples from PV infected and SQ 
treated cells [lanes 5, 9+10 for HIV-1/2, figure 67]. However this was not the 
case; PV infection did not alter the ratio of Gag isoforms produced. This 
suggests that hypothesised IRES elements linked to internal AUG sites are 
non-functional and unable to compensate for the shutdown of cap-dependent 
translation under these conditions. The expression of Gag isoforms may 
therefore be a result of alternative translation events such as leaky scanning.  
4.4 HIV-1/2 Gag translation initiation: 5’ UTR secondary 
structure 
4.4.1 Folding energy 
4.4.1.1 Full HIV-1/2 5’ UTR folding energies 
The 5’ UTR folding energy of HIV-1 and HIV-2 may affect translation. A high 
folding energy indicates a higher level of secondary structure which may 
inhibit ribosomal scanning or spatially impede formation of a translation 
initiation complex. The average 5’ UTR folding energy of HIV-1/2 strains, 
referenced from the Los Alamos Database, were compared 
(http://www.hiv.lanl.gov/content/sequence/HIV/mainpage.html) and the folding 
energy calculated for HIV-1 sequences >300 nt and HIV-2 sequences >500 
nt using UNAfold (http://www.bioinfo.rpi.edu/applications/hybrid/download.php). 
Additionally, the average folding energy per nucleotide for each 5’ UTR was 
calculated [table 8]. 
 Kcal (AVG) Kcal/nt (AVG) 
HIV-1 -113.6 -0.320 
HIV-2 -191.0 -0.356 
 
Table 8: The average folding energy (Kcal) and folding energy per nucleotide (Kcal/nt) 
for the 5’ UTR of several HIV-1 and HIV-2 strains. A greater negative energy value 
represents a more stable RNA structure. 
The HIV-2 5’ UTR has a more negative folding energy (-191.0 Kcal) than 
HIV-1 (-113.6 Kcal) suggesting it has a more stable RNA structure. The 
folding energy per nucleotide of the HIV-2 5’ UTR (-0.356 Kcal/nt) is also 
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more negative than for HIV-1 (-0.320 Kcal/nt). Given that the HIV-2 5’ UTR is 
also longer (545 nt compared to 335 nt for HIV-1), this suggests that the HIV-
2 5’ UTR is intrinsically more structured than the HIV-1 5’ UTR. Thus 
impeded ribosomal scanning of the HIV-2 5’ UTR may hinder the rate of HIV-
2 Gag translation to a greater extent than for HIV-1. 
4.4.1.2 ΔTAR HIV-1/2 5’ UTR folding energies 
Specific sequences or structures within HIV RNA may affect translation 
efficiency, especially those at the very 5’ end of the RNA where initial 
ribosome recruitment may occur. The 5’ terminus of the HIV 5’ UTR contains 
a highly conserved, secondary stem-loop TAR structure [figure 68].  
      
   
Figure 68: The HIV TAR structures found at the start of the HIV-1/2 5’ UTR. HIV-1 TAR 
consists of a 59 nucleotide structure whereas HIV-2 has an extended, 123 nucleotide 
structure (Dirac et al., 2001; Jossinet et al., 2001; Purzycka and Adamiak, 2008; Strong 
et al., 2009). 
TAR RNA has a different structure in HIV-1 and HIV-2 (Brady and Kashanchi, 
2005). The HIV-2 TAR consists of an extended 123 nucleotide structure 
compared to 59 nucleotides for HIV-1. HIV-2 TAR may therefore obstruct 
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ribosomal scanning to a greater extent than HIV-1 TAR, contributing to the 
lower HIV-2 translation rate. 
The folding energy (Kcal) and folding energy per nucleotide (Kcal/nt) were 
calculated following removal of the TAR structure from HIV-1/2 5’ UTR 
sequences to see if this resulted in more equivalent 5’ UTR folding energies 
[table 9]. 
 Kcal (AVG) Kcal/nt (AVG) 
HIV-1 ∆TAR -85.8 -0.295 
HIV-2 ∆TAR -135.1 -0.326 
 
Table 9: The average folding energy (Kcal) and folding energy per nucleotide (Kcal/nt) 
for ∆TAR HIV-1/2 5’ UTRs. A greater negative energy value represents a more stable 
RNA structure. 
The HIV-2 ∆TAR 5’ UTR still had a more negative folding energy (-85.8 Kcal) 
than the HIV-1 ∆TAR 5’ UTR (-135.1 Kcal) indicating that there are further 
structural differences between the HIV-1/2 5’ UTRs than just those observed 
within the TAR region. Removal of the TAR structure slightly reduced the 
difference between the HIV-1/2 folding energies, from a difference of 77.4 
Kcal with TAR, to 49.3 Kcal without TAR. Therefore, although TAR is not 
solely responsible for folding energy differences between HIV-1/2, it partly 
contributes to the greater negative score, and thus greater level of structure, 
for the HIV-2 5’ UTR. 
4.4.1.3 TAR G-C content 
The folding energy of RNA is dependent on the level of G-C and A-U base 
pairing within the RNA sequence. G-C base pairing contributes a higher level 
of stability, thus indicating the presence of more structure and contributing to 
a higher folding energy. The G-C nucleotide pair content of the HIV-1 and 
HIV-2 TAR structures was compared to see if introducing base pairing 
mutations could reduce the folding energy of HIV-2 TAR to a similar level to 
the HIV-1 TAR folding energy. HIV-1 TAR contains 12 G-C pairs, whereas 
HIV-2 TAR contains 30 G-C pairs [figure 69].  
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The TAR folding energy of HIV-1/2 TAR was calculated using MFOLD 
[http://bibiserv.techfak.uni-bielefeld.de/mfold]. The folding energy of HIV-1 
TAR is -29.6 Kcal and HIV-2 TAR is -65.5 Kcal. A-U base pairs are less 
stable than G-C base pairs  and thus reduce folding energy (Yakovchuk et 
al., 2006). G-C to A-U exchanges were therefore introduced into the TAR 
base pairs of the HIV-2 5’ UTR sequence and the folding energy calculated 
using MFOLD. The effect of reducing G-C concentration on the overall TAR 
folding energy was analyzed [Table 10].  
A single G-C to A-U substitution within HIV-2 TAR had little impact on the 
MFOLD folding energy of HIV-2 TAR. This suggests that there is not a single 
G-C base pair that contributes a significant amount to the high folding energy 
of HIV-2 TAR. Therefore, a greater number of G-C to A-U substitutions were 
made to HIV-2 TAR to see how many G-C substitutions were necessary to 
reduce the HIV-2 TAR folding energy (-65.5 Kcal) to a similar folding energy 
as HIV-1 TAR (-29.6 Kcal). The folding energies for differing numbers of G-C 
to A-U substitutions, whilst still retaining the original HIV-2 TAR structure, 
were calculated using MFOLD and plotted in Excel [figure 70]. 
Figure 69: HIV-2 TAR 
showing G-C base pairs 
(dark grey) numbered 1-30 
and A-U base pairs (light 
grey). 
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GC-AU 
substitution # 
Folding energy 
(Kcal) 
Energy difference 
to wt (Kcal) 
26 -64.60 -0.9 
3 -64.30 -1.2 
4,23 -64.10 -1.4 
10 -64.00 -1.5 
1 -63.80 -1.7 
25,30 -63.60 -1.9 
2, 6, 13, 16, 
17, 18, 19, 21, 
29 
-63.50 -2 
12,14, 20, 22, 
28 
-63.10 -2.4 
5, 7, 9, 11, 15 -62.80 -2.7 
8 -62.50 -3.0 
27 -60.60 -4.9 
 
Table 10: The folding energy of HIV-2 TAR for individual G-C to A-U substitutions. G-C 
pair numbers are based on the position of G-C [figure 69]. Energy difference is shown 
as the deviation in folding energy from the wild type HIV-2 TAR structure (-65.6 Kcal). 
 
 
Figure 70: G-C to A-U substitutions within HIV-2 TAR. The number of G-C to A-U 
substitutions (shown above each data point) is plotted alongside the corresponding 
TAR folding energy. The folding energy of both HIV-1 and HIV-2 TAR are indicated in 
red. 
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The introduction of G-C to A-U substitutions reduced the folding energy of 
HIV-2 TAR relative to the number of substitutions introduced. To achieve a 
HIV-2 TAR structure with a similar folding energy to that of the HIV-1 TAR 
structure it is necessary to introduce between 17 and 18 G-C to A-U 
substitutions to HIV-2 TAR. Future work could include synthesis of an HIV-2 
reporter with these substitutions to test its translation efficiency. 
4.4.2 Deletion of the HIV-1/2 TAR structure 
4.4.2.1 In vitro ΔTAR translation 
To investigate the translational effect of deleting TAR, and ascertain whether 
this results in more equivalent HIV-1/2 Gag translation levels, 60 ng of HIV-
1/2 RNA reporters [figure 47] with or without TAR deletions (ΔTAR) were 
used in an in vitro RRL translation system. Translated proteins were 
visualised by SDS-PAGE and autoradiography [figure 71] and used in a 
luciferase assay [figure 72]. 
 
 
 
Figure 71: Expression of 
35
S-methionine labelled proteins from HIV-1/2 RNA reporters 
(with/without TAR deletions) during an in vitro RRL translation. 
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Figure 72: A luciferase assay of 
35
S-methionine labelled proteins translated from HIV-
1/2 RNA reporters (with/without TAR deletions) during an in vitro RRL translation. 
Both HIV-1 and HIV-2 Gag translation levels appeared to be similar in the 
presence and absence of TAR when visualised by autoradiography [figure 
71] or used in a luciferase assay [figure 72]. Therefore deleting TAR 
appeared to have relatively little effect on the translation level of either HIV-1 
or HIV-2 Gag. HIV-1 Gag translation remained more efficient than HIV-2 
whether TAR was present or not. These results were surprising considering 
the contribution of HIV-2 TAR to a higher 5’ UTR folding energy. However, 
additional translational factors may negate the structural impediment 
imposed by HIV-2 TAR. As deleting HIV TAR did not produce equivalent 
translation rates for HIV-1/2, it is likely that the presence of a different TAR 
structure in HIV-2 is not accountable for the lower HIV-2 Gag translation rate 
in vitro. 
4.4.2.2 Cellular ΔTAR translation 
The contribution of HIV-1/2 TAR to the translation efficiency of HIV-1/2 Gag 
was also compared in cells. 50 ng, 500 ng or 1000 ng of HIV-1/2 reporter 
RNA (with/without TAR) was used to transfect HeLa cells for 6 h and the rate 
of Gag translation measured by a luciferase assay of harvested protein. 
Results were normalised to a co-transfected Renilla luciferase RNA control 
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[figure 73]. Transfections were carried out in duplicate and results shown are 
the average of 2 experiments. 
 
Figure 73: Luciferase assay results from HeLa cell translation of varying 
concentrations of HIV-1/2 Gag-Luc RNA reporters (with and without TAR) for 6 h. Error 
bars represent the SEM. 
Surprisingly, both HIV-1 and HIV-2 gag RNA was translated less efficiently 
when TAR was deleted. In the absence of TAR, translation of gag RNA was 
up to 62% (for HIV-1) and up to 45% (for HIV-2) less efficient. Interestingly, at 
higher concentrations of HIV-2 gag RNA, TAR deletions were less 
detrimental, and for 1000 ng even beneficial, to HIV-2 gag translation levels. 
At lower concentrations, HIV-2 ΔTAR RNA may not have been able to 
compete with naturally occurring cellular translation. However, at higher 
concentrations, the abundance of HIV-2 ΔTAR RNA may overwhelm 
translational machinery allowing this normally inefficient RNA to be 
preferentially translated.  
Although removing TAR did not enhance HIV-2 Gag translation levels 
equivalent to wild type HIV-1 Gag translation levels, when TAR was deleted 
HIV-1 and HIV-2 Gag translation was more equivalent. HIV-1 TAR 
suppresses PKR, thus enhancing translation. Removing HIV-1 TAR may 
therefore effect a decrease in translation as active PKR is able to 
phosphorylate eIF2; this inhibits translation (Cole, 2007). A similar 
mechanism may not be present for HIV-2 TAR; this may contribute to the 
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lower rate of HIV-2 Gag translation and explain why deleting TAR does not 
further reduce HIV-2 Gag translation to the same extent as for HIV-1. 
Additionally, BSRT7 cells were transfected with 250 ng or 1000 ng of the 
same HIV-1/2 Gag-Luc RNA reporters (with/without TAR), in duplicate, for 6 
h and total cellular protein harvested. Again, a luciferase assay was carried 
out to determine the rate of Gag-Luc translation from reporter RNAs [figure 
74].  
 
Figure 74: BSRT7 translation of HIV-1/2 Gag-Luc RNA reporters (with and without 
TAR) for 6 h for varying concentrations of RNA. Gag-Luc expression is shown in 
relative light (RL) units and is normalised to a co-transfected Renilla luciferase RNA 
control. Error bars represent the SEM. 
As for HeLa cell transfections, HIV-1 Gag-Luc translation levels were 
consistently higher than HIV-2 Gag-Luc translation levels, even in the 
absence of TAR. Additionally, deleting TAR reduced the translation levels of 
HIV-1 (by up to 33%) and HIV-2 (by up to 29%). However, unlike with HeLa 
cell transfections, when both HIV-1 and HIV-2 TAR elements were deleted 
HIV-2 ΔTAR Gag-Luc RNA translation remained much lower than for HIV-1. 
BSRT7 cells stably express T7 RNA polymerase allowing for transfection of 
reporter plasmids containing a T7 promoter. Consequently, 1 μg of HIV-1/2 
Gag-Luc plasmids (with and without TAR deletions) were used to transfect 
BSRT7 cells for 24 h. Total cell protein was harvested and a luciferase assay 
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carried out to measure the level of HIV-1/2 Gag-Luc expression in the 
presence and absence of TAR. Gag-Luc expression was normalised to 
Renilla luciferase protein levels expressed from co-transfection of a Renilla 
luciferase plasmid (pTK Renilla) [figure 75]. Transfections were carried out in 
duplicate and results shown are the average of 2 experiments. 
(A)
 
(B)
 
Figure 75: Transfection of BSRT7 cells with 500 ng and 1000 ng of HIV-1/2 Gag-Luc 
plasmids (with and without TAR) for 24 h. Gag-Luc translation is measured in relative 
light (RL) units. Gag-Luc expression was normalised to Renilla luciferase expressed 
from a co-transfected Renilla luciferase plasmid (A). Results are expressed as a 
percentage of 1000 ng TAR RNA reporter values to compare the HIV-1/2 percentage 
change in Gag-Luc expression levels (B). Error bars represent the SEM. 
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When Gag levels were quantified following reporter plasmid transfections, 
deleting TAR appeared to increase the level of Gag expression by up to 1.8-
fold for both HIV-1 and HIV-2 Gag [figure 75]. This is directly opposed to the 
results shown for RNA reporter transfections where deleting TAR decreased 
Gag translation. This effect is not an artefact caused by cell type as both 
reporter RNA [figure 74] and reporter plasmid DNA [figure 75] were 
transfected into BSRT7 cells. Thus it appears that when Gag is transcribed 
and translated from a DNA plasmid, deleting TAR enhances expression 
whereas when Gag is translated from reporter RNA, deleting TAR reduces 
Gag translation. 
4.4.2.3 ΔTAR RNA stability 
To determine whether ΔTAR affects reporter RNA stability, a comparison of 
TAR/ΔTAR RNA reporter degradation rates was carried out using qPCR. 60 
ng HIV-1/2 (TAR/ΔTAR) RNA reporters were used to transfect HeLa cells 
and total RNA harvested at 3 h and 6 h post-transfection. Following the 
production of cDNA, qPCR was carried out in duplicate using primers to HIV-
1 Gag (primer # 22, 23) and HIV-2 Gag (primer # 23, 24). Gag gene 
expression was normalised to a GAPDH housekeeping gene (primer #18, 19) 
and expressed as 2ΔCt [figure 76]. 
(A)      (B)
 
Figure 76: Luciferase assay showing the level of HIV-1/2 (TAR/ΔTAR) RNA 3 h (A) and 
6 h (B) post-transfection. RNA levels are normalised to GAPDH and expressed as 2
ΔCt
. 
A comparison of HIV TAR and ΔTAR RNA levels for both HIV-1 and HIV-2 at 
3 h and 6 h post-transfection revealed that deleting TAR did not reduce the 
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stability of reporter RNA. By 6 h HIV-1 TAR/ΔTAR RNA levels were 
equivalent as were HIV-2 TAR/ΔTAR RNA levels. Consequently, HIV-1/2 
ΔTAR/TAR RNA reporter stability does not differentially affect translation 
rates. 
4.5 HIV-1/2 Gag translation: elongation 
4.5.1 A comparison of HIV-1/2 Gag codon bias 
The translation elongation rate can be reduced by the presence of rare 
codons. Within the human genome, 20 amino acids are encoded by 61 
codons. The cellular concentration of amino-acyl tRNAs, which recognise 
these codons, is asymmetric and can vary by up to 10-fold. Therefore the 
rate of codon translation can vary dependent on the availability of the 
cognate amino-acyl tRNA. Codons that are recognised by abundant tRNA 
maximise translation efficiency, whereas rare tRNAs can cause stalling of the 
ribosome whilst it waits to encounter a cognate tRNA. Some synonymous 
codons are more commonly used and therefore dominate in genes which are 
frequently expressed, introducing the concept of codon bias (Zhang et al., 
2009). 
The human codon usage table was used to calculate the frequency of each 
codon within the HIV-1 and HIV-2 Gag ORFs 
[http://genome.imim.es/courses/Lisboa01/slide3.8.html]. The average codon bias 
of the entire HIV-1/2 Gag ORF was calculated to see if elongation rates may 
contribute to differences in the translation efficiencies of these two viruses 
[table 11]. 
 HIV-1 HIV-2 
Codon Bias (Average) 0.364 0.379 
 
Table 11: The average codon usage within the HIV-1/2 Gag ORF. A lower value reflects 
the occurrence of more rare codons. 
The average frequency of codon usage, and therefore the average codon 
bias, does not appear to differ greatly between HIV-1 (0.364) and HIV-2 
(0.379) considering the range of codon bias within human genes (from 0.06 
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to 1). Moreover, the HIV-2 frequency of codon usage is actually marginally 
higher than HIV-1; therefore fewer rare codons are present within HIV-2 Gag. 
This would result in more efficient elongation for HIV-2. Consequently, 
overall, codon bias is unlikely to reduce HIV-2 elongation sufficiently to cause 
the observed reduction in HIV-2 Gag translation levels. 
The average codon bias as a continuous window of 10 codons was plotted to 
indicate regions of high or low codon bias within the HIV-1/2 Gag ORF. The 
results were plotted as a line graph to compare the peaks and troughs in 
codon bias throughout HIV-1 and HIV-2 Gag [figure 77]. 
 
Figure 77: The codon bias throughout the HIV-1/2 Gag ORF. The average codon bias 
of a sliding 10 codon window is plotted along the length of the Gag ORF. 
The HIV-1/2 average codon bias graphs are reasonably equivalent, with 
peaks and troughs in rare codon usage at similar locations in Gag. This 
further demonstrates that it is unlikely that rare codon use differentially alters 
HIV-1/2 elongation rates to contribute to the lower rate of HIV-2 Gag 
translation. 
4.5.2 A comparison of HIV-1/2 Gag codon pair bias (CPB) 
Translation efficiency can also be affected by the combination of adjacent 
codon pairs. Under-represented codon pairs have poor translatability. This is 
known as the codon pair bias (CPB). CPB was compared in the HIV-1/2 Gag 
ORF using codon pair scores (CPS) from the human ORFeome (Coleman et 
al., 2008; supplementary online material) [table 12]. 
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 HIV-1 HIV-2 
Codon Pair Bias 
(Average) 
0.029 0.021 
 
Table 12: The average codon pair usage within the HIV-1/2 Gag ORF. A lower value 
reflects the occurrence of more rare codon pairs. 
The average CPB is 0.029 for HIV-1 and 0.021 for HIV-2 compared to an 
average of 0.07 (and a range of -2.191 to 1.516) for all annotated human 
genes [figure 78].  
 
 
 
Figure 78: The CPB score of genes within the human genome. Each dot represents 
the CPB score of one gene plotted against the gene length (in amino acids). Genes 
containing increasing numbers of rare amino acids yield a more negative score and 
show decreased translatability (Coleman et al., 2008). 
Given the range of CPB scores within the human genome, it is apparent that 
the HIV-1/2 average CPB do not differ significantly from each other within the 
distribution. An increased prevalence of rare codon pairs does not, therefore, 
account for the reduced translatability of HIV-2 Gag.  
The average CPB was plotted as a continuous window of 10 codons along 
the HIV-1/2 Gag ORF to compare the distribution of high or low regions of 
codon pair bias [figure 79]. 
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Figure 79: Codon pair usage within the HIV-1/2 Gag ORF. The average CPS for 
continuous groups of 10 codons is plotted along the length of the Gag ORF. 
The distribution of rare codon pairs does not differ significantly throughout the 
HIV-1/2 Gag ORF, suggesting the presence of rare codon pairs is unlikely to 
differentially affect HIV-1/2 elongation or translation. Overall, codon bias and 
codon pair bias do not differ significantly between HIV-1 and HIV-2 Gag. 
Therefore, translational differences between HIV-1/2 are not likely to be due 
to elongation. 
4.6 Discussion 
4.6.1 A comparison of HIV-1/2 Gag translation 
HIV-1/2 Gag translation from reporter RNA was compared in vitro and in 
several cell types. In all cases, HIV-1 Gag was translated much more 
efficiently than HIV-2 Gag; by 20.8-fold in vitro [figure 72], by 6.9-fold in 
HeLa, 11.9-fold in COS-1 and 3.2-fold in Jurkat cells. HeLa were chosen as 
these are a robust cell line well documented for their transfectability. HIV is a 
virus of primate origin and therefore COS-1 monkey cells are representative 
of a natural SIV host cell. Likewise, Jurkat cells are physiologically relevant 
cells to HIV infection as T-lymphocytes are targets of HIV infection in vivo. 
HIV-1/2 RNA stability was not shown to differ, therefore differences in the 
level of Gag produced from HIV-1/2 RNA reporters were due to translation 
efficiency. Thus translation of HIV-2 may be a limiting factor during its 
replication, potentially accounting for, or contributing to, the reduced viral 
load attributed to infection with HIV-2. 
-0.4 
-0.2 
0 
0.2 
0.4 
0.6 
1 26 51 76 101 126 151 176 201 226 251 276 301 326 351 376 401 426 451 476 501 
C
o
d
o
n
 p
a
ir
 b
ia
s
 (
A
V
G
 
1
0
 c
o
d
o
n
s
) 
Gag ORF codons 
HIV-1 
HIV-2 
Chapter 4        HIV Gag translation 
 
158 
 
 
It was noticeable that HIV-2 transfection in Jurkat cells showed the lowest 
fold change in Gag translation from HIV-1. This suggests that factors within 
the Jurkat cell line may enhance HIV-2 translation thereby reducing the HIV-2 
Gag translation deficit observed in other cell types. Potentially, these factors 
could contribute to HIV-1/2 cell tropism; T-lymphocytes may support more 
efficient translation than other cell types in vivo. 
The presence of viral proteins expressed from HIV-1/2 provirus did not 
differently affect the rate of either HIV-1/2 Gag translation. Simultaneous 
provirus transfections resulted in a reduction in RNA reporter translation, but 
this is likely due to translational competition as the same effect was observed 
with a pcDNA GFP control. The presence of high levels of Gag protein has 
previously been shown to alter Gag translation levels (Anderson and Lever, 
2006). However, it may have been that insufficient Gag was translated from 
HIV-1/2 proviruses, due to competition from reporter RNA, to specifically 
observe this effect. Likewise, during the 6 h reporter transfection, enough 
Gag may not have been produced to observe the start of translational 
inhibition via this mechanism. Alternatively, Gag expressed from the 
proviruses may not have localised to where the transfected reporter RNAs 
were being translated. 
4.6.2 A comparison of HIV-1/2 Gag translation initiation 
Literary evidence suggests both ribosomal scanning and IRES activity as a 
means for HIV translation initiation. In order to clarify how HIV translation is 
initiated we investigated the effect of shutting down cap-dependent initiation 
on HIV-1/2 Gag translation levels. Several experiments were undertaken to 
shutdown cap-dependent translation by eIF4G cleavage; poliovirus infection 
was shown to be the most effective method. Poliovirus infection resulted in 
complete cleavage of eIF4G and significantly reduced the translation of cap-
dependent controls. Likewise, eIF4G cleavage by poliovirus was shown to 
stimulate IRES-driven translation in our experimental system, in accordance 
with the literature (Svitkin, Y.V. et al., 2001). In addition to eIF4G cleavage, 
infection with poliovirus provides additional RNAs to the cell which compete 
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for translational apparatus. Consequently, this assay provided a stringent 
environment in which to test for true IRES activity. An efficient IRES would be 
able to convincingly compete for translation within this environment, whereas 
inefficient IRES activity would remain undetected. 
When HIV-1/2 Gag translation was monitored in cells where cap-dependent 
translation was shut down using poliovirus, both HIV-1 and HIV-2 Gag 
translation levels were significantly impaired. This strongly confirms that both 
HIV-1 and HIV-2 Gag translation is reliant on cap-dependent initiation. 
Furthermore, whereas IRES-driven controls showed stimulated translation 
under conditions of eIF4G cleavage, neither HIV-1 nor HIV-2 Gag translation 
was enhanced. Instead, the decrease in HIV-1 and HIV-2 Gag translation, 
following shut down of cap-dependent translation, mirrored that of a solely 
cap-dependent RNA control. Taken together, these results conclude that 
both HIV-1 and HIV-2 translation is primarily cap-dependent with little 
evidence of IRES activity. 
Experimental results from Buck et al. (2001) reported little decrease in HIV 
translation in poliovirus infected cells and therefore they concluded that HIV-1 
translation was not cap-dependent. This is in direct contrast to our results 
which show HIV-1 translation is significantly decreased in poliovirus infected 
cells, thus indicating a cap-dependent translation mechanism. However, the 
experiments carried out by Buck et al. (2001) looked at Gag translation from 
the transfection of plasmids encoding Gag linked to a CAT reporter. 
Consequently, these experiments do not isolate translation in the same way 
as our RNA reporter transfections because plasmid transfection necessitates 
both transcription and translation to synthesise proteins. Importantly, the 
entire HIV-1 5’ UTR was also not included in the plasmids used for Gag 
expression in the experiments by Buck et al 2001. Consequently, expression 
of Gag would not occur under the natural circumstances for Gag translation. 
This experiment therefore lacks the qualities necessary for comparing 
changes in natural Gag translation levels in the presence of poliovirus. 
Additionally, Buck et al. (2001) measured the level of Gag produced by anti-
HIV-anti-CAT antibody immunoprecipitation which is a less sensitive method 
of detection than a direct luciferase assay of harvested proteins.  
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We also inhibited cap-dependent translation by removal of the 5’ cap 
structure from HIV-1/2 Gag RNA reporters. In the absence of a 5’ cap, both 
HIV-1 and HIV-2 Gag translation was decreased, again highlighting the 
importance of cap-dependence for HIV-1/2 translation. However, HIV-2 
translation was not decreased to the same extent as HIV-1. This may 
indicate that HIV-2 RNA is less dependent on its 5’ cap structure for 
translation. However, within the cell HIV RNAs produced are always capped 
as they are produced by the same process that makes capped cellular 
mRNA. Subsequent removal of the 5’ cap structure from HIV-1/2 RNA does 
not imitate a naturally occurring event and therefore these RNAs may be 
subject to enhanced degradation by the exosome (Hocine et al., 2010). 
Uncapped HIV-1 RNA may, therefore, have been less stable than uncapped 
HIV-2 RNA, resulting in the lower rate of translation from uncapped HIV-1 
RNA. Despite this, these results still highlight the importance of the cap 
structure to HIV-1/2 translation. 
Although full-length HIV-1 and HIV-2 Gag RNA was primarily shown to 
undergo cap-dependent translation initiation, we wanted to investigate 
reports of IRES-activity resulting in the translation of Gag isoforms. It was 
necessary to prevent Gag cleavage to detect only full-length Gag (and 
potential isoforms) in a western blot using an antibody to the capsid region of 
Gag. When cleavage of Gag was inhibited, using the HIV Protease inhibitor 
saquinavir, full-length Gag proteins (p55 for HIV-1 and p57 for HIV-2) were 
observed without subsequent cleavage products. Additionally, HIV-1 p40 and 
HIV-2 p44 and p50 Gag isoforms were detected. Ricci et al. (2008) proposed 
that IRES-driven translation from internal AUGs produces these Gag 
isoforms. However, when poliovirus infection was used to shut down cap-
dependent translation in the presence of saquinavir, the levels of Gag 
isoform translation were not affected. If the translation of internal Gag 
isoforms was IRES-driven, it would be expected that in the presence of 
cleaved eIF4G (which stimulates IRES activity) a greater level of isoform 
translation would occur. Likewise, shut down of cap-dependent translation 
would limit competition for translational machinery, facilitating more efficient 
IRES-driven translation. However, this was not the case. Increased 
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translational products from HIV-1/2 internal Gag AUG codons were not 
observed during this experiment. Consequently, neither HIV-1 nor HIV-2 Gag 
isoforms appear to undergo expression via IRES-activity. An alternative 
proposal, that HIV-1/2 IRES-driven translation compensates for the shutdown 
of cap-dependent translation, was also not evident from our experiments. 
The function of Gag isoforms is currently unknown. It may be that Gag 
isoforms are merely a product of aberrant translational events, such as leaky 
scanning, and are as such inconsequential to the life cycle of HIV. Further 
work is necessary to assess whether Gag isoforms are found in HIV 
particles. 
Brasey et al. (2003) found that HIV-1 translation was increased when cap-
dependent translation was shut down and proposed IRES-activity from the 5’ 
UTR to be responsible for continued translation under these conditions. 
However, we observed the opposite; HIV-1/2 Gag translation decreased in 
poliovirus infected cells where cap-dependent translation was shut down. 
The experiment by Brasey et al. (2003) used FMDV L-protease to inhibit cap-
dependent translation in an in vitro RRL system. This may have been less 
effective than using poliovirus infection in a cellular environment. Likewise, 
Brasey et al. (2003) monitored HIV translation by SDS-PAGE. This may be a 
less sensitive, and therefore less accurate, method of determining 
translational efficiency than the luciferase assays of harvested lysates which 
we used in our experiments. 
Furthermore, the work of Brasey et al. (2003) contradicts the work of Buck et 
al. (2001). Whereas Brasey et al. (2003) detect no IRES activity within the 
HIV-1 gag ORF, Buck et al. (2001) reported no IRES-activity within the HIV-1 
5’ UTR and, instead, propose that the ribosome scans backwards from an 
IRES within the gag ORF to the upstream gag start codon. This is an 
unorthodox translational event and has not yet been proven. Currently, the 
data from either Buck et al. (2001) or Brasey et al. (2003) have not been 
confirmed by other groups and it remains unclear as to whether HIV-1 
demonstrates IRES activity during infection.  
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Similarly, Herbreteau et al. (2005) and Weill et al. (2010) suggest that HIV-2 
Gag isoforms are a product of IRES-activity. This contrasts with our findings 
that HIV-2 Gag isoform translation did not show enhanced translation under 
conditions favourable for IRES activity. However, the experiments by 
Herbreteau et al. (2005) and Weill et al. (2010) are not physiologically 
relevant as they were carried out using HIV-2 RNA without the 5’ UTR which 
is not how it is present within the cell. This may account for why we did not 
observe IRES activity from our HIV-2 RNA; inclusion of the HIV-2 5’ UTR 
appears to promote cap-dependent translation which negates IRES-activity 
occurring otherwise. Although, alike to HIV-1, HIV-2 translation is 
predominantly cap-dependent, more work is necessary to determine whether 
HIV-2 translation can also operate under an IRES. Further work requires the 
demonstration of HIV-2 IRES activity in a setting more reflective of natural 
infection. 
HIV Gag is produced via cellular transcription mechanisms and likewise 
translated via cellular machinery. Consequently, it is unlikely that cap-
dependent translation does not contribute to Gag translation at all as this 
would suggest a redundancy of function. In view of this, a preferable model of 
Gag translation is one where IRES activity does not occur consistently, rather 
providing a means to facilitate Gag translation during unfavourable conditions 
for cap-dependent translation. HIV IRES activity has been proposed to result 
from cellular proteins available during the G2/M transition phase, providing 
further evidence for temporal HIV IRES activity (Vallejos et al., 2011) 
We conclude that HIV-1/2 Gag translation is primarily cap-dependent. This is 
in compliance with the work of Miele et al. (1996) which shows that the HIV 
leader cannot function as an IRES, and in accordance with the evidence of 
ribosomal scanning throughout the HIV 5’ UTR put forward by Berkhout et al. 
(2011). Despite reported findings of HIV-1/2 IRES structures, IRES-driven 
translation does not compensate when cap-dependent translation is shut 
down and we could find no evidence of IRES activity for either HIV-1 or HIV-
2. Furthermore, enhanced IRES-driven translation from internal Gag AUGs 
was not observed when cap-dependent translation was shut down. Thus, at 
least in our system, the HIV-1/2 IRESs appear to be non-functional or, 
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alternatively, are an artefact of experiments that do not mirror typical 
translational events from naturally occurring capped and 5’ UTR containing 
viral mRNA. 
4.6.3 A comparison of HIV-1/2 5’ UTR secondary structure 
Extensive structure within the 5’ UTR can slow the rate of translation by 
impeding ribosomal scanning. RNA folding energy is a measure of secondary 
structure. The folding energy and folding energy per nucleotide of the HIV-2 
5’ UTR were both found to be more negative than for the HIV-1 5’ UTR. 
Consequently, the HIV-2 5’ UTR, with its greater length, is intrinsically more 
structured. The extensive structure of the HIV-2 5’ UTR may hinder the rate 
of translation by inhibiting ribosomal scanning or spatially impeding the 
formation of a translation initiation complex on the Gag AUG within the HIV-2 
5’ UTR. 
TAR was investigated as a specific structure responsible for the high folding 
energy of the HIV-2 5’ UTR. When TAR was deleted from both the HIV-1 and 
HIV-2 5’ UTR, the difference in folding energy was slightly reduced but not 
abolished. Therefore TAR alone is not responsible for the enhanced folding 
energy of the HIV-2 5’ UTR, although it is a contributor. Consequently, it is 
possible that HIV-2 TAR may obstruct ribosomal scanning to a greater extent 
than the HIV-1 TAR and partly factor in the lower translation rate of HIV-2.  
A high number of G-C base pairings within HIV-2 TAR contributes to its 
folding energy. The high folding energy of HIV-2 TAR was shown to be a 
consequence of a high number of G-C base pairs, rather than one or two 
critical base pairs contributing to the overall folding energy. It is, however, not 
surprising that the number of G-C bonds corresponded to the TAR sequence 
folding energy as the MFOLD programme (used to calculate folding energy) 
is reliant on G-C content for its calculation. Thus, this correlation seen within 
our results may be an artefact of this. 17 G-C to A-U mutations would be 
necessary to reduce the folding energy of the HIV-2 TAR to an equivalent 
value to the HIV-1 TAR. Future work could introduce these mutations to HIV-
2 TAR and assess whether this enhances the translatability of HIV-2 Gag by 
reducing the structural hindrance imposed by HIV-2 TAR. 
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4.6.4 A comparison of HIV-1/2 Gag translation in the absence of TAR 
HIV-1 TAR was shown to be inhibitory to translation of heterologous 
transcripts in vitro (Svitkin, Y.V et al., 1994). Likewise, mutating HIV-1 TAR to 
disrupt its structure increased the efficiency of HIV-1 translation 190-fold 
(Parkin et al., 1988). In view of these results, it was thought that TAR might 
be inhibitory to HIV-1/2 translation and that HIV-2 TAR, with its extended 
structure and increased folding energy, may have been more inhibitory and 
contribute to the lower translation rate of HIV-2 Gag. Consequently, the 
translation of HIV-1/2 in the absence of TAR was monitored to see whether 
deleting the HIV-2 TAR structure would alleviate translational repression, 
resulting in translational levels more similar to HIV-1 Gag. Surprisingly, this 
was not the case; deleting TAR decreased the translation of both HIV-1/2 
Gag RNA reporters in HeLa cells, particularly for HIV-1. 
HIV-1 TAR binds to and down-regulates the activity of cellular PKR. If HIV-1 
TAR is deleted, PKR is not down-regulated so functions to phosphorylate 
eIF2, inhibiting translation (Cole, 2007). This may account for the decrease in 
HIV-1 Gag translation observed when HIV-1 TAR was deleted. It was 
interesting to note that, although HIV-2 translation was not equivalent to HIV-
1 wild type Gag translation, in the absence of TAR HIV-1 and HIV-2 levels of 
translation were equivalent. HIV-1 TAR may, therefore, function to enhance 
HIV-1 translation such that when it is deleted, translation efficiency is 
reduced. It is possible that a corresponding function is not present for HIV-2 
TAR. However, in BSRT7 cells, HIV-2 Gag RNA translation remained below 
the level of HIV-1 translation for TAR and ΔTAR RNA reporters. Likewise, in 
BSRT7 cells, deleting TAR reduced the translatability of both HIV-1 and HIV-
2 Gag RNA. The stability of HIV-1/2 ΔTAR RNA was shown to be equivalent, 
and additionally comparable to the stability of TAR RNA. Thus RNA stability 
was not responsible for changes in translational rates. 
BSRT7 cells were also transfected with HIV-1/2 reporter plasmids to 
compare HIV-1/2 TAR/ΔTAR transcription/translation rates. Deleting TAR 
appeared to increase the levels of Gag-Luc expressed from reporter 
plasmids. This is the opposite effect observed from RNA transfection results. 
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Reporter plasmids rely on a T7 promoter for Gag mRNA transcription. This is 
not the natural means of wild type Gag transcription from integrated provirus. 
Likewise, expression of Gag from reporter plasmids involves two stages of 
expression: both transcription and translation. Thus this assay does not 
directly monitor the effect of TAR deletions on translation alone. These 
factors may partly explain why such conflicting results were produced from 
RNA and DNA transfections of ΔTAR reporters. 
Overall, results suggest that HIV TAR may have several functions in 
translation. Deleting TAR does not enhance HIV-2 translation to the levels of 
wild type HIV-1. However, deleting TAR from both HIV-1 and HIV-2 may 
result in more analogous levels of HIV-1/2 translation, possibly by decreasing 
HIV-1 TAR enhancement of translation via PKR suppression and, 
additionally, removing excessive structure from the HIV-2 5’ UTR. Thus TAR 
may serve to enhance HIV-1 translation via a mechanism which is not 
accessible to HIV-2 due to its differing TAR structure. However, HIV-2 TAR 
alone is not responsible for the lower rates of translation in HIV-2. It would be 
interesting to note whether adding HIV-1 TAR to HIV-2 reporters would 
enhance HIV-2 translation via interactions with PKR. Investigations into the 
phosphorylation status of eIF2α (a measure of PKR activity) within these 
experiments might shed some light on the effect of TAR and PKR on HIV-1/2 
translation rates. Further investigation into the effect of TAR deletions on 
both transcription and translation are therefore necessary in order to 
elucidate the role of TAR for HIV-1 and HIV-2 translation.  
4.6.5 A comparison of HIV-1/2 Gag elongation 
Additional factors such as codon bias may contribute differently to the rate of 
HIV-1/2 Gag translation. The presence of rare codons or codon pairs can 
reduce gene translatability by causing the ribosome to stall. Thus the 
composition of Gag can affect the rate of translational elongation via the 
presence of rare codons or codon pairs. A higher level of rare codons or 
codon pairs incorporated into Gag may differentially affect the rate of Gag 
translation between HIV-1/2 by slowing ribosomal elongation. Consequently, 
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the codon bias and codon pair bias were compared for both HIV-1 and HIV-2 
Gag. 
The average frequency of Gag codons, and thus the average codon bias, 
was calculated to be similar for HIV-1 and HIV-2. Likewise, the HIV-1/2 
codon pair bias was calculated as 0.029 for HIV-1 Gag and 0.021 for HIV-2 
Gag, compared to an average of 0.07 for all annotated human genes. 
Although the HIV-1 and HIV-2 codon pair bias is slightly lower than that of the 
average human gene, suggesting a greater presence of rare codon pairs, the 
HIV-1/2 values are fairly similar. Overall, codon bias and codon pair bias do 
not differ significantly between HIV-1 and HIV-2 Gag. Therefore, translational 
differences between HIV-1/2 are not likely to be due to elongation. 
4.6.6 Future work 
Various avenues of future work could proceed from work on HIV-1/2 
translation. Although we have established that the rate of HIV-1 translation is 
more efficient than HIV-2, more work is necessary to define the origins of this 
translational difference. 
With regard to RNA structure, we could investigate other notable sequences 
or structured components of the HIV-1/2 genome which may prove important 
to the rate of HIV-1/2 translation. Various structures within the HIV-2 5’ UTR 
could be swapped with equivalent HIV-1 structures to see whether this 
equalises the rate of translation between HIV-1 and HIV-2. Additionally, the 
HIV-2 5’ UTR contains a recently identified splice site (Strong et al., 2009); 
removal of the putative 142 nt 5’ UTR intron has been reported to increase 
the translation efficiency of HIV-2 Gag. Comparing translation of the spliced 
HIV-2 variant to HIV-1 translation levels could indicate whether the HIV-2 
spliced region contributes to the reduced HIV-2 Gag translation levels.  
Cellular helicases are required to unwind HIV RNA structure during 
replication. As the 5’ UTR of HIV-1/2 differs in size and structure, the 
efficiency with which the 5’ UTR interacts with cellular helicases may differ, 
subsequently affecting the rate of replication. Investigation into which cellular 
helicases interact with HIV-1 and HIV-2 RNA, and the rate at which they 
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unwind the HIV-1/2 5’ UTRs could, therefore, reveal a mechanism which 
causes translation of HIV-2 to proceed less efficiently than HIV-1. 
Finally, establishing whether IRES activity contributes to HIV translation 
during infection, and evaluating the importance of IRES activity to HIV-1/2 
translation, could provide a clearer picture of how HIV translation is 
regulated. In order to do this, more work is necessary to understand the 
cellular conditions and viral components governing cap-dependent or IRES-
driven HIV-1/2 translation. 
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5. CHAPTER 5: HIV RNA-PROTEIN INTERACTIONS 
5.1 Introduction 
RNA-protein interactions take place throughout the HIV RNA genome. In 
particular, the highly structured HIV 5’ UTR is important in regulating many 
stages of the viral replication cycle and this, predominantly, occurs through 
interactions with both cellular and viral proteins. The roles of viral RNA-
binding proteins, such as Tat, Rev, Gag, and RT have been well 
characterised within the life cycle of the HIV virus. However, a greater variety 
of cellular proteins also interact with HIV RNA. Consequently, there are 
potentially numerous interactions between the HIV genome and cellular 
RNA-binding proteins which remain unexplored.  
This chapter examines the cellular RNA-binding proteins interacting primarily 
with the HIV-1/2 5’ UTR. Initial discussion focuses on the recognised cellular 
proteins binding to the HIV 5’ UTR and Gag, before results are presented 
identifying 5’ UTR/Gag HIV binding proteins from cross-linking reactions with 
proteins from cellular extracts. Differential protein binding patterns are 
recognised between the HIV-1/2 5’ UTRs and attempts to characterise the 
nature of these unknown proteins are outlined. 
5.1.1 RNA binding proteins 
Cellular proteins are important functional contributors to every post-
transcriptional process within the cell. As the HIV virus hijacks cellular 
processes to coordinate its own gene expression, cellular proteins are, 
therefore, essential components of the HIV life cycle. Several types of protein 
RNA-binding domains with different properties permit RNA-protein 
interactions. Cellular proteins can recognise and bind to both nucleotide 
sequences or secondary structure within single-stranded RNA (ssRNA) or 
double-stranded (dsRNA). Moreover, protein binding may be determined 
either by a single RNA domain or the interactions of multiple protein-binding 
domains. Likewise, the RNA structure consists of several features: ribose 
sugars, phosphate groups and RNA bases - all of which can act as binding 
points for cellular proteins (Elliott and Ladomery, 2010). 
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5.1.2 Cellular proteins binding to HIV 
The 5’ UTRs of HIV-1 and HIV-2 are long (335 nt and 545 nt respectively) 
and heavily structured with numerous structures and sequences that have 
the capacity to interact with cellular RNA-binding proteins [figure 80]. 
 
Figure 80: Structures within the HIV-1 5’ UTR which may present binding sites for 
cellular proteins. The unpaired 6 nt and tripyrimidine bulge of TAR (green), the 
AAUAAA polyadenylation signal (orange), the primer activation site (PAS) (purple), 
the primer binding site (PBS) (blue), the 6 nt GCGCGC dimer initiation site (DIS) (pink), 
the major splice donor (SD) (grey) and the GGAG tetraloop packaging signal (ψ) 
(yellow) are all highlighted. The Gag AUG start codon is also indicated (*). 
Several stages of the HIV replication cycle entail the involvement of cellular 
RNA-binding proteins. These are outlined below and summarised in table 13. 
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RNA-binding proteins Function 
P-TEFb (Cyclin T1, Cyclin T2a, 
Cyclin T2b, CDK9), SBP 
Transcription regulation (via HIV TAR) 
La autoantigen 
Transcription, promoting IRES-driven 
translation, alleviating translation 
repression 
hnRNP A1, hnRNP H, hnRNP F, 
PTB, SR proteins 
mRNA splicing 
hnRNP C1/C2 mRNA nuclear localisation and packaging 
hnRNP A2/B1 Cellular RNA trafficking 
HuR RNA stability 
DDX3 Nuclear Export (unwinding RNA) 
PABP, eIF1, eIF1A, eIF2, eIF3, 
eIF4B, eIF4F (eIF4A, eIF4GI, 
eIF4GII, eIF4E) 
Cap-dependent translation initiation 
PKR, TRBP Translation regulation 
Staufen1 Assembly (genomic RNA) 
 
Table 13: Cellular RNA-binding proteins implicated in the HIV lifecycle. 
The viral protein Tat binds to the HIV-1 TAR RNA structure. Human Cyclin T1 
facilitates this via interactions with the TAR central loop and the activation 
domain of viral Tat. Additional factors Cyclin T2a, Cyclin T2b and CDK9 
(cyclin-dependent kinase 9) together with Cyclin T1 produce a complex 
termed the positive transcription elongation factor b (P-TEFb) complex. P-
TEFb functions to hyperphosphorylate RNA polymerase II resulting in trans-
activation of Tat (Fujinaga et al., 1999). 
La autoantigen is a 48 kDa human cellular protein which is involved in the 
termination of RNA polymerase III transcription. Cleavage of La can produce 
a 43 kDa protein (Ayukawa et al., 2000). La autoantigen is predominantly a 
nuclear protein, but is also found in the cytoplasm. For example, during 
poliovirus infection it is transported from the nucleus to the cytoplasm 
(Svitkin, Y.V et al., 1994). La has been shown to bind HIV-1 TAR RNA 
(Chang et al., 1994) and to stimulate translation of TAR-containing transcripts 
in vitro (Svitkin, Y.V et al., 1994). During HIV infection, La could potentially be 
translocated from the nucleus to the cytoplasm as a ribonucleoprotein by 
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binding to TAR on HIV transcripts. Cheung et al. (2002) propose a model 
whereby La-HIV ribonucleoproteins (RNPs) are transported from the nucleus 
into the cytoplasm. La-bound HIV mRNAs are subsequently preferentially 
translated over mRNAs which do not have La bound to them (Cheung et al., 
2002). A role for La in the initiation of IRES-dependent translation has also 
been suggested following UV cross-linking studies which showed that La 
binds to the 5’ UTR of coxsackievirus B3 RNA. Furthermore, La was the first 
identified ITAF which was shown to stimulate cap-independent translation 
from the poliovirus IRES (Meerovitch et al., 1993). An additional TAR-binding 
protein, TRBP, has been shown to increase the rate of translation from HIV 
RNA by repressing cellular PKR (Gatignol et al., 2005). 
Post-transcription, cellular proteins are involved in modifying RNA and 
coordinating nuclear export. HnRNPs (heterogenous nuclear 
ribonucleoproteins) are a well-characterised and abundant group of cellular, 
multi-functional RNA-binding proteins. Many post-transcriptional processes 
involve hnRNPs; splicing (hnRNP A1, hnRNP H, hnRNP F), nuclear 
localisation and packaging of pre-mRNA (hnRNP C1/C2), RNA trafficking 
(hnRNPA2/B1) and RNA stability (HuR). Around 20 hnRNP proteins have 
been identified and have been shown to direct a diverse array of activities 
from RNA processing, folding and nucleocytoplasmic export (Cullen, 2000). 
In conjunction with their role in modulating processing, hnRNP complexes 
have also been shown to form the main components of the spliceosome. In 
particular, hnRNPs function to maintain single-stranded RNA for splicing 
(Elliott and Ladomery, 2010). Additional cellular proteins PTB and members 
of the SR protein family have also been shown to play a role in cellular 
splicing (Asai et al., 2003). Following RNA processing, cellular DDX3 
helicase has been shown to interact with HIV-1 viral mRNA, facilitating CRM-
1 dependent nuclear export by unwinding RNA secondary structure 
(Yedavalli et al., 2004). 
In the cytoplasm, numerous RNA-binding proteins are involved in translation 
and are therefore likely to bind HIV RNA. During translation initiation, PABP 
binds to the mRNA poly(A) tail. Several proteins of the eIF4F cap-binding 
complex: eIF4A, eIf4G (eIF4GI and eIF4GII) and eIF4E, interact with the 5’ 
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cap structure of viral mRNA (Mathews et al., 2007). An additional RNA-
binding protein, eIF4B, stimulates activity from the eIF4A helicase (López-
Lastra et al., 2005). Furthermore, proteins eIF2, eIF3 and the 40S ribosomal 
subunit form a 43S initiation complex which binds to mRNA during translation 
initiation (Lapointe and Brakier-Gingras, 2003). Factors eIF1 and eIF1A bind 
to mRNA to coordinate 5’-3’ transport of the 43S complex to the initiation 
codon. Consequently, an array of cellular proteins combine with both cellular 
and viral mRNA to allow it to undergo translation (López-Lastra et al., 2005). 
HIV RNA functions both as a template for translation and as genomic RNA 
incorporated into virions. To facilitate packaging, HIV genomic RNA 
associates with host RNA-binding proteins to form a ribonucleoprotein 
complex which is incorporated into immature virions. Staufen 1 is a dsRNA-
binding protein which binds to the Gag nucleocapsid region and modulates 
RNA inclusion into assembling virions (Milev et al., 2010). Staufen 1 has also 
been reported to stimulate translation of TAR-containing transcripts (Dugré-
Brisson et al., 2005). 
Structural and sequential differences between the HIV-1/2 genome may 
result in variations in cellular protein binding. Thus the coordination of HIV-
1/2 gene expression could vary as a result of differences in RNA-protein 
binding interactions. Consequently, the aim of the work in this chapter is to 
identify any differences in cellular protein binding to the HIV-1/2 RNA. 
5.2 Results 
5.2.1 A comparison of protein binding to HIV-1/2 5’ UTR-gag RNA. 
Binding of cellular proteins to HIV-1 and HIV-2 gag RNA may differ, and thus 
provide an explanation for the differing rates of gene expression observed for 
HIV-1 and HIV-2. UV cross-linking was used to investigate HIV-1 and HIV-2 
RNA-protein interactions. Cellular proteins were extracted from HeLa cells 
(S100 extracts) and used in a cross-linking reaction with 1 mg/ml tRNA and 
α-32P UTP radioactively labelled HIV-1 and HIV-2 RNA reporters [figure 81]. 
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(A)
(B)  
Figure 81: Truncated HIV-1/2 UTR-Gag RNA reporters (A) and HIV-1/2 5’ UTR RNA 
reporters (B). 
Proteins associated with radioactively labelled HIV-1 or HIV-2 RNA were 
visualised by SDS-PAGE and autoradiography [figure 82]. Unradiolabelled 
‘cold’ RNA was used in UV cross-linking binding reactions to act as a 
competitor for protein binding. This permitted identification of RNA-specific 
competition for protein binding. 
Several proteins of differing sizes were shown to bind to HIV-1/2 UTR-gag 
RNAs although no qualitative differences in protein binding were identified 
[figure 82A]. However, when UV cross-linking was carried out with the HIV-
1/2 5’ UTRs [figure 82B] several bands of differing intensities were produced. 
In particular, a band of around 45 kDa was identified binding to the HIV-1 5’ 
UTR but not to the HIV-2 5’ UTR. The tRNA non-specific competitor did not 
remove binding of the 45 kDa protein to the HIV-1 5’ UTR [lane 1, figure 
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82B]. In contrast, when an unlabelled, HIV-1 5’ UTR competitor was present, 
it competed for the same protein thereby removing the band at 45 kDa [lane 
2, figure 82B]. Equally, the presence of an unlabelled HIV-2 5’ UTR 
competitor did not compete away this band, confirming that the 45 kDa 
protein does not bind to the HIV-2 5’ UTR [lane 3, figure 82B]. Therefore the 
45 kDa band represents a protein which binds uniquely to the HIV-1 5’ UTR 
and not the HIV-2 5’ UTR. 
(A)   (B)  
Figure 82: UV cross-linking of HeLa cell proteins binding to ‘hot probes’:
 
HIV-1/2 UTR-
gag (A) and HIV-1/2 UTR radiolabelled RNA reporters (B). Binding reactions included 
either unradiolabelled ‘cold’ tRNA, HIV-1/2 5’ UTR-gag or HIV-1/2 5’ UTR competitor 
RNA. 
Binding of the 45 kDa protein to the HIV-1, but not the HIV-2, 5’ UTR was 
also shown to occur in the presence of additional non-specific ‘cold’ 
competitors: the human rhinovirus 2 (HRV-2) 5’ UTR RNA and Renilla RNA  
(data not shown). 
The 45 kDa protein appears to bind weakly to HIV-2 5’ UTR-gag RNA [lane 
4, figure 82A] but not to HIV-2 5’ UTR RNA alone [lane 4, figure 82B]. 
Chapter 5   HIV RNA-protein interactions 
175 
 
Consequently, an additional binding reaction requiring part of gag may be 
necessary for binding of this protein to HIV-2 RNA. Alternatively, the 
conformation of the HIV-2 5’ UTR may be altered when gag is present, 
allowing binding of the 45 kDa protein. 
Further bands of interest migrated between 95-130 kDa [figure 82]. The 
binding profile of these proteins is less obvious; they both appear to bind to 
the HIV-1 and HIV-2 5’ UTR albeit with differing binding affinities. The top 
band (~130 kDa) appeared to bind better to the HIV-2 5’ UTR, producing a 
strong band [lane 4, figure 82B]. This protein is also present binding to the 
HIV-1 5’ UTR but the band is fainter [lane 1, figure 82B]. The presence of a 
HIV-2 5’ UTR unlabelled competitor [lanes 3+6, figure 82B] competes away 
the 130 kDa band better than the HIV-1 5’ UTR competitor does [lanes 2+5, 
figure 82B] confirming that this protein has a stronger binding affinity for the 
HIV-2 5’ UTR. Alternatively, the slightly smaller protein band migrating at 
~120 kDa appears to bind more strongly to the HIV-1 5’ UTR [lane 1, figure 
82B] with a fainter band present at this size for the HIV-2 5’ UTR [lane 4, 
figure 82B]. In the presence of a HIV-1 5’ UTR competitor [lanes 2+5, figure 
82B], the 120 kDa band is reduced more than in the presence of the HIV-2 5’ 
UTR competitors [lanes 3+6, figure 82B]. This confirms that the 120 kDa 
protein binds more strongly to the HIV-1 5’ UTR. 
5.2.2 La protein binding to the HIV-1/2 5’ UTR 
A number of experiments were carried out to test whether the ~45 kDa 
protein was La, which has been shown to bind to the HIV-1 5’ UTR. 
Recombinant La protein was purchased [Prospec-Tany Technogene Ltd] and 
used in a UV cross-linking assay alongside HeLa extract and 32P-labelled 
HIV-1/2 5’ UTR [figure 83]. 
1 μg La bound both HIV-1 and HIV-2 5’ UTRs (whereas 100 ng La bound 
neither), although stronger labelling was observed with the HIV-1 5’ UTR 
[figure 83]. However, the size of the band representing recombinant La [lane 
3, figure 83] was larger than the ~45 kDa band in HeLa extract [lane 1, figure 
83], suggesting it may not be La. 
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Figure 83: UV cross-linking of 2 μl HeLa extract or 100 ng/1 μg recombinant La with 
the HIV-1/2 5’ UTR. 
Anti-La antibody was used to immunoprecipitate La from UV cross-linking 
reactions. However, despite a number of attempts, using protein G agarose 
beads and magnetic Dynabeads, La could not be detected following 
immunoprecipitation of UV cross-linking reactions (data not shown). 
Western blotting showed that the anti-La antibody could detect recombinant 
La and native La from HeLa extract [figure 84, lanes 4+3 respectively]. 
Immunoprecipitation of recombinant La [lane 1, figure 84] demonstrated that 
La could be immunoprecipitated, however the band was very weak. La was 
unable to be immunoprecipitated from HeLa extract (data not shown), 
therefore it was not surprising that La immunoprecipitation from HeLa extract 
UV cross-linking reactions was unsuccessful. 
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Figure 84: A western blot with an antibody to La. Lanes 1+2: La immunoprecipitation 
in the presence and absence of recombinant La. Lane 3: 2 μl HeLa extract. Lane 4: 100 
ng recombinant La. 
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An alternative approach was used to test whether the ~45 kDa protein was 
La. It is reported that La interacts with the poliovirus IRES (Meerovitch et al., 
1993) so poliovirus (PV1) IRES RNA was used as a competitor in UV cross-
linking assays with HIV-1/2 5’ UTR RNAs [figure 85]. 
 
Figure 85: UV cross-linking of HeLa proteins to radiolabelled
 
HIV-1/2 5’ UTR RNA (hot 
probes) in the presence of unlabelled PV1 IRES RNA competitor (cold competitors) at 
various concentrations. 
A 45 kDa protein was present binding to the HIV-1 5’ UTR but not to the HIV-
2 5’ UTR [figure 85]. However, the PV1 IRES RNA competitor did not 
compete for binding of the 45 kDa protein band. This suggests that the 45 
kDa protein is not La. Additionally, PV1 IRES RNA competes for binding of 
other proteins at 72 kDa, 55 kDa and 36 kDa. It also appears that the 45 kDa 
band may be a duplet, possibly representative of two proteins, or different 
forms of the same protein. 
La is reported to bind to the TAR structure within the HIV-1 5’ UTR (Chang et 
al., 1994). HIV-1 ΔTAR 5’ UTR RNA was used as a probe in a UV cross-
linking assay to see whether the 45 kDa protein was able to bind to the HIV-1 
5’ UTR in the absence of TAR [figure 86]. 
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Figure 86: UV cross-linking of HeLa cell proteins, 100 ng or 1 µg recombinant La to 
labelled HIV-1, HIV-1 ΔTAR or HIV-2 5’ UTR RNAs. 
The 45 kDa protein from HeLa extract was still able to bind to HIV-1 ΔTAR 
RNA [lane 4, figure 86]. However, 1 µg recombinant La also bound to HIV-1 
ΔTAR RNA [lane 6, figure 86]. La is known to bind TAR, but it may also have 
additional binding sites within the HIV-1 5’ UTR. Interestingly, whereas 
recombinant La bound to both the HIV-1 and HIV-2 5’ UTRs, the 45 kDa 
protein from HeLa extract was only able to bind to the HIV-1 5’ UTR 
suggesting it is not La. Although this experiment doesn’t rule out La as a 
candidate for the 45 kDa protein, together with other experiments results 
suggests that the 45 kDa protein is not La. 
5.2.3 RNA affinity chromatography 
To isolate the 45 kDa unknown protein binding to the HIV-1 5’ UTR, RNA 
affinity chromatography was carried out using biotinylated RNA pulled down 
by Magnetic Dynabeads® M-280 Streptavidin [Invitrogen]. To assess 
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whether the unknown protein would still bind to biotinylated HIV-1 5’ UTR 
RNA, a UV cross-linking assay was carried out. 32P-labelled biotinylated or 
non-biotinylated RNA was UV cross-linked to HeLa S100 extract [figure 87]. 
 
Figure 87: UV cross-link of biotinylated (lanes 1+2) and non-biotinylated (lanes 3+4) 
32
P-labelled HIV-1/2 5’ UTR RNA with HeLa extract. 
Lanes 3 and 4 showed the usual cross-linking pattern of HeLa extract 
proteins to HIV-1 and HIV-2 5’ UTR RNA. The biotinylated RNAs [lanes 1 
and 2, figure 87] gave a similar cross-linking pattern; the 45 kDa target 
protein bound to biotinylated HIV-1 5’ UTR RNA but not HIV-2. However, the 
binding of this protein to (or labelling of) biotinylated RNA was less efficient 
than to non-biotinylated RNA resulting in a fainter band. 
To assess the binding capacity of biotinylated HIV-1/2 RNA to Magnetic 
Dynabeads® M-280 Streptavidin, a known quantity of HIV-1/2 biotinylated 5’ 
UTR RNA was added to a binding reaction with the beads. When beads were 
placed on a magnet, the subsequent level of RNA remaining in the 
supernatant was quantified by Nanodrop. This provided an indication of how 
much RNA was bound to the beads as a percentage of the starting quantity 
[table 14]. Comparisons were made to an unbiotinylated HIV-1 5’ UTR RNA 
control. 
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RNA 
RNA added to 
beads (ng) 
RNA in 
supernatant (ng) 
RNA bound 
to beads (%) 
Biotin HIV-1 6660 4160 37.5 
Biotin HIV-2 7335 4920 32.9 
Control 4748 4365 8.1 
 
Table 14: The binding capacity of biotinylated HIV-1/2 5’ UTR RNAs to streptavidin 
beads. 
Both HIV-1/2 biotinylated 5’ UTR RNAs bound much better to beads than the 
control. HIV-1 biotinylated RNA appeared to bind marginally better to the 
beads, although both HIV-1 and HIV-2 biotinylated RNA showed a 
reasonable level of binding for RNA affinity chromatography to continue. 
RNA affinity chromatography was carried out using 2 μg biotinylated HIV-1 5’ 
UTR RNA bound to 10 μl of Magnetic Dynabeads® M-280 Streptavidin 
[Invitrogen] followed by protein binding of 2 μl HeLa S100 extract in a total 
volume of 30 μl. Beads were washed 3 times in B&W buffer and bound 
products eluted by boiling in 20 μl SDS. Products were separated by SDS-
PAGE and protein bands identified by silver stain [figure 88]. 
  
A lot of non-specific protein bands were detected binding to the magnetic 
beads when no biotinylated RNA was present [lane 2, figure 88]. RNA affinity 
Figure 88: RNA affinity 
chromatography of 2 μl HeLa S100 
extract and either HIV-1 5’ UTR 
biotinylated RNA or a control with no 
RNA. 
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chromatography was repeated using HIV-1/2 5’ UTR biotinylated RNA and a 
Renilla RNA control. Varying salt concentration washes (100-1000 mM NaCl) 
were used to elute RNA-binding proteins, followed by final elution: boiling 
beads in SDS buffer. 10 μl of each wash was used for SDS-PAGE and the 
gel silver stained to identify the proteins in each fraction [figure 89]. 
 
 
Figure 89: Silver stain of RNA affinity chromatography washes. Wash fractions at 
varying salt concentrations (100-1000 mM NaCl) were used to elute RNA-binding 
proteins from HIV-1 (H1) and HIV-2 (H2) 5’ UTR RNAs and a control reaction (C) 
containing Renilla RNA. A final elution was carried out by boiling beads in SDS buffer. 
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Many proteins were eluted in low concentration washes (100 mM) for both 
HIV-1 and HIV-2 [figure 89]. At higher salt washes (400 mM) proteins binding 
more specifically to the HIV-1 5’ UTR were eluted. 
We wished to use fractions in a UV cross-linking reaction with 32P-labelled 
HIV-1/2 5’ UTR RNA to see whether we could identify which fraction 
contained the 45 kDa protein interacting with the HIV-1 5’ UTR. Firstly, it was 
necessary to check that the unknown protein would still bind to the HIV-1 5’ 
UTR RNA at stronger salt concentrations. UV cross-linking was therefore 
carried out with 32P-labelled HIV-1 5’ UTR RNA and 2 μl HeLa extract at 
increasing salt concentrations [figure 90]. 
 
 
Figure 90: UV cross-linking of 
32
P-labelled HIV-1 5’ UTR RNA with 2 μl HeLa extract at 
varying salt concentrations; lane 1: 50 mM KCl, lane 2: 50 mM NaCl, lane 3: 100 mM 
NaCl, lane 4: 200 mM NaCl. 
The unknown 45 kDa protein was able to bind to the HIV-1 5’ UTR even at 
high salt concentrations although binding was decreased slightly as salt 
concentration increased [figure 90]. 
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100-400 mM salt washes from the RNA affinity chromatography were used in 
a UV cross-linking reaction with 32P-labelled HIV-1/2 5’ UTR RNA to 
investigate whether we could isolate which wash fraction contained the 
unknown 45 kDa protein [figure 91]. 
 
Figure 91: SDS-PAGE of UV cross-linking with the HIV-1 (H1) and HIV-2 (H2) 5’ UTR 
and 100-400 mM NaCl salt washes from RNA affinity chromatography with HIV-1/2 5’ 
UTRs. 
Protein bands were identified at ~55 kDa binding to both the HIV-1/2 5’ UTR 
from the HIV-2, 200 mM wash fraction [lanes 7+8, figure 91]. A further band 
at ~ 45 kDa binding to the HIV-1, but not the HIV-2 5’ UTR [lane 7, figure 91], 
suggests that the unknown protein is also contained in this wash fraction. 
10 μl of the same wash fractions were separated by SDS-PAGE and stained 
with Instant Blue [Expedeon] to see whether we could identify the same 45 
kDa band for extraction and analysis by mass spectrometry [figure 92]. 
A faint band at ~45 kDa was observed in the H2, 200 mM wash fraction [lane 
4, figure 92]. This band was excised and processed for analysis by mass 
spectrometry. Mass spectrometry identified seven proteins [table 15], of 
which three were actin and the other four metabolic enzymes. 
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Figure 92: SDS-Page of 100-400 mM NaCl salt washes from RAC with HIV-1 (H1) and 
HIV-2 (H2) RNA. 
 
 
Resource Entry name Protein name Gene name 
UniProtKB 
ENSEMBL 
IP100894365.2 ACTG1 protein ACTB, 
ACTG1 
UniProtKB 
ENSEMBL 
IP100922693.1 cDNA FU53662, highly similar to 
actin alpha skeletal muscle 
ACTB 
UniProtKB 
ENSEMBL 
IP100027223.2 Isocitrate dehydrogenase[NADP] 
cytoplasmic 
IDH1, PICD 
UniProtKB 
ENSEMBL 
IP1000022977.1 Creatine kinase β-type CKB, CKBB 
UniProtKB IP100555809.3 Actin-like protein ACT 
ENSEMBL IP100815732.1 PAICS 
(Phosphoribosylaminoimidazole 
carboxylase) 
PAICS 
UniProtKB 
ENSEMBL 
IP00012007.6 Adenosylhomocysteinase AHCY, 
SAHH 
 
Table 15: Mass spectrometry results [Sources; UniProtKB: 
http://www.uniprot.org/uniprot, ENSEMBL: http://www.ensembl.org/Homo_sapiens/Info/Index]. 
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None of the proteins identified by mass spectrometry are classical RNA-
binding proteins or candidate proteins of known interactions with HIV-1 RNA, 
although actin has recently been reported to bind to respiratory syncytial 
virus RNA (Harpen et al., 2009). It may be that an insufficient quantity of the 
target protein was therefore available in the sample for analysis.  
5.2.4 Investigation of the binding site of the 45 kDa protein 
To narrow down the binding location of the unknown 45 kDa protein, 3’ 
truncated HIV-1 reporters were produced for UV cross-linking by digestion of 
the template for in vitro transcription with Afl II, HindIII, NarI and BssHII 
[figure 93].  
 
Figure 93: Restriction sites within the HIV-1 5’ UTR used to linearise HIV-1 reporter 
plasmids to make truncated HIV-1 5’ UTR RNAs [adapted from (Russell et al., 2004)]. 
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32P-labelled full-length HIV-1/2 5’ UTRs and the truncated HIV-1 5’ UTR 
RNAs were used in UV cross-linking assays with HeLa S100 extract [figure 
94]. 
 
Figure 94: UV cross-linking of full-length HIV-1/2 5’ UTR and truncated HIV-1 5’ UTR 
RNAs with HeLa S100 extract. 
The 45 kDa band was clearly visible bound to full-length, BssHII and NarI 
truncated HIV-1 RNAs [figure 94], suggesting that the binding site for this 
protein is in the 5’ region of the 5’ UTR. Weak binding of the 45 kDa protein 
to Afl II was also seen suggesting poor binding to the TAR structure. This is 
corroborated by strong protein binding to ΔTAR RNA [lane 6, figure 94]. 
Binding was enhanced when more of the HIV-1 5’ UTR was present, 
suggesting multiple binding domains may be required for efficient protein 
binding. The HindIII lane [lane 3, figure 94] was empty, suggesting this RNA 
may have been unstable and therefore degraded. Lack of binding to Afl II 
truncated RNA [lane 2, figure 94] suggests lack of protein binding to the TAR 
structure. 
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5.3 Discussion 
5.3.1 A comparison of cellular proteins binding to HIV-1/2 5’ UTR-
gag RNA 
A 45 kDa protein from HeLa extract was shown to specifically bind to the 
HIV-1 5’ UTR but not to the HIV-2 5’ UTR. If this protein is shown to play an 
important role in gene expression, its enhanced binding to the HIV-1 5’ UTR 
may indicate a mechanism by which HIV-1 gene expression is able to occur 
more efficiently than for HIV-2. It appears that the presence of gag is 
necessary to allow the 45 kDa protein to interact with HIV-2 RNA, as binding 
of the 45 kDa protein was only weakly detected for HIV-2 UTR-gag and not 
for the HIV-2 5’ UTR alone. Potentially, for HIV-2, the 45 kDa binding site 
may be located within gag. Alternatively, the HIV-2 5’ UTR may adopt a 
different conformation in the presence of gag. Abbink et al. (2003) report two 
different structural conformations within the HIV-1 5’ UTR, highlighting the 
dynamic role of RNA structure for HIV-1 gene expression (Abbink and 
Berkhout, 2003). Although similar conformational variations have not been 
investigated for HIV-2, it may be that the HIV-2 5’ UTR is also able to adopt 
different conformations and these are influenced by the presence of gag 
RNA. Thus the 45 kDa protein may only be able to bind to the HIV-2 5’ UTR if 
gag is present. However, even in the presence of gag, this protein only 
interacts weakly with HIV-2. If the 45 kDa protein is shown to be important to 
HIV-1 transcription or translation, its lack of binding to the HIV-2 5’ UTR may 
therefore account for the lower efficiency of HIV-2 gene expression. 
Additional proteins of ~120 and 130 kDa showed differential binding to the 
HIV-1/2 5’ UTRs. Although the identity of these proteins remains unknown, 
these results suggest that different RNA-binding proteins may interact with 
the HIV-1/2 5’ UTRs, thus highlighting a way in which HIV-1/2 gene 
expression may differ. 
5.3.2 La autoantigen binding to the HIV-1/2 5’ UTR 
La autoantigen has previously been shown to bind to the HIV-1 5’ UTR. La 
was therefore considered as a candidate protein for the 45 kDa protein we 
identified binding to the HIV-1 5’ UTR. A UV cross-link with recombinant La 
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showed that it was able to bind to the HIV-1 5’ UTR, although the size of 
recombinant La was larger than that of the unknown 45 kDa protein from 
HeLa extract. Attempts to immunoprecipitate native La from UV cross-linking 
reactions with HeLa extract were unsuccessful. However, this was 
unsurprising given that even recombinant La could only be weakly 
immunoprecipitated. Binding of the 45 kDa protein to the HIV-1 5’ UTR was 
not reduced in the presence of a poliovirus IRES competitor, which is known 
to bind La. Furthermore, the 45 kDa protein was shown to bind to the HIV-1 
5’ UTR in the absence of TAR indicating that TAR is not the binding site for 
this protein. Recombinant La also bound to the HIV-2 5’ UTR whilst the 45 
kDa protein does not. Given these results, we therefore conclude that the 
unknown 45 kDa protein is unlikely to be La autoantigen. 
Interestingly, during cross-linking of HIV-1 5’ UTR RNA to HeLa extract in the 
presence of poliovirus IRES RNA, it appeared that the 45 kDa protein band 
interacting with the HIV-1 5’ UTR may, in fact be a duplet band 
representative of more than one RNA-binding protein of similar size. 
Alternatively, the dual bands could be representative of isoforms or post-
translational modifications of the same protein. 
5.3.3 Isolating the 45 kDa binding protein 
Initial attempts to isolate the 45 kDa protein by RNA affinity chromatography 
resulted in a lot of non-specific binding. This masked attempts to specifically 
extract the protein of interest. Several variations in the RNA affinity 
chromatography protocol were consequently investigated, to see whether we 
could reduce background levels of protein binding and enhance the level of 
specific protein binding. These included pre-absorption of HeLa extract with 
magnetic beads to remove non-specific binding proteins prior to use in the 
RNA affinity chromatography, blocking beads in 5% Marvel TBS-T for 1 h 
before use to inhibit non-specific protein binding to beads, and increasing the 
RNA concentration used to saturate the beads and prevent non-specific 
protein binding. Additionally, following protein-RNA binding, beads were 
washed in increasing concentrations of salt washes to remove non-specific or 
weak protein interactions prior to elution of bead-bound proteins. Varying the 
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order of the RNA affinity chromatography stages, to initially bind proteins to 
RNA before carrying out the pull-down using magnetic beads, was also tried. 
Despite the numerous approaches undertaken, a lot of non-specific protein 
binding to the beads was still observed. Furthermore, very little specific 
protein binding was detected. This may have been because only a fraction of 
the specifically bound proteins were isolated, or that the proteins of interest 
were masked by non-specific protein binding. 
Introducing increasing salt concentration washes as part of the protein elution 
stage resulted in fewer proteins eluted in later washes. These possibly 
represented more specific HIV RNA-protein interactions. After confirming that 
UV cross-linking experiments would still function at increasing salt 
concentrations, wash fractions were used in a UV cross-link with HIV-1/2 5’ 
UTR RNA to analyse which fraction contained the unknown 45 kDa protein. 
The HIV-2 RNA, 200 mM wash fraction yielded an interesting band at 45 kDa 
binding solely to the HIV-1 5’ UTR. This fraction was separated by SDS-
PAGE and the gel stained to excise the resulting 45 kDa band. Analysis of 
this fraction was carried out by mass spectrometry. However, the 45 kDa 
band was only faintly present following staining, and mass spectrometry 
results did not yield any well-known RNA-binding proteins. Thus it is likely 
that there was not sufficient protein in this band fraction to produce an 
accurate assessment of the 45 kDa protein (or proteins) present. 
However, the most abundant protein identified by mass spectrometry was an 
actin isoform: Beta-actin (ACTB). Although not well-known as an RNA-
binding protein, actin was shown to be important for the transcription of the 
negative-strand RNA virus: respiratory syncytial virus (RSV). Direct binding of 
actin to the RSV genome is mediated by the actin divalent-cation-binding 
domain. Thus actin is proposed to act as a transcription factor for RSV 
replication (Harpen et al., 2009). Although no interaction between actin and 
the HIV genome has been reported, these findings could be of relevance to 
HIV if actin is shown to be the 45 kDa protein binding to the HIV-1 5’ UTR. If 
actin is able to enhance HIV-1 transcription by binding to the 5’ UTR, but the 
same is not true for HIV-2, this may provide a rationale for the less efficient 
transcription rate of HIV-2 evidenced in chapter 3.  
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Further work is necessary to validate the identity of this unknown 45 kDa 
protein. Optimisation of the RNA affinity chromatography protocol requires 
scaling up the production of HeLa S100 extract and biotinylated RNA, using a 
greater quantity of magnetic streptavidin beads, including larger volumes for 
initial salt washes and tailoring washes to a smaller quantity for expected 
protein elution fractions. Likewise, additional considerations, including 
carrying out protein precipitation to concentrate proteins in wash fractions 
and dialysis of fractions prior to testing in UV cross-linking assays, will allow 
easier detection and isolation of protein bands by SDS-PAGE. It is hoped 
that a coordinated scale-up and optimisation of this protocol may permit 
isolation of the unknown HIV-1 5’ UTR RNA-binding protein in sufficient 
quantity for better identification by mass spectrometry. 
Alternative approaches could also be investigated as a means to isolate the 
unknown HIV-1 5’ UTR binding protein in greater abundance. One method, 
called the MS2:MBP pull down, involves fusing the HIV-1 5’ UTR to multiple 
copies of the 3’ UTR stem loop of bacteriophage MS2 [figure 95]. 
 
Figure 95: Isolation of specific RNA-binding proteins using the MS2: MBP RNA pull 
down method. 
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MS2 coat protein is an RNA-binding protein which binds efficiently to the 
MS2 stem loops. MS2 coat protein can be fused to a maltose binding protein 
(MBP) forming MS2:MBP. When cellular extract is added to a reaction with 
the RNA-stem loops, RNA-binding proteins specifically interact with the RNA 
of interest. The RNA-bound proteins attached to the MS2 stem loops can 
form a complex with MS2:MBP which is all extracted via MBP binding to an 
amylose column. In this way, specific RNA-binding proteins can be isolated 
from non-specific proteins and identified (Elliott and Ladomery, 2010). 
5.3.4 Identifying the 45 kDa protein binding site 
Despite the unknown identity of the protein binding to the HIV-1 5’ UTR, it 
was hoped that narrowing down the binding location of this protein within the 
5’ UTR might provide an indication of its function. Furthermore, this could 
potentially facilitate isolation of the protein by RNA affinity chromatography by 
reducing the non-specific binding associated with excess RNA. This would 
only be possible, however, assuming that just a specific region of the HIV-1 
5’ UTR was implicated in binding to this protein. The 45 kDa protein bound 
strongly to more complete, lengthier HIV-1 5’ UTR RNAs. This suggests that 
perhaps multiple protein binding domains within the HIV-1 5’ UTR enhance 
binding of the unknown protein rather than a small, specific motif. 
Conversely, the RNA-binding site of this protein may be located at the 5’ end 
of the HIV-1 5’ UTR. Further work is consequently necessary to isolate the 
exact binding position of the unknown 45 kDa protein. 
Future work will endeavour to uncover the identity of the unknown 45 kDa 
protein binding to the HIV-1 5’ UTR and, moreover, elucidate a potential role 
for this RNA-protein interaction in the life cycle of HIV-1. After optimising the 
methods necessary to achieve this, the identity of other HIV-1/2 RNA-binding 
proteins, such as the 120/130 kDa proteins binding with opposing strengths 
to the HIV-1/2 5’ UTR, will be investigated. 
Future work could also look to isolate protein extracts from HIV-infected 
HeLa cells for use in cross-linking. This will determine whether viral proteins 
bind differently to HIV-1 and HIV-2 RNA or whether cellular proteins bind 
differently in the presence of viral proteins. If cross-linking results show 
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differences in viral or cellular proteins binding to  HIV-1/2 RNA, RNA-affinity 
chromatography and proteomics will be necessary to identify those proteins. 
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6. CHAPTER 6: THE EFFECT OF AP-1 ON GAG  
 PROTEIN LEVELS 
6.1 Introduction 
This chapter explores the role of the clathrin adaptor protein AP-1 in HIV Gag 
expression and trafficking. In the introduction, the roles of adaptor proteins in 
facilitating vesicular transport are discussed alongside the relevance of this to 
HIV Gag transport to, and assembly at, the plasma membrane. Results are 
presented showing that specific knockdown of AP-1 effects a reduction in the 
cellular levels of both HIV-1 and HIV-2 Gag. The role of AP-1 in both HIV-1 
and HIV-2 Gag expression and cellular transport was explored by inhibiting 
this adaptor protein and visually assessing the effect on HIV-1/2 Gag protein 
levels within the cell by confocal microscopy. 
6.1.1 Gag trafficking 
Genomic RNA, Gag and Env proteins are transported on endosomes to the 
plasma membrane during virus assembly to form immature virions. Although 
progress has been made in determining the components of viral assembly 
and budding, the pathways used to traffic HIV Gag to assembly sites at the 
plasma membrane have not yet been clearly defined (Gousset et al., 2008). 
Gag interactions with endosomal sorting proteins are fundamental to 
retroviral assembly and virus-like particles (VLPs) have been shown to 
assemble when only the HIV Gag protein is expressed (Camus et al., 2007). 
Gag has been shown to localize to the plasma membrane and is also found 
associated with internal, cellular components which bear a resemblance to 
multi-vesicular bodies (MVBs) (Gousset et al., 2008). Two groups of proteins 
associated with cellular trafficking have been linked to HIV Gag; MVB 
proteins and clathrin adaptor (AP) proteins. Within the cell, ESCRT 
(endosomal sorting complexes required for transport) protein complexes 
recognise and sort ubiquitinated cargo proteins into the intralumenal vesicles 
of MVBs, and clathrin APs sort target proteins into clathrin coated transport 
vesicles (Camus et al., 2007). The mechanism of clathrin coated vesicular 
transport is outlined in figure 96. Clathrin and adaptor proteins are essential 
components of clathrin coated vesicles (Orzech et al., 2001). 
Chapter 6                                           The effect of AP-1 on Gag protein levels 
195 
 
 
Figure 96: During the formation of a clathrin coated vesicle, ligands bind to, and 
activate, their cognate receptors. Clathrin and adaptor proteins subsequently bind to 
activated receptors forming a coated pit which, in turn, becomes a vesicle. Dynamin 
mediates the separation and release of coated vesicles from the lipid membrane 
[http://www.zoology.ubc.ca/~berger/B200sample/unit_8_protein_processing/images_u
nit8/14_19.jpg]. 
Eukaryotic protein transport relies on the movement of vesicles between 
celllular, membrane-bound compartments. Both endocytic and exocytic 
protein pathways involve budding of vesicles from a donor compartment and 
subsequent fusion with an acceptor compartment (Orzech et al., 2001).  
6.1.2 The adaptor proteins and AP-1 
Heterotetrameric adaptin protein complexes are important in vesicular 
transport where they have a duality of function; selecting cargo proteins for 
vesicle incorporation through specific receptor binding, and providing an 
anchor for clathrin coat formation [figure 97].  
 
Figure 97: AP complexes form a link between receptor-ligand complexes and clathrin 
triskelions (A). A peptide recognition sequence within the receptor specifically binds 
to adaptin to mediate this interaction. The assembly of many receptor-ligand 
complexes bound to clathrin results in the formation a clathrin-coated vesicle (B) 
[adapted from http://www.erin.utoronto.ca/~w3bio315/lecture17.htm]. 
Chapter 6                                           The effect of AP-1 on Gag protein levels 
196 
 
Four AP complexes (AP-1-4) exist in eukaryotes. Transport between the 
trans-Golgi network (TGN) and endosomes relies on AP-1 and AP-3; AP-1 
facilitates the formation of exocytic vesicles whereas AP-3 is involved in 
anterograde transport to endosomes and lysosomes (Odorizzi et al., 1998). 
AP-2 permits the formation of endocytic vesicles at the plasma membrane 
and AP-4 functions during transport between the TGN and cell surface 
(Nevin and Dacks, 2009; Orzech et al., 2001). AP complexes are composed 
of a small subunit (ζ1-4), a medium subunit (μ1-4) and two large subunits 
(γ/β1, /β2, δ/β3, ε/β4) (Camus et al., 2007). The composition of AP-1 is 
shown in table 16.  
 
 
 
Component Size 
Β1-adaptin ~100 kDa 
γ-adaptin ~100 kDa 
μ1 47 kDa 
ζ1 19 kDa 
 
Table 16: Components of the mammalian adaptor protein AP-1 and their molecular 
weights. 
6.1.3 The role of AP in Gag trafficking 
Retroviral release relies on AP-1. Camus et al. (2007) showed that the HIV-1 
Gag matrix region interacts specifically with the μ1A medium chain of AP-1μ 
(but not with AP-2 and AP-3 homologous μ2 and μ3 subunits). Mutation or 
knockdown of AP-1 significantly decreases Gag trafficking, viral replication 
and the number of budding virions (shown by an 80% decrease in the 
release of Gag p24) (Camus et al., 2007). It is plausible that HIV-1 may 
exploit the interaction of AP-1 with clathrin (and its role in forming coating 
vesicles) as a scaffold for the production of virus particles (Camus et al., 
2007). 
Binding of HIV-1 Gag to AP-2 was shown to regulate the release and 
assembly of HIV-1 virions. However, disruption of the interaction between 
Gag and AP-2 enhances viral budding (Batonick et al., 2005) The matrix 
region (N-terminus) of HIV-1 Gag has also been shown to bind to the δ 
Chapter 6                                           The effect of AP-1 on Gag protein levels 
197 
 
subunit of the AP-3 complex, which enhanced Gag budding by directing Gag 
to late endosomal compartments (Dong et al., 2005). This indicates that the 
Gag assembly pathway involves late endosomal trafficking.  
Camus et al. (2007) suggest that AP-1 and AP-3 are involved in two different 
steps of the Gag budding pathway as mutations in AP-1 and AP-3 did not 
have an additive effect on HIV-1 Gag release. Alternatively, targeting of Gag 
to the plasma membrane for budding may preferentially use AP-1 or AP-3 
(Camus et al., 2007). 
In addition to the effect on budding, preliminary results from our group 
(E.Anderson, unpublished) suggested that AP-1 knockdown may also result 
in a reduction in cellular HIV-1 Gag levels. However, the finer details of HIV 
Gag interactions with adaptor proteins, and in particular AP-1, have yet to be 
resolved.  
6.2 Results 
6.2.1 AP-1 knockdown in cells 
To confirm whether we could successfully knock down the expression of AP-
1 in cells, HeLa cells were transfected with siRNA to AP-1, a siRNA negative 
control and a mock transfection control. Total cellular protein was harvested 
at 48 h and 72 h post-transfection, separated by SDS-PAGE and western 
blotted with an antibody to the gamma subunit of AP-1 (AP-1 ) [figure 98]. 
 
Figure 98: Western blot with an antibody to AP-1  showing AP-1 knockdown in mock, 
negative siRNA and AP-1 siRNA (either 20 nM or 50 nM) treated cells at 48 h or 72 h 
post-transfection. 
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AP-1 appears as a 104 kDa protein [figure 98]. Results showed that AP-1 
knockdown was achieved using 20 nM siRNA. AP-1 knockdown was better 
after 72 h, but still detectable after 48 h. Knockdown was specific as the 
negative control siRNA had no effect on AP-1 levels. 
6.2.2 A comparison of AP-1 knockdown on HIV-1/2 Gag levels 
We then tested the effect of AP-1 knockdown on the cellular levels of HIV-1/2 
Gag. HeLa cells were transfected with AP-1 siRNA (or a negative siRNA 
control) for 24 h followed by transfection with HIV-1 or HIV-2 provirus for a 
further 24 h to produce viral proteins. After this time, total protein was 
harvested from cells and analysed by western blotting with an antibody to 
HIV-1 Gag p24 (Capsid) or HIV-2 Gag p27 (Capsid) [figure 99]. 
(A)                  HIV-1       (B)                 HIV-2 
Figure 99: Western blot of AP-1 transfection protein using antibodies to HIV-1 Gag 
(p24) and HIV-2 Gag (p27). HIV-1/2 Gag expression from transfected provirus is shown 
in the presence [lane 1] or absence [lane 3] of AP-1 siRNA or with a negative control 
siRNA [lane 2]. 
AP-1 siRNA knockdown reduced the level of full-length p55 (HIV-1) and p57 
(HIV-2) Gag products, the HIV-1 p41 Gag processing intermediate, and both 
p24 (HIV-1) and p27 (HIV-2) Capsid proteins, when compared to a negative 
control siRNA or no siRNA. This suggests that specific knockdown of AP-1 
reduces the cellular levels of both HIV-1 and HIV-2 Gag. 
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6.2.3 Visualisation of AP-1 knockdown in cells 
Confocal microscopy was then used to visualise AP-1 knockdown within 
cells. HeLa cells were transfected with AP-1 siRNA, negative control siRNA 
or no siRNA for 48 h, fixed, and stained with an antibody to AP-1 and 
secondary Alexaflour antibody. Cellular nucleic acid was stained using DAPI 
and cells were visualised at different magnifications using a confocal 
microscope [figures 100+101]. 
   
(A)  AP-1 siRNA 
   
(B) Negative control siRNA 
   
(C) No siRNA 
 
Figure 100: Confocal microscopy images showing blue DAPI staining of the nucleus 
and green AP-1 fluorescence in AP-1 siRNA (A), negative control siRNA (B) and mock 
‘no siRNA’ (C) transfected HeLa cells. 
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(A)  AP-1 siRNA 
 
(B)  Negative control siRNA 
 
(C)  No siRNA 
Figure 101: Confocal microscopy images showing blue DAPI staining of the nucleus 
and green AP-1 in AP-1 siRNA (A), negative control siRNA (B) and mock ‘no siRNA’ 
(C) transfected HeLa cells. 
AP-1 could be detected in cells mock transfected or treated with negative 
control siRNA. AP-1 staining localised to perinuclear structures, likely 
corresponding with the trans-Golgi network (TGN). Additionally, punctate AP-
1 staining throughout the cell was suggestive of cytoplasmic vesicles and 
likely represents AP-1 bound to endosomes. AP-1 clathrin coats are 
principally located at the TGN and mediate endosomal transport (Odorizzi et 
al., 1998). The specific AP-1 staining pattern we visualised correlates with 
both AP-1 function and, furthermore, matches other literary reports of AP-1 
staining (Meyer et al., 2000). We were thus able to successfully visualise AP-
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1 within the cell. siRNA knockdown of AP-1 was also successful. Although 
not every cell treated with siRNA showed knockdown, there was a significant 
reduction in AP-1 immunofluorescence in most of the cells treated with AP-1 
siRNA. 
6.2.4 Visualisation of HIV-1/2 Gag in cells 
To verify whether Gag p24/p27 antibodies were suitable for visualisation of 
HIV-1/2 Gag by confocal microscopy, HeLa cells were transfected with HIV-
1/2 provirus for 24 h. Cells were subsequently fixed and stained with primary 
HIV-1/2 Gag antibodies and secondary Alexa Fluor antibodies [figure 102]. 
  
 (A) HIV-1      (B) HIV-2 
 
Figure 102: Confocal microscopy images showing blue DAPI staining of the nucleus 
and red HIV-1 (A) or HIV-2 (B) Gag expression in HeLa cells.  
HIV-1/2 antibodies were able to detect Gag and allowed visualisation of the 
cellular localisation of HIV-1/2 Gag. Gag staining patterns differed between 
HIV-1/2. HIV-1 was expressed extensively throughout the cell, with localised 
staining at the plasma membrane. This likely represents the coordination of 
Gag molecules during viral particle assembly which occurs at the plasma 
membrane. HIV-1/2 Gag staining within the cytoplasm likely represents 
localisation of Gag at translation sites and Gag molecules undergoing 
transport to the plasma membrane via cellular endosomes or alternative 
mechanisms. Staining of HIV-2 Gag was diffuse within the cytoplasm, with 
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isolated, punctate Gag clusters and a lower overall level of Gag expression. 
HIV-2 Gag also showed little localisation to the plasma membrane.  
The staining patterns of HIV-1/2 Gag reflect the enhanced rate of HIV-1 
replication leading to an abundance of Gag within the cell, in contrast to the 
inefficient replication of HIV-2 reflected by slower accumulation of Gag within 
the cell. Likewise, HIV-1 staining represents a more advanced stage of the 
viral life cycle with Gag molecules undergoing assembly at the plasma 
membrane, whereas the HIV-2 virus appears to be much slower at 
progressing Gag to viral assembly. Alternatively, HIV-2 Gag may 
preferentially assemble at intracellular sites such as MVBs rather than at the 
plasma membrane. 
6.2.5 Co-staining of AP-1 and HIV-1/2 Gag 
Differences in the interaction of HIV-1/HIV-2 Gag proteins with AP-1, and 
subsequent trafficking through the cell, may indicate a mechanism by which 
HIV-1 and HIV-2 replication differ. Confocal microscopy was used to visualise 
the location of AP-1 within the cell and identify whether HIV-1/HIV-2 Gag 
proteins co-localised with AP-1. HeLa cells were transfected with HIV-1/2 
provirus for 40 h. Cells were fixed, stained with both DAPI nuclear stain and 
antibodies to AP-1 and HIV-1 p24/HIV-2 p27 Gag proteins, and visualised by 
confocal microscopy [figure 103].  
Both HIV Gag and AP-1 could be stained within the same cells and thus 
viewed, simultaneously, by confocal microscopy. AP-1 was localised to 
perinuclear structures whereas HIV-1/2 Gag staining was more diffuse within 
the cells. Additionally, HIV-1 Gag levels were at a greater intensity at the 
plasma membrane whereas HIV-2 Gag showed less localisation to the 
plasma membrane. Although HIV-1 Gag is reported to interact with AP-1 
(Camus et al., 2007), neither HIV-1 nor HIV-2 Gag showed significant co-
localisation with AP-1. It may have been difficult to visualise this association 
due to the transient nature of the Gag trafficking interaction with AP-1.  
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(A)  HIV-1 
 
(B)  HIV-2 
 
(C)  HIV-1 
 
(D)  HIV-2 
 
Figure 103: Confocal microscopy images showing green AP-1 staining, red HIV-1 
(A+C) and HIV-2 (B+D) Gag staining and blue DAPI staining of the HeLa cell nucleus. 
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6.2.6 Visualisation of the effect of AP-1 knockdown on cellular HIV-
1/2 Gag levels 
Knockdown of AP-1 resulted in a reduction in the level of both HIV-1 and 
HIV-2 Gag proteins within HeLa cells when compared by western blot. 
Subsequently, confocal microscopy was used to visually assess the impact of 
AP-1 knockdown on HIV-1 and HIV-2 Gag expression. HeLa cells were 
transfected with AP-1 siRNA for 24 h to knockdown AP-1, followed by HIV-
1/2 provirus transfection for 24 h/40 h to allow expression of HIV-1/2 Gag 
with and without AP-1. Cells were fixed and stained with antibodies to AP-1 
and HIV-1/2 Gag. Cell nuclei were stained with DAPI [figure 104].  
AP-1 knockdown could be detected in cells transfected with AP-1 siRNA 
[figure 104, B+D]. For transfections in which AP-1 was knocked down, there 
were fewer cells expressing HIV-1 and HIV-2 Gag. Conversely, an increased 
number of cells were stained for HIV-1/2 Gag when AP-1 was not down-
regulated. This suggests that AP-1 is important for Gag expression. 
Additionally, irrespective of AP-1 siRNA treatment, cells which showed good 
AP-1 staining (suggesting good AP-1 expression) also demonstrated a higher 
level of Gag expression. Consequently, results suggest that AP-1 enhances 
the level of HIV-1 and HIV-2 Gag expressed within the cell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6                                           The effect of AP-1 on Gag protein levels 
205 
 
 
 
(A)  HIV-1, 40 h, No siRNA 
 
(B)  HIV-1, 40 h, AP-1 siRNA 
 
(C)  HIV-2, 24 h No siRNA 
 
(D)  HIV-2, 24 h AP1 siRNA 
Figure 104: Confocal microscopy images of HIV-1/2 provirus transfected HeLa cells. 
Cells were transfected in the presence or absence of AP-1 siRNA. Cellular AP-1 is 
shown in green, HIV-1/2 Gag is shown in red and cell nuclei were stained with DAPI 
(blue). 
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6.2.7 GFP controls 
To assess whether AP-1 siRNA transfections reduced gene expression and 
cell viability non-specifically, HeLa cells were transfected with (or without) 50 
nM AP-1 siRNA and a GFP expression plasmid (pcDNA GFP) for 24 h. Cells 
were subsequently fixed and viewed under a confocal microscope [figure 
105]. 
   
No siRNA   AP-1 siRNA 
   
No siRNA   AP-1 siRNA 
Figure 105: Confocal microscopy of HeLa cells transfected for 24 h with pcDNA GFP 
(green) in the presence/absence of 50 nM AP-1 siRNA.  
GFP was well expressed in both mock and AP-1 siRNA co-transfected cells 
suggesting that AP-1 siRNA transfection did not significantly reduce non-
specific gene expression or cell viability. To confirm these results in the 
presence of the HIV-1 provirus, the level of HIV-1 Gag was assessed in mock 
and AP-1 siRNA-treated cells alongside the GFP control. HeLa cells were 
transfected with HIV-1 provirus and a pcDNA GFP control with/without 50 nM 
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AP-1 siRNA for 24 h before fixing and staining with DAPI nuclear stain and 
antibodies to HIV-1 Gag p24 [figure106]. 
AP-1 siRNA 
No siRNA 
Figure 106: Confocal microscopy of HeLa cells co-transfected with HIV-1 provirus and 
pcDNA GFP in the presence and absence of AP-1 siRNA. GFP expression is shown in 
green, HIV-1 Gag is expressed in red and cell nuclei are stained with DAPI (blue). 
GFP expression was similar between AP-1 siRNA and mock-treated cells, 
confirming that AP-1 knockdown does not affect GFP expression. However, 
HIV-1 Gag staining was reduced in AP-1 knockdown cells compared to 
mock-treated cells, indicating that AP-1 is important for HIV-1 Gag 
expresssion specifically. 
6.2.8 Monitoring temporal Gag localisation 
Confocal microscopy could be used to visualise HIV Gag expression and 
cellular localisation at various time points during the virus replication cycle. 
The expression of HIV-1/2 Gag was monitored at 24 h and 40 h post provirus 
transfection in HeLa cells to assess whether differences in Gag appearance 
could be observed at different times post-transfection. Cells were fixed, 
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stained with DAPI and antibodies to HIV-1 Gag p24/HIV-2 Gag p27, and 
viewed using a confocal microscope [figure 107]. 
        24 h      40 h 
  
(A)  HIV-1      
  
(B)  HIV-2 
Figure 107: Confocal microscope images of HIV-1/2 Gag expressed from provirus 
transfection at 24 h and 40 h post-transfection. Cell nuclei are stained with DAPI 
(blue), cellular AP-1 is shown in green and HIV-1/2 Gag is shown in red. 
Differences in HIV-1/2 Gag appearance and localisation could be seen at 24 
h and 40 h post-transfection. At 24 h, extensive HIV-1 Gag expression was 
seen throughout the cell with some localisation to the plasma membrane. By 
40 h, almost all cellular HIV-1 Gag was localised at the cellular membrane 
with evidence of extracellular Gag beyond the plasma membrane. This 
potentially represents HIV-1 Gag within budding viral particles or particles 
released by viral-mediated cell lysis. Initially, at 24 h, HIV-2 Gag expression 
was less extensive within the cell than HIV-1. By 40 h, most of the HIV-2 Gag 
had localised to the plasma membrane and was more reminiscent of HIV-1 
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Gag staining at 24 h. This may reflect the slower rate of HIV-2 Gag 
expression. 
6.3 Discussion 
Confocal microscopy was carried out to visualise the impact of AP-1 
knockdown on HIV-1/2 Gag levels. Initial experiments confirmed that we 
were able to knock down AP-1 using siRNA and, importantly, detect AP-1 
deficient cells by confocal microscopy. Knockdown of AP-1 was not complete 
as some cells maintained AP-1 expression. This is most likely due to less 
than 100% transfection efficiency. However, we were able to observe many 
cells in which AP-1 expression was severely reduced.  
Staining of HIV-1/2 Gag produced differing patterns. Prevalent HIV-1 Gag 
staining was seen throughout the cell and, in particular, staining localised to 
the plasma membrane. Observations of HIV-1 Gag report that it accumulates 
both at the plasma membrane (representing sites of viral assembly) and 
within internal cellular compartments resembling late endosomes (Gousset et 
al., 2008). Our observations of HIV-1 Gag support this. HIV-2 Gag produced 
a more punctate and dispersed staining pattern of lower intensity than HIV-1. 
Whereas HIV-1 Gag formed large clusters along the inside edge of the 
plasma membrane, HIV-2 Gag only formed isolated patches at the plasma 
membrane. HIV-1 transcription (Chapter 3) and Gag translation (Chapter 4) 
was shown to be more efficient than for HIV-2. Thus, it was expected that 
HIV-1 provirus transfection would result in a higher Gag expression level 
within the cell than HIV-2. Likewise, if the HIV-1 life cycle progresses more 
rapidly than HIV-2 (as suggested by results on nuclear export in Chapter 3), 
this may cause HIV-1 Gag to accumulate at the plasma membrane more 
quickly than HIV-2 Gag. Indeed, at 40 h post-transfection HIV-2 Gag staining 
showed more localisation to the plasma membrane and was more equivalent 
to the HIV-1 staining pattern evidenced at 24 h. 
However, in addition to variations in transcription and translation efficiency, 
differences in Gag trafficking between HIV-1 and HIV-2 may also account for 
differences in the cellular localisation of HIV-1/2 Gag. Differences within the 
HIV-1 and HIV-2 Gag matrix (MA) region may alter cellular trafficking. The N-
Chapter 6                                           The effect of AP-1 on Gag protein levels 
210 
 
terminus of the Gag MA region contains a myristyl group (myr) that has two 
conformations; exposed or sequestered. Gag binding to the plasma 
membrane is mediated by exposure of the myr group which engages with the 
interior of the plasma membrane (Waheed and Freed, 2009). The myr group 
of HIV-2 MA has been shown to be more tightly sequestered than the myr 
group of HIV-1 MA. Likewise, conformational switching of HIV-2 myr is less 
sensitive than for HIV-1 (Saad et al., 2008). This may account for the 
observation that HIV-2 Gag proteins form a less stable association with the 
plasma membrane than HIV-1 Gag (Morikawa et al., 2007). Importantly, 
sequestering of myr may hinder HIV-2 Gag assembly and consequently 
contribute to the slow and inefficient localisation of HIV-2 to the plasma 
membrane which we observed by confocal microscopy. 
Additionally, targeting of Gag to the plasma membrane is aided by PI(4,5)P2 
recognition of the Gag MA domain. PI(4,5)P2 binds to MA and triggers a 
conformational change which exposes myr, facilitating membrane binding 
(Saad et al., 2008). Variations within HIV-1/2 MA may thus alter this 
interaction with PI(4,5)P2, and account for the slower, less efficient HIV-2 
Gag trafficking through the cell. If HIV-2 MA is unable to engage easily with 
PI(4,5)P2, HIV-2 Gag molecules may be diverted during trafficking by loss of 
this association or, alternatively, may traffic via a different route to the plasma 
membrane. This could account for the slower localisation of HIV-2 Gag to the 
plasma membrane which we observed. 
It was ascertained that both HIV-1/2 Gag and AP-1 could be co-stained 
within the cell and viewed concurrently by confocal microscopy. As expected, 
AP-1 staining localised to a discrete perinuclear structure, likely representing 
the TGN, and to cytoplasmic vesicles, most probably reflecting cytoplasmic 
endosomes. Although HIV-1 Gag is reported to interact with AP-1, 
surprisingly we did not observe co-localisation beween AP-1 and HIV-1/2 
Gag by confocal microscopy. This may be due to the transient nature of this 
interaction. Trafficking is a dynamic cellular process; cellular vesicles are 
rapidly formed, transported to target membranes, and disassembled. 
Likewise, efficient cellular trafficking is important to ensure that this is not a 
rate limiting stage of cellular pathways. Consequently, movement of Gag 
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molecules through the cell may occur very quickly. Therefore the interaction 
between HIV Gag molecules and AP-1 may occur within such a short time 
frame that it was not easy to observe this process by confocal microscopy.  
A western blot of lysates from HIV provirus transfected cells pre-treated with 
AP-1 siRNA showed reduced levels of both HIV-1 and HIV-2 Gag. Confocal 
microscopy was used to gain more insight into these results by permitting 
visualisation of AP-1 and Gag levels within individual cells. These 
experiments showed that cells in which AP-1 expression was significantly 
reduced by siRNA treatment also had severely reduced levels of HIV-1 or 
HIV-2 Gag staining. Control experiments using GFP showed that AP-1 
knockdown did not affect cell viability or indeed the level of GFP expression, 
suggesting that the observed reduction of HIV-1/2 Gag levels was not due to 
non-specific effects of AP-1 siRNA on gene expression or cell growth. 
Whilst AP-1 knockdown has previously been shown to affect HIV-1 budding 
from cells (Camus et al., 2007), this experiment provides the first indication 
that AP-1 is required for Gag expression or stability. At this stage it is not 
possible to tell whether AP-1 is required for Gag synthesis or whether AP-1 
knockdown results in rapid turnover of Gag. Metabolic labelling pulse-chase 
immunoprecipitation experiments, in which newly synthesised proteins are 
labelled with 35S for a short time, may allow us to discern whether AP-1 
siRNA treatment reduces the amount of Gag synthesised in the pulse period 
or increases the rate of Gag turnover in the chase period. 
Following Gag synthesis, transport of Gag molecules away from their site of 
synthesis may be required to permit more Gag translation to occur. High 
concentrations of Gag have been shown to inhibit the translation of HIV-1 
(Anderson and Lever, 2006). Therefore HIV-1 Gag synthesis may be reliant 
on the transport of Gag away from its site of synthesis to prevent the build-up 
of Gag in the vicinity of translating mRNA from inhibiting translation. Proteins 
such as AP-1, which are propsed to mediate Gag trafficking, may 
consequently play an additional role in the viral life cycle: regulating the rate 
of Gag translation. 
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Finally, down-regulation of AP-1 may induce the down-regulation of HIV Gag 
proteins via degradation. HIV Gag has been shown to localise to MVBs or 
late endosomes. If AP-1 is unable to faciliate the subsequent transport of 
Gag molecules to the plasma membrane, Gag may become sequestered into 
MVBs. This protein sorting failure may result in fusion of the MVB with the 
lysosome and subsequent degradation of Gag by lysosomal proteases. 
Alternatively, in the absence of AP-1, misdirected Gag may target to aberrant 
cellular locations resulting in subsequent degradation. Ubiquitylation provides 
a sorting signal for both MVB and the proteasome (Katzmann et al., 2001). 
As HIV Gag also appears to target to MVBs, in the absence of AP-1, a similar 
signalling mechanism may result in Gag mistargetting to the proteasome. As 
a result, AP-1 may be important in ensuring Gag stability by prompting its 
efficient transport to viral assembly sites at the plasma membrane. 
6.3.1 Future work 
Previous AP-1 knockdown experiments have resulted in conflicting results. 
Following AP-1 shutdown, cargo proteins were shown to accumulate in the 
Golgi, at the plasma membrane or in endosomal/post-endosomal 
compartments. Additional difficulties in knockdown experiments can arise 
due to the longevity of AP-1 proteins. Existing AP-1 proteins may remain in 
the cell for several days after the knockdown event, and therefore continue to 
undertake cargo protein transport albeit at a reduced rate. Furthermore, 
removing one protein from the cellular trafficking pathways may induce 
compensatory measures by other trafficking proteins or pathways. 
Alternatively, the components of other trafficking pathways may be 
transported via AP-1; the resulting protein deficit may thus effect a down-
regulation in other trafficking pathways as a consequence of inhibiting AP-1 
transport (Robinson et al., 2010).  
Consequently, additional trafficking pathways may require monitoring to, 
firstly, see whether these compensate when AP-1 trafficking is shutdown 
and, secondly, assess how this impacts HIV-1/2 Gag trafficking. Further work 
is required to better understand the role of AP-1 in cellular transport and 
elucidate how this impacts HIV replication via AP-1 interactions with Gag. 
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Likewise, determining whether AP-1 imparts regulatory control over Gag 
synthesis or Gag degradation may highlight a useful inhibitory step within the 
life cycle of HIV. 
Monitoring the cellular localisation of HIV-1/2 Gag at short intervals post-
transfection would provide a more detailed, temporal assessment of Gag 
localisation within the cell. Combining these observations with co-localisation 
experiments using markers of cellular trafficking may provide a better 
overview of HIV-1/2 Gag trafficking mechanisms. This would allow for a more 
detailed comparison of HIV-1/2 Gag transport mechanisms.  
Any differences in Gag trafficking mechanisms may contribute to the lower 
replication efficiency of HIV-2. Overall, additional work is necessary to clarify 
the routes of HIV-1/2 Gag transport within the cell and determine how AP-1 
alters both HIV-1 and HIV-2 Gag expression levels. 
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7. CHAPTER 7: CONCLUSIONS AND FUTURE WORK 
The work presented in this thesis investigates several avenues by which HIV-
1 and HIV-2 Gag gene expression differ. In this last chapter, I will summarise 
the conclusions from these studies and highlight future work which could 
proceed from our conclusions. I will also describe how the work of this thesis 
fits in with current views and emphasize the areas in which it has expanded 
on our current knowledge. 
7.1 HIV gag transcription and nuclear export 
a) The level of HIV-1/2 gag mRNA transcribed from provirus transfections of 
HeLa cells was quantified by qPCR. HIV-1 transcription was shown to be 
more efficient than HIV-2 transcription. This resulted in higher levels of HIV-1 
gag mRNA than for HIV-2. The stability of HIV-1/2 gag mRNA was not 
responsible for the difference in HIV-1/2 RNA levels. 
b) Nuclear and cytoplasmic levels of HIV-1/2 gag mRNA were compared at 
several time points following provirus transfection into HeLa cells. The rate of 
HIV-1 gag mRNA export from the nucleus was more efficient than for HIV-2. 
This resulted in a quicker accumulation of HIV-1 gag mRNA in the cytoplasm 
and a more rapid decrease in nuclear HIV-1 gag mRNA levels following an 
initial period of synthesis. HIV-2 gag mRNA levels were slow to accumulate 
in the nucleus and equally slow at appearing in the cytoplasm indicating that 
both HIV-2 transcription and export were inefficient. Cytoplasmic HIV-1/2 gag 
mRNA was shown to have a comparable stability, affirming that differences in 
cytoplasmic gag mRNA levels were due to inefficient HIV-2 export. 
c) Future work will look to control for additional factors affecting cellular gag 
mRNA levels, such as the incorporation of viral mRNA into virions. Likewise, 
calculating the actual number of RNA copies within sub-cellular fractions will 
provide a more accurate assessment of HIV-1/2 transcription rates. The 
factors involved in more efficient HIV-1 mRNA transcription and nuclear 
export remain to be uncovered, in addition to elucidating how these factors 
affect the mechanisms of HIV-1/2 transcription and export differently. 
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d) Finally, investigations are currently underway to investigate the 
contribution of a spliced HIV-2 gag transcript to sub-cellular mRNA pools. 
Identifying whether the singly-spliced HIV-2 gag transcript is preferentially 
exported from the nucleus over unspliced transcripts may suggest a 
mechanism by which HIV-2 counteracts the inefficient export of its full-length 
mRNA. 
7.2 HIV Gag translation 
a) Translation of HIV-1 gag RNA was shown to be more efficient than HIV-2 
gag RNA in vitro and in HeLa, COS-1 and Jurkat cells. Neither the presence 
of viral proteins nor the stability of HIV-1/2 RNA was shown to affect HIV-1/2 
translation rates differently.  
b) Initiation of translation for both HIV-1 and HIV-2 was shown to be primarily 
cap-dependent. Shut down of cap-dependent translation by poliovirus 
infection severely reduced the translation of both HIV-1 and HIV-2 Gag. 
Uncapped HIV-1/2 RNAs also demonstrated a reduced translational 
capability. No additional translation of Gag isoforms was evidenced from 
internal AUGs to compensate for the shut-down of cap-dependent 
translation. IRES-driven activity was therefore not evidenced as a means to 
initiate translation from either HIV-1 or HIV-2 RNAs. 
c) The lengthier 5’ UTR of HIV-2 was shown to be intrinsically more 
structured than the shorter HIV-1 5’ UTR. A more negative folding energy 
and folding energy per nucleotide was calculated for the HIV-2 5’ UTR when 
compared to the HIV-1 5’ UTR. The HIV-2 TAR structure, shown to contain a 
high level of G-C base pairing, was partly responsible for the higher folding 
energy of HIV-2. An enhanced level of structure within the HIV-2 5’ UTR is 
therefore thought to impair ribosomal scanning and hinder the rate of cap-
dependent translation initiation for HIV-2.  
d) When the TAR structure was deleted from both HIV-1 and HIV-2 5’ UTRs, 
surprisingly the translation rate of both HIV-1 and HIV-2 gag RNA decreased 
in HeLa cells and BSRT7 cells. This was not due to an enhanced ΔTAR RNA 
degradation rate. The down-regulation of PKR (which inhibits translation by 
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phosphorylating eIF2) by TAR was proposed to account for decreased 
translatability of RNAs in the absence of TAR. Further investigations into the 
phosphorylation status of eIF2 within these experiments may confirm whether 
this is, in fact, the case. 
e) A comparison of codon bias and codon pair bias within the HIV-1 and HIV-
2 Gag ORFs found that these did not vary sufficiently to cause differences in 
HIV-1/2 Gag elongation. Therefore the slower rate of HIV-2 translation is 
unlikely to be due to a reduced elongation rate relative to HIV-1. 
f) The importance of cap-dependent ribosomal scanning or IRES-driven 
activity to the translation of HIV proteins remains a divisive issue. Although 
we find no evidence for IRES activity, and all of our results implicate cap-
dependent translation, further work into the conditions and factors necessary 
to stimulate HIV translation may enable a conclusion to this debate. 
Deconstructing the necessary components for HIV translation therefore 
remains the focus of contemporary work in this field. We have shown that 
HIV-2 translation may be impaired by extensive 5’ structure hindering 
ribosomal scanning. However, factors such as the efficiency of cellular 
helicases, additional structure within the 5’ UTR, viral or cellular RNA-binding 
proteins, the cellular environment and the role of splicing may further 
contribute to the translational difference between HIV-1/2 RNAs and 
therefore provide areas for further investigation. 
7.3 HIV RNA-protein interactions 
a) UV cross-linking experiments identified a 45 kDa protein from HeLa cells 
which binds specifically to the HIV-1 5’ UTR but not to the HIV-2 5’ UTR. 
Non-specific competitors were unable to reduce binding of this protein 
whereas an unlabelled HIV-1 5’ UTR competitor reduced binding. Although 
this protein does not bind to HIV-2 5’ UTR RNA, it binds weakly to HIV-2 5’ 
UTR-gag RNA suggesting additional binding sites within gag or a reliance on 
a structural conformation involving the gag coding region. The absence of 
this protein binding to the 5’ UTR of HIV-2, and the weaker interaction with 
HIV-2 5’ UTR-gag RNA, may highlight a mechanism to account for the less 
efficient transcription or translation reported for HIV-2 in Chapters 3 and 4 
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respectively. Additional proteins around 120 and 130 kDa in size were shown 
to bind with opposing affinities to the HIV-1/2 5’ UTR. The identity and role of 
these RNA-protein interactions remains unknown and is therefore an avenue 
for future work. 
b) La autoantigen was a candidate for the 45 kDa protein binding to the HIV-
1 5’ UTR. However, La was shown to be larger than the 45 kDa protein. 
Whereas La binds to the poliovirus IRES (Meerovitch et al., 1993), binding of 
the 45 kDa protein to the HIV-1 5’ UTR was not reduced in the presence of a 
poliovirus IRES RNA competitor. Likewise, La is reported to bind to TAR 
(Chang et al., 1994), yet the 45 kDa protein was able to bind to the HIV-1 5’ 
UTR when TAR was deleted. La was also able to bind to the HIV-2 5’ UTR 
whereas the 45 kDa protein was not. The conclusion from this work is that 
the 45 kDa protein is not La autoantigen. 
c) Several attempts were made to isolate and identify the 45 kDa protein with 
limited success. Initial mass spectrometry results indicate that actin may be a 
candidate. Although not typically recognised for its role as an RNA-binding 
protein, actin is reported to interact with the negative-sense RNA genome of 
respiratory syncytial virus and enhance transcription (Harpen et al., 2009). 
Current research has yet to identify actin binding to the HIV RNA genome, 
therefore further work is required to confirm this interaction and assess the 
implications for HIV. 
d)  Truncated HIV-1 5’ UTR RNAs were used to narrow down the binding site 
of the 45 kDa protein. Studies with La revealed that TAR is not the binding 
site of the 45 kDa protein and preliminary results using truncated RNAs 
suggests that the 45 kDa protein binds to the 5’ end of the HIV-1 5’ UTR. 
Future work will endeavour to deduce the structural binding requirements of 
this protein and therefore fathom the role of this protein within the life cycle of 
HIV-1. 
e) An obvious direction for future work is the identification of the 45 kDa 
protein binding to the HIV-1 5’ UTR and the clarification of its function. 
Optimisation and scaling up of the RNA affinity chromatography protocol is 
the initial direction future work on this topic will take. Once successful, other 
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RNA-binding proteins, such as the 120 and 130 kDa proteins which also bind 
with different affinities to the HIV-1/2 5’ UTRs, could be investigated. 
Additionally, the protein-binding profile of the HIV-1/2 5’ UTR could be 
examined further using protein extract from HIV-infected cells. This may 
enable us to detect whether the presence of viral proteins affects cellular (or 
viral) protein interactions with the HIV-1/2 5’ UTRs. 
7.4 The effect of AP-1 on Gag protein levels 
a) AP-1 knockdown was achieved in cells using siRNA and shown to result in 
a decrease in the expression levels of HIV-1/2 Gag. 
b) Confocal microscopy showed AP-1 staining localised to perinuclear 
structures representing the trans-Golgi network and to cytoplasmic vesicles 
likely reflecting cytoplasmic endosomes. Visualisation of cellular HIV-1/2 Gag 
by confocal microscopy highlighted differences in the expression level of 
Gag. HIV-2 Gag was present in the cell at a lower level than HIV-1 Gag 
(likely a result of inefficient transcription, nuclear export and translation 
observed in Chapters 3 and 4) and did not localise to the plasma membrane 
as quickly as HIV-1 Gag. Despite reports of an interaction between HIV-1 
and AP-1 (Camus et al., 2007), we were unable to visualise HIV-1/2 Gag 
staining co-localising with AP-1 by confocal microscopy. 
c) When AP-1 was shut down, the level of both HIV-1/2 Gag expressed 
within the cell was reduced. Even when AP-1 was not knocked down, cells 
which showed good expression of AP-1 demonstrated higher levels of HIV-
1/2 Gag staining. Results therefore indicate that either AP-1 is required for 
Gag synthesis or that AP-1 is important for Gag stability. 
d) Further work could take several directions. Determining the involvement of 
AP-1 in either Gag synthesis or Gag degradation may underline a previously 
unknown cellular mechanism by which Gag gene expression is regulated. 
Alternatively, the role of AP-1, and other cellular trafficking components, in 
delivering HIV Gag to sites of viral assembly have yet to be clearly defined. 
Monitoring the movement of HIV-1/2 Gag throughout the cell at short time 
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intervals may provide a clearer indication of the trafficking mechanisms 
employed by HIV-1 and HIV-2. 
7.5 Discussion 
In drawing together the results from this thesis it is now apparent that there 
are numerous ways in which the life cycles of HIV-1 and HIV-2 differ. Rather 
than a defining, critical step limiting the rate of HIV-2 replication, we have 
shown that the relative inefficient replicative capacity of HIV-2 compared to 
HIV-1 is likely to be due to differences at several stages of the life cycle. This 
work provides a comprehensive, but by no means exhaustive, insight into the 
rate limiting aspects of HIV-2 Gag expression as a basis to highlight the 
proficiency of the equivalent stages in the replication of HIV-1. It was hoped 
that in understanding what makes HIV-1 so formidable and devastating a 
virus, and equally establishing the areas where HIV-2 fails to be so effective, 
we may uncover novel targets or mechanisms by which to limit the replicative 
capacity of HIV-1. 
We have shown that HIV-2 is less efficient than HIV-1 during stages of 
transcription, nuclear export and translation. Both HIV-1 and HIV-2 rely on 
cap-dependent translation initiation and differences in elongation are unlikely 
due to the similar codon composition of Gag. However, the lengthier and 
more structured HIV-2 5’ UTR is likely to hinder ribosomal scanning and 
therefore restrict cap-dependent translation initiation for HIV-2. Novel and 
uncharacterised HIV RNA-protein interactions have also been identified 
between the HIV-1/2 5’ UTRs which may contribute to transcriptional and 
translational variations between these two viruses. Taken together, it is 
therefore not surprising that fewer HIV-2 particles are produced during a HIV-
2 infection due to the restrictions which appear to limit many stages of the 
HIV-2 replication cycle. Although it is well established that HIV-2 infections 
progress less severely than HIV-1, this work provides a more detailed insight 
into the causes for this. In better understanding the differences between 
these two viruses, we are now able to appreciate the ways in which these 
viruses can be limited at a molecular level; information which is vital for the 
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development of novel therapies or a protective vaccine to discourage 
infection by these viruses.  
In conclusion, the main aim of this work: to identify and characterise 
differences in HIV-1/2 replication at the level of gag gene expression, has 
been achieved. Several differences in HIV-1 and HIV-2 gene expression 
have been identified and work has progressed to characterise these 
differences fully or in part. The particular focus of my work: to highlight 
potential differences between HIV-1/2 translation, has also been 
accomplished by establishing translation as a less efficient step for HIV-2 and 
determining that this is not due to initiation strategy or elongation but likely 
due to inefficient translation initiation. My work has helped to gain a greater 
understanding of the relationship between viral strategy and HIV-1/2 
pathogenesis. Therefore it will hopefully provide a springboard for further 
work to better characterise these viruses in the hope that, by knowing HIV 
better, we may finally vanquish its threat to humanity. 
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9.  APPENDIX 
1: HIV Gag-Luc reporter plasmid maps 
 
 
 
2: HIV ΔTAR Gag-Luc reporter plasmid maps 
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3: pcDNA3-2A plasmid map 
 
 
4: pcDNA3-2A-IRES plasmid map 
 
